CN101538267A - Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment - Google Patents
Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment Download PDFInfo
- Publication number
- CN101538267A CN101538267A CNA200910132469XA CN200910132469A CN101538267A CN 101538267 A CN101538267 A CN 101538267A CN A200910132469X A CNA200910132469X A CN A200910132469XA CN 200910132469 A CN200910132469 A CN 200910132469A CN 101538267 A CN101538267 A CN 101538267A
- Authority
- CN
- China
- Prior art keywords
- aryl
- alkyl
- group
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 230000000840 anti-viral effect Effects 0.000 title claims description 16
- 238000000034 method Methods 0.000 title abstract description 76
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical class C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 280
- 230000009385 viral infection Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 208000036142 Viral infection Diseases 0.000 claims abstract description 6
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- -1 heterocyclic radical Chemical class 0.000 claims description 184
- 125000003118 aryl group Chemical group 0.000 claims description 146
- 229910052739 hydrogen Inorganic materials 0.000 claims description 94
- 239000001257 hydrogen Substances 0.000 claims description 89
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 74
- 150000002431 hydrogen Chemical class 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical class 0.000 claims description 50
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 37
- 150000003254 radicals Chemical class 0.000 claims description 36
- 125000005110 aryl thio group Chemical group 0.000 claims description 32
- 125000004104 aryloxy group Chemical group 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000000539 amino acid group Chemical group 0.000 claims description 30
- 241000711549 Hepacivirus C Species 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims description 17
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000005362 aryl sulfone group Chemical group 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 150000003457 sulfones Chemical class 0.000 claims description 12
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 11
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 10
- 229920002477 rna polymer Polymers 0.000 claims description 9
- 150000003462 sulfoxides Chemical class 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 241000710781 Flaviviridae Species 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical group [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 3
- 241000709687 Coxsackievirus Species 0.000 claims description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229940100050 virazole Drugs 0.000 claims description 3
- GSFNQBFZFXUTBN-UHFFFAOYSA-N 2-chlorothiophene Chemical compound ClC1=CC=CS1 GSFNQBFZFXUTBN-UHFFFAOYSA-N 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 57
- 239000000651 prodrug Substances 0.000 abstract description 14
- 229940002612 prodrug Drugs 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 239000002585 base Substances 0.000 description 62
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- 239000000243 solution Substances 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 239000000047 product Substances 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- 239000000463 material Substances 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 239000002253 acid Substances 0.000 description 28
- 239000003153 chemical reaction reagent Substances 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 239000000126 substance Substances 0.000 description 25
- 239000007787 solid Substances 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 21
- 150000001721 carbon Chemical group 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 16
- 238000001953 recrystallisation Methods 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 15
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- 230000002163 immunogen Effects 0.000 description 14
- 239000002207 metabolite Substances 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
- 238000001035 drying Methods 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 229960001866 silicon dioxide Drugs 0.000 description 8
- 125000002769 thiazolinyl group Chemical group 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 241000710778 Pestivirus Species 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 230000012447 hatching Effects 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- RKIOBDYNFLHVQZ-UHFFFAOYSA-N 3-benzyl-1h-pyridin-2-one Chemical class OC1=NC=CC=C1CC1=CC=CC=C1 RKIOBDYNFLHVQZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000005526 G1 to G0 transition Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 150000002923 oximes Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- 241000710831 Flavivirus Species 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 239000005864 Sulphur Substances 0.000 description 5
- 230000002152 alkylating effect Effects 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 125000005936 piperidyl group Chemical group 0.000 description 5
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000003222 pyridines Chemical class 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000531123 GB virus C Species 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 229910019093 NaOCl Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000005956 isoquinolyl group Chemical group 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 3
- IWKXBHQELWQLHF-CAPFRKAQSA-N (ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N\O)\C1=CC=CC=C1 IWKXBHQELWQLHF-CAPFRKAQSA-N 0.000 description 3
- MKFCBJOVMMLPRT-UHFFFAOYSA-N 3-(chloromethyl)-1,2-oxazole Chemical compound ClCC=1C=CON=1 MKFCBJOVMMLPRT-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 125000005042 acyloxymethyl group Chemical group 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052728 basic metal Inorganic materials 0.000 description 3
- 150000003818 basic metals Chemical class 0.000 description 3
- 229940073608 benzyl chloride Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229950008161 enviroxime Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 3
- 229960000471 pleconaril Drugs 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000005588 protonation Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- YYXFJSDMOVHLMJ-UHFFFAOYSA-N (4-hydroxyphenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(O)C=C1 YYXFJSDMOVHLMJ-UHFFFAOYSA-N 0.000 description 2
- VTWKXBJHBHYJBI-SOFGYWHQSA-N (ne)-n-benzylidenehydroxylamine Chemical compound O\N=C\C1=CC=CC=C1 VTWKXBJHBHYJBI-SOFGYWHQSA-N 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- LBMKFQMJURUPKC-UHFFFAOYSA-N 1-(chloromethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CCl)C=C1 LBMKFQMJURUPKC-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 2
- DFXVIZQVJLSYOJ-UHFFFAOYSA-N 2-(2-fluorophenyl)-3h-imidazo[4,5-c]pyridine Chemical compound FC1=CC=CC=C1C1=NC2=CC=NC=C2N1 DFXVIZQVJLSYOJ-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- VGJLGPCXUGIXRQ-UHFFFAOYSA-N 3-methylpyridin-4-amine Chemical compound CC1=CN=CC=C1N VGJLGPCXUGIXRQ-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- PNWSHHILERSSLF-UHFFFAOYSA-N 4-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=C1C(O)=O PNWSHHILERSSLF-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 150000003934 aromatic aldehydes Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 125000001743 benzylic group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001722 carbon compounds Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000005232 imidazopyridines Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000007932 molded tablet Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 238000004537 pulping Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical compound [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- KOFNQIAWWVBBJZ-UHFFFAOYSA-N (4-fluoro-2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1O KOFNQIAWWVBBJZ-UHFFFAOYSA-N 0.000 description 1
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- AKQIJUCZWUAMNJ-UHFFFAOYSA-N 1,3-benzoxazole;quinoline Chemical compound C1=CC=C2OC=NC2=C1.N1=CC=CC2=CC=CC=C21 AKQIJUCZWUAMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- JROOBQJYNPTFHN-UHFFFAOYSA-N 1-(2,3-dihydropyrrol-1-yl)piperidine Chemical compound C1=CCCN1N1CCCCC1 JROOBQJYNPTFHN-UHFFFAOYSA-N 0.000 description 1
- XPGHWBDZNQUUQD-UHFFFAOYSA-N 1-(chloromethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CCl)C(F)=C1 XPGHWBDZNQUUQD-UHFFFAOYSA-N 0.000 description 1
- MCHDHQVROPEJJT-UHFFFAOYSA-N 1-(chloromethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CCl)C=C1 MCHDHQVROPEJJT-UHFFFAOYSA-N 0.000 description 1
- VNBFUGOVQMFIRN-UHFFFAOYSA-N 1-chlorobutan-2-ol Chemical compound CCC(O)CCl VNBFUGOVQMFIRN-UHFFFAOYSA-N 0.000 description 1
- YGRSXJJORLXYPT-UHFFFAOYSA-N 1-naphthalen-1-ylisoquinoline Chemical compound C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=NC=CC2=C1 YGRSXJJORLXYPT-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- BUTGVBZBUDLKCM-UHFFFAOYSA-N 1h-benzimidazole;pyridine Chemical class C1=CC=NC=C1.C1=CC=C2NC=NC2=C1 BUTGVBZBUDLKCM-UHFFFAOYSA-N 0.000 description 1
- ARUHZHIPYAOZDW-UHFFFAOYSA-N 1h-indol-3-yl-[3-(2-methylimidazo[4,5-c]pyridine-5-carbonyl)phenyl]methanone Chemical compound C1=CC=C2C(C(=O)C=3C=CC=C(C=3)C(=O)N3C=CC4=NC(=NC4=C3)C)=CNC2=C1 ARUHZHIPYAOZDW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- DGPBVJWCIDNDPN-UHFFFAOYSA-N 2-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=CC=C1C=O DGPBVJWCIDNDPN-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- UNWQNFJBBWXFBG-UHFFFAOYSA-N 2-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(F)=C1 UNWQNFJBBWXFBG-UHFFFAOYSA-N 0.000 description 1
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical group OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- MHNNAWXXUZQSNM-UHFFFAOYSA-N 2-methylbut-1-ene Chemical compound CCC(C)=C MHNNAWXXUZQSNM-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WIKVRBTVPSOQHJ-UHFFFAOYSA-N 2h-1,5,2-dithiazine Chemical compound C1SNC=CS1 WIKVRBTVPSOQHJ-UHFFFAOYSA-N 0.000 description 1
- YTFVRYKNXDADBI-UHFFFAOYSA-N 3,4,5-trimethoxycinnamic acid Chemical compound COC1=CC(C=CC(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-N 0.000 description 1
- FOGYNLXERPKEGN-UHFFFAOYSA-N 3-(2-hydroxy-3-methoxyphenyl)-2-[2-methoxy-4-(3-sulfopropyl)phenoxy]propane-1-sulfonic acid Chemical compound COC1=CC=CC(CC(CS(O)(=O)=O)OC=2C(=CC(CCCS(O)(=O)=O)=CC=2)OC)=C1O FOGYNLXERPKEGN-UHFFFAOYSA-N 0.000 description 1
- JEOLWVGGGFZWHS-UHFFFAOYSA-N 3-(4-chlorophenyl)-1,2-oxazole Chemical compound C1=CC(Cl)=CC=C1C1=NOC=C1 JEOLWVGGGFZWHS-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- BFOWXBARPYDGQE-UHFFFAOYSA-N 3-methyl-5-nitropyridin-4-amine Chemical compound CC1=CN=CC([N+]([O-])=O)=C1N BFOWXBARPYDGQE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- UVGYSEIWAOOIJR-UHFFFAOYSA-N 4-chloro-2-fluorobenzaldehyde Chemical compound FC1=CC(Cl)=CC=C1C=O UVGYSEIWAOOIJR-UHFFFAOYSA-N 0.000 description 1
- UKIZCTHOMJXNIX-UHFFFAOYSA-N 4-chloro-3-nitro-1h-pyridin-2-one Chemical class [O-][N+](=O)C1=C(Cl)C=CNC1=O UKIZCTHOMJXNIX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- VCZNNAKNUVJVGX-UHFFFAOYSA-N 4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1 VCZNNAKNUVJVGX-UHFFFAOYSA-N 0.000 description 1
- QWLHJVDRPZNVBS-UHFFFAOYSA-N 4-phenoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OC1=CC=CC=C1 QWLHJVDRPZNVBS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- NSPBTJFAUPZOHK-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-chlorophenyl)-1,2-oxazole Chemical compound O1C(CCl)=CC(C=2C=CC(Cl)=CC=2)=N1 NSPBTJFAUPZOHK-UHFFFAOYSA-N 0.000 description 1
- QYUZNXRLTSPBAF-UHFFFAOYSA-N 5-(chloromethyl)-3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2-oxazole Chemical class FC(F)(F)C1=CC(F)=CC=C1C1=NOC(CCl)=C1 QYUZNXRLTSPBAF-UHFFFAOYSA-N 0.000 description 1
- WPEXHEMCFFLDLL-UHFFFAOYSA-N 5-[(4-chlorophenyl)methyl]-2-[(4-methylpiperazin-1-yl)methyl]imidazo[4,5-c]pyridine Chemical compound C1CN(C)CCN1CC1=NC2=CN(CC=3C=CC(Cl)=CC=3)C=CC2=N1 WPEXHEMCFFLDLL-UHFFFAOYSA-N 0.000 description 1
- JCRXLECODBLBHU-UHFFFAOYSA-N 5-benzyl-2-phenylimidazo[4,5-c]pyridine Chemical compound C1=CC2=NC(C=3C=CC=CC=3)=NC2=CN1CC1=CC=CC=C1 JCRXLECODBLBHU-UHFFFAOYSA-N 0.000 description 1
- ATXLHMZMMKUPNH-UHFFFAOYSA-N 5-benzylimidazo[4,5-c]pyridine Chemical compound C1=CC2=NC=NC2=CN1CC1=CC=CC=C1 ATXLHMZMMKUPNH-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- VWYFITBWBRVBSW-UHFFFAOYSA-N 5-chlorothiophene-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)S1 VWYFITBWBRVBSW-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- BMZKZBWPMWEQAY-UHFFFAOYSA-N 6h-1,2,5-thiadiazine Chemical compound C1SN=CC=N1 BMZKZBWPMWEQAY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001118702 Border disease virus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IBRXROHRCHGDLI-UHFFFAOYSA-N C1(=CC=C(C=C1)C=O)C1=CC=CC=C1.C=O Chemical compound C1(=CC=C(C=C1)C=O)C1=CC=CC=C1.C=O IBRXROHRCHGDLI-UHFFFAOYSA-N 0.000 description 1
- CVTLTNCSGWIAHA-UHFFFAOYSA-N C1(=CC=CC=C1)C=1NC=CC1.CC1=C(C(=O)O)C=CC=C1C(=O)O Chemical compound C1(=CC=CC=C1)C=1NC=CC1.CC1=C(C(=O)O)C=CC=C1C(=O)O CVTLTNCSGWIAHA-UHFFFAOYSA-N 0.000 description 1
- YODQPFRVSXMVAP-UHFFFAOYSA-N C=O.C1(=CC=CC=C1)OCCCC Chemical compound C=O.C1(=CC=CC=C1)OCCCC YODQPFRVSXMVAP-UHFFFAOYSA-N 0.000 description 1
- AGKMHOHFNGVNTI-UHFFFAOYSA-N CC1=NOC=C1.C1(=CC=CC=C1)Cl Chemical compound CC1=NOC=C1.C1(=CC=CC=C1)Cl AGKMHOHFNGVNTI-UHFFFAOYSA-N 0.000 description 1
- TYOAYLVUTSWKHK-UHFFFAOYSA-M COOO[Re] Chemical compound COOO[Re] TYOAYLVUTSWKHK-UHFFFAOYSA-M 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 206010014978 Epidemic pleurodynia Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 201000006219 Herpangina Diseases 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- LFWPBQPULNEDSY-UHFFFAOYSA-N OC1=CC(=C(C=C1)OB(O)O)C Chemical compound OC1=CC(=C(C=C1)OB(O)O)C LFWPBQPULNEDSY-UHFFFAOYSA-N 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101100055332 Pseudomonas oleovorans alkN gene Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- MHKOVSRFDDLIFU-UHFFFAOYSA-N [4-hydroxy-2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1C(F)(F)F MHKOVSRFDDLIFU-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- FXGZWIYYEDRRDP-UHFFFAOYSA-N [O].C(CCC)C=1C(=C(C=CC1)CCCC)CCCC Chemical compound [O].C(CCC)C=1C(=C(C=CC1)CCCC)CCCC FXGZWIYYEDRRDP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
- 229960004012 amifampridine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000676 anti-immunogenic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- XXRGLCKZBCIEKO-DLMDZQPMSA-N azocine Chemical compound C/1=C/C=C\N=C/C=C\1 XXRGLCKZBCIEKO-DLMDZQPMSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical class [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- VZSXFJPZOCRDPW-UHFFFAOYSA-N carbanide;trioxorhenium Chemical compound [CH3-].O=[Re](=O)=O VZSXFJPZOCRDPW-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000001023 centrifugal evaporation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- UEDPOKRSAJZANL-UHFFFAOYSA-N cumene formaldehyde Chemical compound C=O.C(C)(C)C1=CC=CC=C1 UEDPOKRSAJZANL-UHFFFAOYSA-N 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- WAXSUAIGRGARIT-UHFFFAOYSA-N cycloheptyne Chemical compound C1CCC#CCC1 WAXSUAIGRGARIT-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940089256 fungistat Drugs 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ASKSDLRLUXEOOR-SUFRFZPQSA-N gbv-c Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC(C)C)=CNC2=C1 ASKSDLRLUXEOOR-SUFRFZPQSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229910000765 intermetallic Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- SFJSKDLRXSUQQZ-UHFFFAOYSA-N molecular hydrogen pyridine Chemical compound [H][H].c1ccncc1 SFJSKDLRXSUQQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- DNYZBFWKVMKMRM-UHFFFAOYSA-N n-benzhydrylidenehydroxylamine Chemical compound C=1C=CC=CC=1C(=NO)C1=CC=CC=C1 DNYZBFWKVMKMRM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 201000006995 paralytic poliomyelitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 125000004932 phenoxathinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical class OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000005000 thioaryl group Chemical group 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.
Description
The application is to be the dividing an application of female case of the method that December 21, application number in 2004 are 200480038144.0, denomination of invention is imidazo [4,5-c] pyridine compounds and antiviral therapy the applying date.
Invention field
The present invention relates to the imidazo [4 of a series of novelties, 5-c] pyridine compounds, their preparation method, their purposes and their purposes in the medicine of preparation treatment or prophylaxis of viral infections in treatment or prophylaxis of viral infections, infection in particular for the virus of flaviviridae and pico+ribonucleic acid+virus section causes more preferably is used for the infection that is caused by hepatitis C virus (HCV).
Background of invention
Flaviviridae is made up of 3 genus: pestivirus, arboviruses belong to and Hepacivirus, and still the hepatitis G virus of uncertain genus (HGV/GBV-C) is also contained in wherein.Pestivirus, for example classical Pig Fever virus (CSFV), bovine viral diarrhea virus (BVDV) and edge disease virus (Border Disease Virus, BDV) can cause the infection of domestic animal (being respectively pig, ox and sheep), and cause worldwide a large amount of financial loss.BVDV is the prototype representative of pestivirus, its ubiquity also causes the clinical manifestation of certain limit, comprise: miscarriage, teratogeny, breathing problem, chronic wasting disease, immunity system function hinder and are subject to secondary virus and infectation of bacteria, also can cause the acute fatal disease.The tire ox can be by the BVDV persistent infection, and these animals all can continue to carry virus (remain viremic) all the life, and become lasting virus disseminating source in herd.
Use vaccine successfully to control the plague virus disease to some extent in some countries.In other countries, the method control plague virus illness outbreak that adopts animal to reject and butcher.
Estimate 1,700,000,000 people (account for world population 3%) are arranged in the world wide by the HCV chronic infection according to the World Health Organization.These chronic carrier have the danger that develops into liver cirrhosis and/or liver cancer.In the follow-up investigation of 10-20, the patient of 20-30% develops into liver cirrhosis, and the 1-5% among them can develop into liver cancer between the several years subsequently.It is to use interferon (or form of its PEGization) separately or with itself and virazole coupling that the treatment that only can adopt is at present selected.Yet, only in about 40% patient, observes and continue to reply, and treatment is with severe side effect.Therefore, press for the potent and selective depressant that HCV duplicates, HCV infects with treatment.In addition, the research of the specific inhibitor that duplicates for HCV be subjected to always can not be in cell culture fluid the obstruction of this fact of (effectively) breeding HCV.Because HCV and pestivirus belong to same Viraceae, and have many similarities (genomic composition, similar gene product and replicative cycle), adopted model and the surrogate of pestivirus as HCV.For example, (HCV) is closely related for BVDV and hepatitis C virus, is used as in the drug development that infects at HCV and substitutes virus.
It is reported compound 3-[((2-dipropyl amino) ethyl) sulphur]-5H-1,2,4-triazine also [5,6-b] indoles can selectivity suppresses the duplicating of BVDV and other pestivirus (Baginski SG etc., Proc.Natl.Acad.Sci.U.S.A.2000 July 5; 97 (14): 7981-6).At present, also there is not to be used to control the treatment plan of the infection that pestivirus causes.
Coxsackie virus belongs to the enterovirus genus of pico+ribonucleic acid+virus section.They cause one group of heterogeneous infection, comprising: herpangina, aseptic meningitis, common cold sample syndrome, non--spinal paralytic poliomyelitis sample syndrome, epidemic pleurodynia (acute, heat generation, be generally epidemic communicable disease), hand-foot-and-mouth syndrome, children and adult's pancreatitis and serious myocarditis.
At present; only to pleconaril (3-13; 5-dimethyl-4-[[3-methyl-5-isoxazolyl] propyl group] phenyl)-5-(Trifluoromethyl-1; 2,4-oxadiazole)) and enviroxime (2-amino-1-(sec.-propyl alkylsulfonyl)-6-benzoglyoxaline phenyl ketoxime) treatment enterovirus infection carried out clinical study.Pleconaril is so-called " viral capsid function-inhibitor "; Enviroxime then can stop formation rna replicon intermediate.Enviroxime only reaches limited clinical and virusology effect in some researchs, and does not have effect in other respects.In some researchs, observed the clinical response of pleconaril, but this compound still fails to obtain the approval of Food and Drug Administration's (hearing on March 18th, 2002).
Relevant announcement comprises: United States Patent (USP) 4,914,108; 4,988,707; 4,990,518; 5,137,896; 5,208,242; 5,227,384; 5,302,601; 5,374,638; 5,405,964; 5,438,063; 5,486,525; 6,479,508; With U.S. Patent Publication No. US 2003/0108862A1, Canadian Patent 2423800A1, German Patent 4211474A1,4236026,4309969,4318813, European patent EP 0138552A2, EP0706795A2, EP 1132381A1, English Patent 2158440A, PCT patent publication No. WO 00/20416, WO 00/39127, WO 00/40583, WO 03/007945A1, WO 03/010140A2, WO 03/010141A2, WO 93/02080, WO 93/14072, WO 96/11192, WO 96/12703, WO 99/27929; Akamatsu etc., " new effective route of benzimidizole derivatives solid phase synthesis (New Efficient Route forSolid-Phase Synthesis of Benzimidazole Derivatives) ", 4:475-483, J.COMB.CHEM, 2002, Cleve etc., " Derivate des Imidazo[4.5-b]-undlmidazo[4.5-c] pyridins ", 747:158-171, JUSTUS LIEBIGS ANNALEN DERCHEMICA, 1971; Kiyama etc. " novel non-peptide class angiotensin II acceptor antagonist: synthetic and assessment (Synthesis and Evaluation ofNovel Nonpeptide Angiotensin II Receptor Antagonists:Imidazo[4; 5-c] pyridine Derivatives with an Aromatic Substituent) " with imidazo [4; 5-c] pyridine derivate of aromatic substituent, 43 (3): 450-60, CHEM PHARM BULL, 1995; Mederski etc., " the synthetic and structure ownership (Synthesis and Structural Assignment of SomeN-substituted Imidazopyridine Derivatives) of the imidazopyridine derivatives that some N-replace ", 48 (48): 10549-58, TETRAHEDRON, 1992; Yutilov etc., 23 (1): 56-9, KHIMIKO-FARMATSEVTICHESKII ZHURNAL, 1989.This paper is included on the equal expressivity of announcement ground in all quoted passages of herein listing as a reference in, and it can make that with reference to degree these announcements are relevant with the content of this paper.
Existence is for the demand of the compound with antiviral and other desired characteristic (biological example availability, effectiveness, nontoxicity, optimization clearance rate, drug effect etc.).Particularly, need have the active compound of selection in the virus of pico+ribonucleic acid+virus section for having virus (comprise hepatitis C virus) and the family dependents of military personel in the liberated areas of the family dependents of military personel in the liberated areas in flaviviridae.With this specification sheets do as a whole consider after, these and other objects of the present invention are conspicuous for those skilled in the art.
Summary of the invention
Compound with general formula (A) is provided in an embodiment of the invention, and salt, tautomer, isomers and solvate,
In the formula:
It is to be adjacent to each other that two keys that dotted line representative is optional, prerequisite do not have two two keys, and dotted line to have represented at least 3, chosen wantonly be two keys of 4;
R
1Be selected from: hydrogen, aryl, heterocyclic radical, C
1-C
10Alkoxyl group, C
1-C
10Alkylthio (thioalkyl), C
1-C
10Alkyl-amino, C
1-C
10Dialkyl-7-amino, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group and C
4-10Cycloalkynyl radical, wherein, they are separately randomly by one or more R
6Replace;
Y is selected from: singly-bound, O, S (O) m, NR
11Or C
1-10Alkylidene group, C
2-10Alkenylene, C
2-10Alkynylene, wherein, each group can randomly comprise 1-3 heteroatoms that is selected from O, S or N;
R
2And R
4Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio (alkylthio), halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio (arylthio), arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy (cycloalkyloxy), C
3-10Cycloalkyl sulfenyl (cycloalkylthio), C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical, prerequisite is for working as R
25Or R
26One of when existing, R
2Or R
4Be selected from: (=O), (=S) and=NR
27
X is selected from: C
1-C
10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene, wherein, each group can comprise the heteroatoms of one or more O of being selected from, S, N, prerequisite be any this kind heteroatoms not with the ring in the N adjacency;
M is any integer of 0-2;
R
3Be selected from: aryl, aryloxy, arylthio, cycloalkyl, cycloalkenyl group, cycloalkynyl radical, aryl-N (R
10)-or heterocyclic radical, wherein, each described substituting group can be randomly by at least one R
17Replace, prerequisite is for cycloalkenyl group, its pair key not with nitrogen adjacency, and R
3-M-Q is not an xenyl;
R
5Be selected from: hydrogen; C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=O) OR
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical;
R
6Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, C
1-18Alkyl sulfoxide, C
1-18Alkyl sulfone, C
1-18Halo-alkyl, C
2-18Halo-thiazolinyl, C
2-18Halo-alkynyl, C
1-18Halo-alkoxyl group, C
1-18Halo-alkylthio, C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, OH, CN, cyano group alkyl ,-CO
2R
18, NO
2,-NR
7R
8, C
1-18Haloalkyl, C (=O) R
18, C (=S) R
18, SH, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, aryl (C
1-18) alkyl, aryl (C
1-18) alkoxyl group, aryl (C
1-18) alkylthio, heterocyclic radical, C
1-18Hydroxyalkyl, wherein, each group can be randomly by at least one R
19Replace;
R
7And R
8Be independently selected from: hydrogen, C
1-18Alkyl, C
1-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, heterocyclic radical ,-C (=O) R
12-C (=S) R
12, the amino-acid residue that connects by amino acid whose carboxyl, or R wherein
7And R
8Form heterocyclic radical with nitrogen;
R
9And R
18Be independently selected from: hydrogen, OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
1-18Alkoxyl group ,-NR
15R
16, aryl, by this amino acid whose amino amino-acid residue, CH that connects
2OCH (=O) R
9aOr CH
2OC (=O) OR
9a, wherein, R
9aBe C
1-C
12Alkyl, C
6-C
20Aryl, C
6-C
20Alkylaryl or C
6-C
20Aralkyl;
R
10And R
11Be independently selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, aryl ,-C (=O) R
12, heterocyclic radical or amino-acid residue;
R
12Be selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
13And R
14Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12,-C (=S) R
12Or amino-acid residue;
R
15And R
16Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-0Cycloalkenyl group or amino-acid residue;
R
17Be M-Q-independently, wherein, M is for randomly by one or more R
19The ring that replaces, and Q is key or M is connected to R
3Linking group, described linking group comprises 1-10 atom and randomly by one or more R
19Replace;
R
19Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
2-18Alkene oxygen base, C
2-18Alkynyloxy group, C
1-18Alkylthio, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
4-10Cycloalkynyl radical, halogen ,-OH ,-CN, cyano group alkyl ,-NO
2,-NR
20R
21, C
1-18Haloalkyl, C
1-18Halogenated alkoxy ,-C (=O) R
18,-C (=O) OR
18, O thiazolinyl C (=O) OR
18,-O alkyl C (=O) NR
20R
21,-O alkyl OC (=O) R
18,-C (=S) R
18, SH ,-C (=O) N (C
1-6Alkyl) ,-(O) (C of N (H) S (O)
1-6Alkyl), aryl, heterocyclic radical, C
1-18Alkyl sulfone, aryl sulfoxide, aryl sulfonamide, aryl (C
1-18) alkoxyl group, aryloxy, aryl (C
1-8Alkyl) oxygen base, arylthio, aryl (C
1-18) alkylthio or aryl (C
1-18) alkyl, wherein, each group can randomly be replaced by one or more groups that are selected from down group :=O ,-NR
20R
21, CN, C
1-18Alkoxyl group, heterocyclic radical, C
1-18Haloalkyl, heterocyclic radical alkyl, by alkyl, alkoxyl group alkoxy or halogen and R
17The heterocyclic radical that connects;
R
20And R
21Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12Or-C (=S) R
12
R
22Be selected from: hydrogen ,-OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
1-18Alkoxyl group ,-NR
23R
24, aryl, C
3-10Cycloalkyl and C
4-10Cycloalkenyl group;
R
23And R
24Be independently selected from: hydrogen, C
1-18Alkyl or by R
22N and C
2-3The heterocyclic radical that alkyl forms together, this heterocyclic radical randomly replace by OH, aryl or by the amino-acid residue that amino acid whose carboxyl connects;
R
25And R
26Do not exist or be independently selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, aryl, heterocyclic radical, wherein, each group can be chosen wantonly independently and be replaced by 1-4 group that is selected from down group: C
1-6Alkyl, C
1-6Alkoxyl group, halogen, CH
2OH, benzyloxy and OH; And
R
27Be selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, (C
3-10Cycloalkyl)-C
1-6Alkyl, aryl and aryl C
1-18Alkyl.
Compound with general formula (A) is provided in another embodiment of the present invention, and salt, tautomer, isomers and solvate,
In the formula:
It is to be adjacent to each other that two keys that dotted line representative is optional, prerequisite do not have two two keys, and this at least 3 of dotted line representative, to choose wantonly be two keys of 4;
R
1Be selected from: hydrogen, aryl, heterocyclic radical, C
1-C
10Alkoxyl group, C
1-C
10Alkylthio (thioalkyl), C
1-C
10Alkyl-amino, C
1-C
10Dialkyl-7-amino, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group and C
4-10Cycloalkynyl radical, wherein, each group is randomly by one or more R
6Replace;
Y is selected from: singly-bound, O, S (O) m, NR
11, or C
1-10Alkylidene group, C
2-10Alkenylene, C
2-10Alkynylene, wherein, each group can randomly comprise 1-3 heteroatoms that is selected from O, S or N;
R
2And R
4Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical, prerequisite is for working as R
25Or R
26One of when existing, R then
2Or R
4Be selected from: (=O), (=S) and=NR
27
X is selected from: C
1-C
10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene, wherein, each group can comprise the heteroatoms of one or more O of being selected from, S, N, prerequisite be any this kind heteroatoms not with the ring in the N adjacency;
M is any integer of 0-2;
R
3Be randomly by at least one R
17The heterocyclic radical that replaces, however prerequisite is randomly by at least one R
17The R that replaces
3Be not pyridyl or 5-chlorothiophene base, and prerequisite is R
3-MQ is not an xenyl;
R
5Be selected from: hydrogen; C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=O) OR
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical;
R
6Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, heterocyclic radical, C
1-18Alkoxyl group, C
1-18Alkylthio, C
1-18Alkyl sulfoxide, C
1-18Alkyl sulfone, C
1-18Halo-alkyl, C
2-18Halo-thiazolinyl, C
2-18Halo-alkynyl, C
1-18Halo-alkoxyl group, C
1-18Halo-alkylthio, C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, OH, CN, cyano group alkyl ,-CO
2R
18, NO
2,-NR
7R
8, C
1-18Haloalkyl, C (=O) R
18, C (=S) R
18, SH, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, aryl (C
1-18) alkyl, aryl (C
1-18) alkoxyl group, aryl (C
1-18) alkylthio, C
1-18Hydroxyalkyl, wherein, each group can be randomly by at least one R
19Replace;
R
7And R
8Be independently selected from: hydrogen, C
1-18Alkyl, C
1-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, heterocyclic radical ,-C (=O) R
12-C (=S) R
12, the amino-acid residue that connects by the amino acid carboxyl, or R wherein
7And R
8Form heterocyclic radical with nitrogen;
R
9And R
18Be independently selected from: hydrogen, OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
1-18Alkoxyl group ,-NR
15R
16, aryl, by this amino acid whose amino amino-acid residue, CH that connects
2OCH (=O) R
9aOr CH
2OC (=O) OR
9a, wherein, R
9aBe C
1-C
12Alkyl, C
6-C
20Aryl, C
6-C
20Alkylaryl or C
6-C
20Aralkyl;
R
10And R
11Be independently selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, aryl ,-C (=O) R
12, heterocyclic radical or amino-acid residue;
R
12Be selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
13And R
14Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12,-C (=S) R
12Or amino-acid residue;
R
15And R
16Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
17Be independently selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, C
1-18Alkyl sulfoxide, C
1-18Alkyl sulfone, C
1-18Haloalkyl, C
2-18Haloalkenyl group, C
2-18Halo alkynyl, C
1-18Halogenated alkoxy, C
1-18Halogenated alkylthio, C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, OH, CN, CO
2H, CO
2R
18, NO
2, NR
7R
8, haloalkyl, C (=O) R
18, C (=S) R
18, SH, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, arylalkyl, alkoxy aryl, alkylthio-aryl, heterocyclic radical, C
1-18Hydroxyalkyl, wherein, each described aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, arylalkyl, alkoxy aryl, alkylthio-aryl, heterocyclic radical or C
1-18Hydroxyalkyl is randomly by one or more R
19Replace;
R
19Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
2-18Alkene oxygen base, C
2-18Alkynyloxy group, C
1-18Alkylthio, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
4-10Cycloalkynyl radical, halogen ,-OH ,-CN, cyano group alkyl ,-NO
2,-NR
20R
21, C
1-18Haloalkyl, C
1-18Halogenated alkoxy ,-C (=O) R
18,-C (=O) OR
18,-O thiazolinyl C (=O) OR
18,-O alkyl C (=O) NR
20R
21,-O alkyl OC (=O) R
18,-C (=S) R
18, SH ,-C (=O) N (C
1-6Alkyl) ,-(O) (C of N (H) S (O)
1-6Alkyl), aryl, heterocyclic radical, C
1-18Alkyl sulfone, aryl sulfoxide, aryl sulfonamide, aryl (C
1-18) alkoxyl group, aryloxy, aryl (C
1-8Alkyl) oxygen base, arylthio, aryl (C
1-18) alkylthio or aryl (C
1-18) alkyl, wherein, each group can randomly be replaced by one or more groups that are selected from down group :=O ,-NR
20R
21, CN, C
1-18Alkoxyl group, heterocyclic radical, C
1-18Haloalkyl, heterocyclic radical alkyl, by alkyl, alkoxyl group alkoxy or halogen and R
17The heterocyclic radical that connects;
R
20And R
21Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12, the heterocyclic radical that replaces of carboxyl ester or-C (=S) R
12
R
22Be selected from: hydrogen ,-OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
1-18Alkoxyl group ,-NR
23R
24, aryl, C
3-10Cycloalkyl and C
4-10Cycloalkenyl group;
R
23And R
24Be independently selected from: hydrogen, C
1-18Alkyl or by R
22N and C
2-3The heterocyclic radical that alkyl forms together, this heterocyclic radical randomly replace by OH, aryl or by the amino-acid residue that amino acid whose carboxyl connects;
R
25And R
26Do not exist or be independently selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, aryl, heterocyclic radical, wherein, each group can be chosen wantonly independently and be replaced by 1-4 group that is selected from down group: C
1-6Alkyl, C
1-6Alkoxyl group, halogen, CH
2OH, benzyloxy and OH; And
R
27Be selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, (C
3-10Cycloalkyl)-C
1-6Alkyl, aryl and aryl C
1-18Alkyl.
Compound with general formula (A) is provided in an embodiment of the invention, and salt, tautomer, isomers and solvate,
In the formula:
It is to be adjacent to each other that two keys that dotted line representative is optional, prerequisite do not have two two keys, and this at least 3 of dotted line representative, to choose wantonly be two keys of 4;
R
1Be selected from: hydrogen, aryl, heterocyclic radical, C
1-C
10Alkoxyl group, C
1-C
10Alkylthio, C
1-C
10Alkyl-amino, C
1-C
10Dialkyl-7-amino, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group and C
4-10Cycloalkynyl radical, wherein, each group is randomly by one or more R
6Replace;
Y is selected from: singly-bound, O, S (O) m, NR
11Or C
1-10Alkylidene group, C
2-10Alkenylene, C
2-10Alkynylene, wherein, each group can randomly comprise 1-3 heteroatoms that is selected from O, S or N;
R
2And R
4Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical, prerequisite is for working as R
25Or R
26One of when existing, R
2Or R
4Be selected from: (=O), (=S) and=NR
27
X is selected from: C
1-C
10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene, wherein, each group can comprise the heteroatoms of one or more O of being selected from, S, N, prerequisite be any this kind heteroatoms not with the ring in the N adjacency;
M is any integer of 0-2;
R
3Be randomly by at least one R
17The heterocyclic radical that replaces, prerequisite is R
3-M-Q is not an xenyl;
R
5Be selected from: hydrogen; C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH, CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=O) OR
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical;
R
6Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, C
1-18Alkyl sulfoxide, C
1-18Alkyl sulfone, C
1-18Halo-alkyl, C
2-18Halo-thiazolinyl, C
2-18Halo-alkynyl, C
1-18Halo-alkoxyl group, C
1-18Halo-alkylthio, C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, OH, CN, cyano group alkyl ,-CO
2R
18, NO
2,-NR
7R
8, C
1-18Haloalkyl, C (=O) R
18, C (=S) R
18, SH, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, aryl (C
1-18) alkyl, aryl (C
1-18) alkoxyl group, aryl (C
1-18) alkylthio, heterocyclic radical, C
1-18Hydroxyalkyl, wherein, each group can be randomly by at least one R
19Replace;
R
7And R
8Be independently selected from: hydrogen, C
1-18Alkyl, C
1-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, heterocyclic radical, C (=O) R
12-C (=S) R
12, the amino-acid residue that connects by its carboxyl, or R wherein
7And R
8Form heterocyclic radical with nitrogen;
R
9And R
18Be independently selected from: hydrogen, OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
1-18Alkoxyl group ,-NR
15R
16, aryl, by this amino acid whose amino amino-acid residue, CH that connects
2OCH (=O) R
9aOr CH
2OC (=O) OR
9a, wherein, R
9aBe C
1-C
12Alkyl, C
6-C
20Aryl, C
6-C
20Alkylaryl or C
6-C
20Aralkyl;
R
10And R
11Be independently selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, aryl ,-C (=O) R
12, heterocyclic radical or amino-acid residue;
R
12Be selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
13And R
14Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12,-C (=S) R
12Or amino-acid residue;
R
15And R
16Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
17Be M-Q-, wherein M is for randomly by one or more R
19The C that replaces
3-10Cycloalkyl, and Q is a key or randomly by one or more R
19The C that replaces
1-10Alkyl;
R
19Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
2-18Alkene oxygen base, C
2-18Alkynyloxy group, C
1-18Alkylthio, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
4-10Cycloalkynyl radical, halogen ,-OH ,-CN, cyano group alkyl ,-NO
2,-NR
20R
21, C
1-18Haloalkyl, C
1-18Halogenated alkoxy ,-C (=O) R
18,-C (=O) OR
18,-O thiazolinyl C (=O) OR
18,-O alkyl C (=O) NR
20R
21,-O alkyl OC (=O) R
18,-C (=S) R
18, SH ,-C (=O) N (C
1-6Alkyl) ,-(O) (C of N (H) S (O)
1-6Alkyl), aryl, heterocyclic radical, C
1-18Alkyl sulfone, aryl sulfoxide, aryl sulfonamide, aryl (C
1-18) alkoxyl group, aryloxy, aryl (C
1-8Alkyl) oxygen base, arylthio, aryl (C
1-18) alkylthio or aryl (C
1-18) alkyl, wherein, each group can randomly be replaced by one or more groups that are selected from down group :=O, NR
20R
21, CN, C
1-18Alkoxyl group, heterocyclic radical, C
1-18Haloalkyl, heterocyclic radical alkyl, by alkyl, alkoxyl group alkoxy or halogen and R
17The heterocyclic radical that connects;
R
20And R
21Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12Or-C (=S) R
12
R
22Be selected from: hydrogen ,-OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
1-18Alkoxyl group ,-NR
23R
24, aryl, C
3-10Cycloalkyl and C
4-10Cycloalkenyl group;
R
23And R
24Be independently selected from: hydrogen, C
1-18Alkyl or by R
22N and C
2-3The heterocyclic radical that alkyl forms together, this heterocyclic radical randomly replace by OH, aryl or by the amino-acid residue that amino acid whose carboxyl connects;
R
25And R
26Do not exist or be independently selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, aryl, heterocyclic radical, wherein, each group can be chosen wantonly independently and be replaced by 1-4 group that is selected from down group: C
1-6Alkyl, C
1-6Alkoxyl group, halogen, CH
2OH, benzyloxy and OH; And
R
27Be selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, (C
3-10Cycloalkyl)-C
1-6Alkyl, aryl and aryl C
1-18Alkyl.
Compound with formula (B) is provided in another embodiment of the present invention,
In the formula:
It is to be adjacent to each other that the optional two keys of dotted line representative, prerequisite do not have two two keys, and dotted line is represented two keys of at least 3, optional 4; R
1, R
2, R
3, R
4, R
5, R
25, R
26, X and Y as mentioned above.
Formula (B) compound is provided in an embodiment of the invention, and wherein, Y is singly-bound and R
1Be aryl.
Formula (B) compound is provided in another embodiment of the present invention, and wherein, X is C
1-C
10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene.
Formula (B) compound is provided in another embodiment of the present invention, wherein, R
3Be heterocyclic radical.
Formula (B) compound is provided in another embodiment of the present invention, wherein, R
3For by R
17The heterocyclic radical that replaces, R
17In Q be that key and M are aryl.
Formula (B) compound is provided in another embodiment of the present invention, and wherein, Y is singly-bound and R
1Be phenyl.
Formula (B) compound is provided in another embodiment of the present invention, wherein, R
3For by R
17Replace the De isoxazole, R
17In Q be that key and M are aryl.
Formula (B) compound is provided in another embodiment of the present invention, wherein, R
3For by R
17Replace the De isoxazole, R
17In Q be that key and M are phenyl.
Formula (C) compound is provided in another embodiment of the present invention,
In the formula, R
1, R
2, R
3, R
4, R
5, R
25, R
26, X and Y as mentioned above.
Formula (C) compound is provided in an embodiment of the invention, and wherein, Y is a singly-bound, and R
1Be aryl.
Formula (C) compound is provided in another embodiment of the present invention, and wherein, X is C
1-C
10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene.
Formula (C) compound is provided in another embodiment of the present invention, wherein, R
3Be heterocyclic radical.
Formula (C) compound is provided in another embodiment of the present invention, wherein, R
3For by R
17The heterocyclic radical that replaces, R
17In Q be that key and M are aryl.
Formula (C) compound is provided in another embodiment of the present invention, and wherein, Y is a singly-bound, and R
1Be phenyl.
Formula (C) compound is provided in another embodiment of the present invention, wherein, R
3For by R
17Replace the De isoxazole, R
17In Q be that key and M are aryl.
Formula (C) compound is provided in another embodiment of the present invention, wherein, for by R
17Replace the De isoxazole, R
17In Q be that key and M are phenyl.
Formula (A) compound can be randomly with pharmacology on acceptable excipient composition.
Formula (A) compound is needed the object (human or animal) of antiviral therapy with the treatment significant quantity, be specially and be used to suppress flavivirus and pico+ribonucleic acid+virus, the especially infection of BVDV, HCV and Coxsackie virus, grow and duplicate.
The invention still further relates to a kind of method of screening antiviral compound, described method comprises the antiviral activity that formula (A) compound is provided and measures described compound.
The meta-bolites that also comprises formula (A) compound in the scope of the present invention, this metabolite are to obtain by the method that gives object with formula (A) compound and reclaim meta-bolites from described object.
The present invention also comprises a kind of structure-active method that is used for mensuration formula (A) compound analogue,
Substituting group wherein is definition to some extent in WO 2004/005286, and described method comprises:
(A) preparation has formula (A) compound that a substituting group does not disclose at least in WO 2004/005286; With
(B) the whose anti-HCV activity of determination step (a) compound.
Detailed Description Of The Invention
" alkyl " is meant saturated hydrocarbyl portion, and that this part can be is acyclic, the combination of cyclic or non-annularity and circular part.Described non-annularity part can comprise 1-3 carbon atom, and each ring can comprise 3-6 carbon atom (for example, 3-methylcyclohexyl).In this definition, term " cycloalkyl " is meant cyclic saturated hydrocarbyl part.The example of " alkyl " comprising: methyl, ethyl, the 1-propyl group, the 2-propyl group, the 1-butyl, 2-methyl isophthalic acid-propyl group (isobutyl-), 2-butyl (sec-butyl) 2-methyl-2-propyl group (tertiary butyl), 1-amyl group (n-pentyl), the 2-amyl group, the 3-amyl group, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl isophthalic acid-butyl, the 2-methyl-1-butene base, the 1-hexyl, the 2-hexyl, the 3-hexyl, 2-methyl-2-amyl group, 3-methyl-2-amyl group, 4-methyl-2-amyl group, 3-methyl-3-amyl group, 2-methyl-3-amyl group, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, suberyl, encircle octyl group etc., or have the C of 7-10 carbon atom
7-10The polycyclic saturated hydrocarbon base, for example: norborneol alkyl, fenchyl, trimethylammonium three suberyl or adamantyl.
" thiazolinyl " is meant that at least one position is the hydrocarbyl portion of unsaturated double-bond, and wherein, that this part can be is acyclic, the combination of cyclic or non-annularity and circular part.Described non-annularity part can comprise 1-3 carbon atom, and each circular part can comprise 3-6 carbon atom.The position of unsaturated double-bond can be in non-annularity part, circular part.In the part of combination, in each several part, all can contain the position of unsaturated double-bond with non-annularity and circular part.In this definition, term " cycloalkenyl group " is meant the hydrocarbyl portion of cyclic unsaturated double-bond.The example of term " thiazolinyl " includes but not limited to: vinyl (CH=CH
2), allyl group (CH
2CH=CH
2), cyclopentenyl (C
5H
7), 5-hexenyl (CH
2CH
2CH
2CH
2CH=CH
2), 1-ring penta-1-thiazolinyl, 1-ring penta-2-thiazolinyl, 1-ring penta-3-thiazolinyl, 1-hexamethylene-1-thiazolinyl, 1-hexamethylene-2-thiazolinyl and 1-hexamethylene-3-thiazolinyl.Two keys can randomly be cis or transconfiguration.
" alkynyl " is meant that at least one position is unsaturated triple-linked hydrocarbyl portion, and wherein, that this part can be is acyclic, the combination of cyclic or non-annularity and circular part.Described non-annularity part can comprise 1-3 carbon atom, and each circular part can comprise 7 or more a plurality of carbon atom.In this definition, term " cycloalkynyl radical " is meant the unsaturated triple-linked hydrocarbyl portion of cyclic.The example of term " alkynyl " includes but not limited to :-C ≡ CH ,-CH
2C ≡ CH ,-CH
2C ≡ C-cyclohexyl or-CH
2-cycloheptyne base.
The prefix " Asia " that is connected with alkyl, thiazolinyl, alkynyl (being equivalent to the suffix " ene " in the English) is meant that these groups have at least two positions to be substituted.This polyvalent alkyl includes but not limited to: methylene radical (CH
2-), ethylene (CH
2CH
2-), trimethylene (CH
2CH
2CH
2-), tetramethylene (CH
2CH
2CH
2CH
2-), vinylene (CH=CH-) ,-C ≡ C-, inferior proyl (CH
2C ≡ C-) and the inferior pentynyl (CH of 4-
2CH
2CH
2C ≡ CH-).
" aryl " is meant the aryl that contains one or more rings, is generally 1,2 or 3 ring, contains 4-6 carbon atom in each ring, is generally 5-6 carbon atom.
" arylalkyl ", " aryl alkenyl " and " aromatic yl polysulfide yl " are meant alkyl, the alkenyl or alkynyl that hydrogen atom (being generally hydrogen atom on end or the sp3 carbon atom) is replaced by aryl respectively.Typical arylalkyl includes but not limited to: benzyl, 2-diphenylphosphino ethane-1-base, 2-phenyl ethene-1-base, naphthyl methyl, 2-naphthyl ethane-1-base, 2-naphthyl ethene-1-base, naphtho-benzyl, 2-naphtho-diphenylphosphino ethane-1-base etc.
As sugg, carbocyclic ring randomly is monocycle or multi-loop system.Usually, the alkyl of formula (A) compound is monocyclic.The monocycle carbocyclic ring comprises 3-6 annular atoms usually, is more typically to comprise 5 or 6 annular atomses.Two ring carbocyclic rings comprise 7-12 annular atoms usually, for example are arranged as two ring [4,5], [5,5], [5,6] or [6,6] system, or comprise 9 or 10 annular atomses, and they are arranged as two ring [5,6] or [6,6] systems.
If the carbonatoms to alkyl does not specify, then carbonatoms is generally 1-18, except the carbonatoms in the unsaturated alkyl is generally 2-18, and is 6-10 in the aryl.
" heterocyclic radical " or " heterocycle " is meant heteroatomic any 4,5,6,7,8 or 9 yuan monocycle or the condensed ring system that comprises one or more O of being selected from, N or S.Heterocycle is optional to be complete aromaticity, saturated fully or comprise the heterocycle of the unsaturated position of one or more intra-annular (being generally two keys).Multicomponent heterocycle (multiple heterocyclicrings, one or more ring contains heteroatoms) is bridge joint or volution.Usually, heterocycle is an aromaticity, and they are generally monocycle.The heterocyclic example comprises: oxaza alkyl (oxazacyloalkyl), morpholinyl, dioxane alkyl (dioxacycloalkyl), sulfo-cycloalkenyl group (thiacycloalkyl), pyridyl, the dihydropyridine base, tetrahydro pyridyl (piperidyl), thiazolyl, tetrahydrochysene thiophenyl (tetrahydrothiophenyl), furyl, thienyl, pyrryl, pyranyl, pyrazolyl, pyrazolidyl, pyrazolinyl, imidazolyl, tetrazyl, benzofuryl, thianaphthenyl, indyl, indolinyl (indolenyl), quinolyl, isoquinolyl, benzimidazolyl-, piperidyl, piperazinyl, pyrrolidyl, 2-pyrrolidyl (2-pyrrolidonyl), pyrrolinyl, tetrahydrofuran base, two-tetrahydrofuran base, THP trtrahydropyranyl, two-THP trtrahydropyranyl, tetrahydric quinoline group, tetrahydro isoquinolyl, decahydroquinolyl, the octahydro isoquinolyl, the azocine base, triazinyl, 6H-1,2,5-thiadiazine base, 2H, 6H-1,5,2-dithiazine base, thianthrenyl, pyranyl, isobenzofuran-base, benzopyranyl, xanthenyl, phenoxathiin base (phenoxathinyl), the 2H-pyrryl, isothiazolyl, different thiazolidine base (isothiazoledinyl) isoxazolyl oxazolinyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrrolidyl, pyrrolinyl, the indolizine base, pseudoindoyl, the 3H-indyl, the 1H-indazolyl, purine radicals, the 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolyl, the cinnoline base, pteridyl, the 4aH-carbazyl, carbazyl, the β-Ka Lin base, phenanthridinyl, acridyl, pyrimidyl, the phenanthroline base, phenazinyl, phenothiazinyl, furazan base phenoxazinyl, the isochroman base, chromanyl, imidazolidyl, imidazolinyl, pyrazolidyl, pyrazolinyl, piperazinyl, indolinyl, iso-dihydro-indole-group, quinuclidinyl oxazolidinyl, the benzotriazole base, the benzoisoxazole base, oxindole base benzoxazole quinoline base, benzothienyl, benzothiazolyl and isatinoyl.Other suitable heterocycle illustration to some extent in the Nomenclature of Organic Compound (Adv.Chem.Ser.126 (1974) 49-64 pages or leaves) of the Nomenclature ofOrganic Chemistry (Sections A-H (1979) 53-76 pages or leaves) of Rigaudy etc. and Fletcher etc.
Not strict for the position on the heterocycle that provides with The compounds of this invention rest part tie point, but those skilled in the art can identify and has best compound stability and/or be easy to synthetic the position of substitution.The heterocycle that carbon connects is connecting with upper/lower positions usually: 2,3,4,5 or 6 of pyridine; 3,4,5 or 6 of pyridazine; 2,4,5 or 6 of pyrimidine; 2,3,5 or 6 of pyrazine; Furans, tetrahydrofuran (THF), thiophene (thiofuran), thiophene (thiophene), pyrroles or Pyrrolidine 2,3,4 or 5; Oxazole, imidazoles or thiazole 2,4 or 5; Isoxazole, pyrazoles or isothiazole 3,4 or 5; 2 or 3 of aziridine; 2,3 or 4 of azetidine; 2,3,4,5,6,7 or 8 of quinoline; Or 1,3,4,5,6,7 or 8 of isoquinoline 99.9.More generally, the heterocycle of carbon connection comprises: 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 6-pyrimidyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl.
Nitrogen heterocyclic ring connects on nitrogen or carbon, connects on carbon atom usually.These comprise, for example: 1 of aziridine, 1-'-aziridino, 1-azelidinyl, 1-pyrryl, 1-imidazolyl, 1-pyrazolyl, piperidino, 2-pyrroline, 3-pyrroline, 2-tetrahydroglyoxaline, 3-tetrahydroglyoxaline, 9-carbazole, 4-morpholine, 9-α or β-Ka Lin, 2-isoindole, 2-pyrazoline and 3-pyrazoline, and similarly: azetidine, pyrroles, tetramethyleneimine, piperidines, piperazine, indoles, pyrazoline, indoline, imidazoles, imidazolidine, 1H-indazole and isoindoline.Those skilled in the art knows these and other nitrogen heterocyclic ring, and their link position is selectable.
Sulfur heterocyclic ring connects by carbon or sulphur.They comprise oxidation state, for example-S (=O) (=O).Usually, contain N heterocyclic mode and connect to be similar at formula (A) compound.
" alkoxyl group ", " cycloalkyl oxy ", " aryloxy ", " alkoxy aryl ", " oxa-ring ", " alkylthio ", " sulfo-cycloalkyl (thiocycloalkyl) ", " arylthio " and " alkylthio-aryl " are meant that alkyl, cycloalkyl, aryl or arylalkyl pass through singly linked substituting group with Sauerstoffatom or sulphur atom respectively, such as but not limited to: methoxyl group, oxyethyl group, propoxy-, butoxy, thio-ethyl, sulphomethyl, phenoxy group, benzyloxy, sulfydryl phenmethyl etc.
" halogen " is meant any atom that is selected from down group: fluorine, chlorine, bromine and iodine.
Any appointment substituting group of finding in a more than position in the reply The compounds of this invention carries out independent selection.
When a certain group of explanation is replaced by " one or more " other group, typically refer to 1-3 substituting group, be generally 1,2 or 3 substituting group.
Those skilled in the art will be appreciated that also compound of the present invention can exist by multiple different protonation state, and this state depends on their environment pH except other factors.Though the structural formula that this paper provided has only been described a kind of in the multiple possible protonation state of compound, be to be understood that these structures just in order to illustrate, and the present invention being not limited to any concrete protonation state---any and whole protonated form of described compound all falls within the scope of this invention.
Amino acid
" amino acid " refers to be derived from and has chemical formula H
2N-CHR
28The group of the molecule of-COOH, wherein R
28It is side-chain radical with natural existence or known synthesizing amino acid.Described amino acid is randomly had the alkyl replacement of 1-8 carbon usually at its one or more carboxyls or amino place, and with after compound rest part of the present invention is connected, these groups can be positioned on the side chain or free at amino acid.
Randomly, described amino-acid residue is a hydrophobic residue, as single-or two-alkyl or aryl amino acid, cycloalkylamino acid etc.Choose wantonly, this residue does not contain sulfydryl or guanidine radicals substituting group.
Naturally occurring amino-acid residue is present in plant, animal or the microorganism, especially in their protein.Most of polypeptide are made up of such natural amino acid residue usually basically.These amino acid are: glycine, L-Ala, Xie Ansuan, leucine, Isoleucine, Serine, Threonine, halfcystine, methionine(Met), L-glutamic acid, aspartic acid, Methionin, hydroxylysine, arginine, Histidine, phenylalanine, tyrosine, tryptophane, proline(Pro), l-asparagine, glutamine and oxyproline.In addition, also comprise alpha-non-natural amino acid, for example valanine, phenylglycocoll and homoarginine.
Usually, on any position in the parent molecule only one by aminoacid replacement, although introduce amino acid also within the scope of the present invention in permission position more than 1.Usually; amino acid whose alpha-amino group or α-carboxyl are connected to the remainder of molecule; that is, carboxyl in the amino acid side chain or amino generally are not used in parent compound and form amido linkage (although needing these groups are protected) during synthetic binding substancess (conjugate).
Under acid (pH<3) or alkalescence (pH>10) condition, amino acid ester in vivo or external optional be hydrolyzable.Randomly, they are stable basically in people's intestines and stomach, but blood or in intracellular environment by enzymic hydrolysis.
R
28Be C
1-C
6Alkyl or quilt are selected from down the C of the group replacement of group
1-C
6Alkyl: amino, carboxyl, acid amides, carboxyl (and aforesaid ester), hydroxyl, C
6-C
7Aryl, guanidine radicals, imidazolyl, indyl, sulfydryl, sulfoxide and/or alkyl phosphate.R
28Also can be nitrogen, it is with amino acid α-form proline residue.Yet, R
28What be generally above to be disclosed naturally exists amino acid whose side-chain radical, for example: H ,-CH
3,-CH (CH
3)
2,-CH
2-CH (CH
3)
2,-CHCH
3-CH
2-CH
3,-CH
2-C
6H
5,-CH
2CH
2-S-CH
3,-CH
2OH ,-CH (OH)-CH
3,-CH
2-SH ,-CH
2-C
6H
4OH ,-CH
2-CO-NH
2,-CH
2-CH
2-CO-NH
2,-CH
2-COOH ,-CH
2-CH
2-COOH, (CH
2)
4-NH
2With-(CH
2)
3-NH-C (NH
2)-NH
2R
28Also comprise 1-guanidine radicals third-3-base, benzyl, 4-hydroxybenzyl, imidazol-4 yl, indol-3-yl, p-methoxy-phenyl and ethoxyl phenenyl.
Exemplary embodiment
R
1Be generally by 1,2 or 3 R
6The aryl or the aromatic heterocycle that replace, wherein, R
6Be halogen, C
1-C
18Alkoxyl group; Or C
1-C
18Haloalkyl.Usually, R
1Be the phenyl that is replaced by 1,2 or 3 halogen (being generally fluorine).
Y is generally singly-bound, O, C
1-6Alkylidene group, C
2-6Alkenylene, C
2-6Alkynylene, or be selected from O, S or NR for containing 1-3 (being generally 1)
11A heteroatomic above-mentioned group.Example comprises :-O (CH
2)
1-5-,-(CH
2)
1-4-O-(CH
2)
1-4-,-S-(CH
2)
1-5-,-(CH
2)
1-4-S-(CH
2)
1-4-,-NR
11-(CH
2)
1-5-,-(CH
2)
1-4-NR
11-(CH
2)
1-4Or C
3-10Cycloalkylidene (cycloalkylidene).Usually, Y is-OCH
2-,-CH
2O-, C
1-2Alkylidene group, C
2-3Alkenylene, C
2-3Alkynylene, O or key, but be generally a key.
Usually, YR
1Be not H, unsubstituted C
3-10Cycloalkyl or C
1-6Among the alkyl any.Usually, YR is the phenyl (and usually on an ortho position or a position 1 or 2 substituting group arranged) of halogen or halogenated methyl (being generally trihalomethyl group) that replace.
X is generally alkylidene group, alkenylene or alkynylene, is generally alkylidene group, perhaps has heteroatoms in the chain, is generally the described alkyl of O or S.Example comprises :-CH
2-,-CH (CH
3)-,-CH
2-CH
2-,-CH
2-CH
2-CH
2,-CH
2-CH
2-CH
2-CH
2,-(CH
2)
2-4-O-(CH
2)
2-4-,-(CH
2)
2-4-S-(CH
2)
2-4-,-(CH
2)
2-4-NR
10-(CH
2)
2-4-, C
3-10Cycloalkylidene, C
2-6Alkenylene (for example-CH=CH-CH
2-) and C
2-6Alkynylene.Usually, X is a methylene radical.
R
3Be generally aryl or heterocycle, be generally the aromaticity heterocycle.Usually comprise 1,2 or 3 N, S or O atom in this heterocyclic ring, be connected with X by ring carbon atom usually, and contain 4-6 (often being 5) total annular atoms usually.This R
3Aryl or heterocycle are often by 1,2 or 3 (being generally 1) R
17Replace.R
3It randomly is not indyl.
Work as R
3By R
17During replacement, R
17Be generally by one or more (being generally 1,2 or 3) R
19The heterocycle or the aryl that replace.
R in some embodiments of the present invention
17Be M-Q.M is ring.Here be meant any cyclic organic structure, no matter be carbocyclic ring or heterocycle, no matter be saturated, unsaturated or aromaticity or monocycle or condensed ring system.M is selected from constitutionally stable lopps in biosystem.Usually, M is aryl or aromaticity heterocycle, and wherein, heterocycle as defined above.
Q is a spacer groups and optional.Usually it is not a cyclic, and does not cover and comprise maximum 3 atoms (being generally C, O or S, often is C or O).
R
17Usually be selected from down group: C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, arylalkyl; Alkoxy aryl (optional is benzyloxy); Alkylthio-aryl (optional is benzylthio-); Heterocycle; C
1-18Hydroxyalkyl, but be generally aryl or heterocycle, and wherein, each described aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, arylalkyl, alkoxy aryl, alkylthio-aryl or heterocyclic radical are randomly by one or more R
19Replace.R
17Be usually located at the far-end of X.Randomly, R
17Be not C (O) R
18
R
9And R
18Be generally H, OH or alkyl.R
18Optional is not NR
15R
16
R
5Be generally H.
R
6Be generally halogen.Randomly, R
6Be not C (O) R
18
R
7, R
8, R
10, R
11, R
13, R
14, R
15, R
16, R
20, R
21, R
23And R
24Usually be H or C independently
1-18Alkyl.
R
12And R
22Usually be OH or alkyl independently.
R
19Be generally H; C
1-18Alkyl; C
2-18Thiazolinyl; C
2-18Alkynyl; C
1-18Alkoxyl group; Alkene oxygen base; Alkynyloxy group; C
1-18Alkylthio; C
3-10Cycloalkyl; C
4-10Cycloalkenyl group; C
4-10Cycloalkynyl radical; Halogen; OH; CN; The cyano group alkyl, NO
2NR
20R
21Haloalkyl; Halogenated alkoxy; C (=O) R
18C (=O) OR
18O thiazolinyl C (=O) OR
18-O alkyl C (=O) NR
20R
21Aryl; Heterocycle;-O alkyl OC (=O) R
18C (=O) N (C
1-6Alkyl), (O) (C of N (H) S (O)
1-6Alkyl); Alkoxy aryl; Aryloxy; Alkoxy aryl and arylalkyl; They are not substituted separately or are replaced by one or more groups that are selected from down group :=O; NR
20R
21CN; Alkoxyl group; Heterocycle; Haloalkyl-or the heterocycle of alkyl-replacement; Be connected to R by alkyl, alkoxyl group alkoxy or halogen
17Heterocycle.At this as substituent R
18Usually be not H.R
19Usually be halogen, N (R independently
20R
21), the alkyl or the alkoxyl group of alkoxy or halogen-replacement.
R
25With
26Usually do not exist, but if present, be generally cyclopentyl or cyclohexyl.If compound is at R
25Or R
26Be substituted, then R
2Or R
4Be selected from: (=O), (=S) and (=NR
27), be generally=O.
M is generally the ring of aromaticity, is generally monocycle or two condensed rings, and contains 4-10 atom.Usually, M is an alkyl, but also can randomly comprise 1-3 N, O and/or S heteroatoms.
Q is generally hydrocarbon chain, Chang Weizheng or secondary thiazolinyl, and it randomly comprises at least one oxygen or thioesters.Usually Q is a 1-6 atom, often is 1-3.Q is not usually by R
19Replace, if but by R
19Replace, then Q is generally by 1 R
19Replace.Go up substituent R as Q
19Be generally halogen, nitro or cyano group.Substituting group randomly indicates key or does not indicate key.No matter whether indicate key, (bond indication), if substituting group is polyvalent (based on its position in the indication structure), substituting group then any and that all may be orientated all is as expected.
Haloalkyl or halogenated alkoxy are generally-CF
3Or-OCF
3
The invention provides formula (A) compound of following formula structure,
Such as the method (for example the part B in the embodiment part " is used to measure antiviral and method cell growth inhibiting activity ") of being instructed in full with specification sheets mensuration, it has antiviral activity.The preparation of this compound has been stated in religion in specification sheets full text, for example in embodiment 6.
The present invention also provides formula (A) compound of following formula,
Such as the method (for example the part B in the embodiment part " is used to measure antiviral and method cell growth inhibiting activity ") of being instructed in full with specification sheets mensuration, it has antiviral activity.The preparation of this compound has been stated in religion in specification sheets full text, for example in embodiment 8A.
Formula (A) has been described optional singly-bound or two key.Should be understood that these keys exist, thus the aromaticity of the formula of keeping (A) core, and promptly these structural formulas will comprise all possible tautomer.For example, if suc as formula shown in and R
25Or R
26Bonded ring N links to each other with lateral (flanking) ring carbon atom by two keys, then R
25Or R
26To not exist.From another point of view, if suc as formula shown in and R
25Or R
26Bonded N atom only links to each other with lateral carbon atom by singly-bound, then can have R
25Or R
26In this case, regulate aromaticity, for example R wherein by other substituting group
2Or R
4Be oxo.
As used herein, term " prodrug " is meant after giving biosystem, as the result of spontaneous chemical reaction, enzymatic chemical reaction, photolysis and/or metabolic chemical reaction and produce the compound of medicine (being activeconstituents).Therefore, prodrug is the covalent modification analogue or the potential form of therapeutical active compound.
Prodrug
Some compound herein can be as the prodrug effect when being replaced by the suitable functional group (functionality) through selecting.These unsettled functional groups separate from the downtrod compound of activity in cell on systematicness ground in metabolic process, this separation is carried out (Bulldgaard by hydrolysis, enzymatic lysis or by some other method, Hans, " Designand Application of prodrugs " (1991) in Textbook of Drug Design and Development one book, P.Krogsgaard-Larsen and H.Bundgaard compiles.Harwood Academic Publishers, the 113-191 page or leaf).These prodrug moieties can be used for strengthening that solubleness, absorptivity and lipotropy are sent to optimize medicine, bioavailability and drug effect.Therefore, " prodrug " is the covalency improvement analogue of therapeutical active compound.Certainly, prodrug moiety itself can have therapeutic activity.
Exemplary prodrug moiety comprises: the responsive or unsettled carboxylic acid (CO to hydrolysis
2H) ester class (CO
2R ') or have other functional group of the acid proton that is incorporated into imidazo of the present invention [4,5-c] pyridine compounds.This type of R ' group responsive to hydrolysis or unsettled ester class can comprise: (i) acyloxy methyl ester ,-CH
2OC (=O) R
9a(ii) acyloxy methyl carbonic-CH
2OC (=O) OR
9a, wherein, R
9aBe C
1-C
6Alkyl, C
1-C
6The alkyl that replaces, C
6-C
20Aryl or C
6-C
20The aryl that replaces.The prodrug moiety that also can be used as The compounds of this invention near variant of acyloxy alkyl ester, alkoxy-carbonyl oxy alkyl ester (carbonic ether) strengthens oral administration biaavailability.Acyloxy methyl ester R group be exemplified as the pivaloyl group Oxymethoxy, (POM)-CH
2OC (=O) C (CH
3)
3Acyloxy methyl carbonic prodrug moiety be exemplified as pivaloyl group oxygen ylmethyl carbonic ether, (POC)-CH
2OC (=O) OC (CH
3)
3Cleavable (cleavable) part that can be used as prodrug functional group randomly is connected on the compound of the present invention in any open ended site, for example R
3And any substituting group.
The compound of getting rid of
The present invention has got rid of all compounds that clearly disclose (excluded ranges constitutes effective novelty or inventive step/apparent property defective for this reference to the application) (also having got rid of the compound that is disclosed in the patent families in any referenced patent) in any prior art reference from the compound that the application sets forth, and can make the application's claim losing novelty or not creative step or be conspicuous any other compound according to the application law.
As institute's requirement, the present invention has got rid of the compound of following general formula (A):
(a) substituent X, Y, R
1, R
2, R
3, R
4, R
5In arbitrary be cynnematin, or wherein substituent X, Y, R
1, R
2, R
3, R
4, R
5Being the azabicyclo group, more specifically is also [4.2.0] oct-2-ene-8-ketone of 5 thias-1-aza-bicyclo;
(b) this compound is bromination 5-(2-piperidines-1-base-ethyl)-2-(4-hydroxy phenyl)-1H-imidazo [4,5-c] pyridine-5-(X=ethyl, Y=key, R
1The phenyl that=contraposition is replaced by OH, R
2=H, R
3=piperidyl, and R
4, R
5=H) (such as embodiment 52 among the EP 1132381 announcement);
(c) this compound be 4-[5-(2-14-[is two-(4-fluorophenyl)-methyl]-piperazine-1-yl-ethyl)-5H-imidazo [4,5-c] pyridine-2-yl] phenol (X=ethyl, Y=key, R
1The phenyl that=contraposition is replaced by OH, R
2=H, R
3=have 2 heteroatomic heterocycles of N, wherein, an involved CH of N (phenyl)
2Arylalkyl replace, and wherein each phenyl all has F in contraposition) (such as embodiment 54 among the EP 1132381 announcement);
(d) this compound be 4-[5-(3-{4-[is two-(4-fluorophenyl)-methyl]-piperazine-1-yl-propyl group) 5H-imidazo [4,5-c] pyridine-2-yl] phenol (X=butyl, Y=key, R
1The phenyl that=contraposition is replaced by OH, R
2=H, R
3=have 2 heteroatomic heterocycles of N, wherein, an involved CH of N (phenyl)
2Arylalkyl replace, and wherein each phenyl all has F in contraposition) (such as embodiment 55 among the EP 1132381 announcement);
(e) this compound is 5-(phenyl methyl)-5H-imidazo [4,5-c] pyridine, and wherein, phenyl is by CONR
15R
16Replace R
15C for side chain
3Alkyl, and R
16Be phenyl (X=-CH
2-; The Y=key; R
1=hydrogen; R
2=H; R
3=by 1 C (=O) R
18The phenyl that replaces, wherein, R
18Be NR
15R
16, and R
15And R
16C for side chain
6Alkyl; R
4=H) (as US 5,302,601 embodiment 35 discloses);
(f) this compound is 6-(5H-imidazo [4,5-c] pyridine-5-base-methyl)-N-(1 methylethyl)-N-phenyl-3-pyridine carboxamides (X=-CH
2-; The Y=key; R
1=hydrogen; R
2=H, R
3=by 1 R
6The pyridine that replaces, wherein, R
6=1 C=OR
18, R
18Be NR
15R
16, R wherein
15=sec.-propyl, and R
16=phenyl) (as US 4,990,518 embodiment 6 discloses);
(g) this compound is following compound: wherein, and X=-CH
2-; The Y=key; R
1=hydrogen; R
2=H, R
3=5-6 unit heterocycle is specially pyridyl or furyl, and it is by 1 R
17Replace, wherein, R
17=C (=O) R
18, and R
18=NR
15R
16, R
15And R
16Perhaps be C
1-18Alkyl (being specially methyl, ethyl or sec.-propyl), C
2-18Thiazolinyl (being specially the 2-methacrylic) or for C
3-10Cycloalkyl (being specially cyclopentyl or cyclohexyl) (as US 4,990,518 announcements);
(h) this compound is following compound: wherein, and X=-CH
2-; The Y=key; R
1=hydrogen; R
2=H, R
3=5-6 unit heterocycle is specially pyridyl or furyl, and it is by 1 R
17Replace, wherein, R
17=C (=O) R
18, and R
18=C
3-10Cycloalkyl or C
4-10Cycloalkenyl group.
(i) this compound is 2,6-two (1,1,-dimethyl ethyl)-4-[[2-(5H-imidazo-[4,5-c] pyridine-5-yl) ethyl] sulphur]-phenol hydrate and/or 2,6-two (1,1,-dimethyl ethyl)-and 4-[[2-(5H-imidazo-[4,5-c] pyridine-5-yl) propyl group] sulphur]-phenol hydrate (X=CH
2-CH
2-; The Y=key; R
1=hydrogen, R
2=H, R
3=by 3 R
6The arylthio (thioaryl) that replaces, wherein, R
6The side chain C of position between=2
4The OH of alkyl and contraposition) (such as among the embodiment 6 of WO 96/12703 announcement);
(j) this compound is 5-[2-(phenylbenzene-4-base oxygen)-ethyl]-5H-imidazo [4,5-c] pyridine (X=CH
2CH
2, Y=key, R
1=hydrogen, R
2=H, R
3=in contraposition by a R
17The phenoxy group that replaces, wherein, R
17=benzyl; R
4=H) (such as among the WO 96/11192 announcement);
(k) this compound is 5-[2-(4-phenoxy group-phenoxy group)-ethyl]-5H-imidazo [4,5-c] pyridine (X=CH
2CH
2, Y=key, R
1=hydrogen, R
2=H, R
3=in contraposition by a R
17The phenoxy group that replaces, wherein, R
17=phenoxy group; R
4=H) (such as among the WO 96/11192 announcement);
(1) this compound is [5-(4-luorobenzyl)-5H-imidazo [4,5-c] pyridine-2-yl]-methylamine (X=CH
2, Y=NR
11, wherein, R
11=methyl, R
1=R
2=H, R
3=in contraposition by a R
17The phenyl that replaces, wherein R
6Be F, R
4=H, R
5=H) (such as among the EP 76530 announcement);
(m) this compound is 2, two (1,1 ,-dimethyl ethyl)-4-[[3-(5H-imidazo-[4, the 5-c] pyridine-5-yl) propyl group of 6-] sulphur]-phenol hydrate (X=CH
2-CH
2-CH
2, the Y=key; R
1=hydrogen, R
2=H, R
3=by three R
6The thiophenyl that replaces, wherein, R
6The side chain C of position between=2
4The OH of alkyl and contraposition) (such as WO 96/12703 announcement);
(n) this compound is 5-[2-(4-phenyl methoxyl group-phenoxy group)-ethyl]-5H-imidazo [4,5-c] pyridine (X=CH
2CH
2, Y=key, R
1=hydrogen, R
2=H, R
3=in contraposition by a R
17The phenoxy group that replaces, wherein, R
17=benzyloxy) (such as WO 96/11192 announcement);
(o) this compound is 5-[3-(4-phenoxy group-phenoxy group)-propyl group]-5H-imidazo [4,5-c] pyridine (X=CH
2CH
2CH
2, Y=key, R
1=hydrogen, R
2=H, R
3=in contraposition by a R
6The phenoxy group that replaces, wherein, R
6=the phenoxy group that replaced by F in contraposition; R
4=H) (such as WO 96/11192 announcement);
(p) this compound is 5-{2-[4-(4-fluorophenoxy)-phenoxy group]-ethyl }-5H-imidazo [4,5-c] pyridine (X=CH
2CH
2, Y=key, R
1=hydrogen, R
2=H, R
3=in contraposition by a R
6The phenoxy group that replaces, wherein, R
6=the phenoxy group that replaced by F in contraposition; R
4=H) (such as WO 96/11192 announcement);
(q) this compound is 5-[3-(4-phenyl methyl-phenoxy group)-propyl group]-5H-imidazo [4,5-c] pyridine (X=CH
2CH
2CH
2, Y=key, R
1=hydrogen, R
2=H, R
3=in contraposition by a R
6The phenoxy group that replaces, wherein, R
6=benzyl; R
4=H) (such as WO 96/11192 announcement);
(r) this compound is (1H-indol-3-yl)-[3-(2-methyl-5H-imidazo [4,5-c] pyridine-5-carbonyl)-phenyl]-ketone (X=-(C=O)-or SO
2, Y=CH
2, R
1=H, R
2=H, R
3=by a R
6The phenyl that replaces, wherein, R
6Be C (=O) R
18, R
18Be indoles) (as US 5,486,525 announcements);
(s) this compound is 4 or 3-[(2-methyl-5H-imidazo [4,5-c] pyridine-5-yl) methyl]-phenylformic acid alkyl ester or 5-[4 or 3-(alkoxy carbonyl-phenyl)-methyl]-2-methyl-5H-imidazo [4,5-c] pyridine, be specially 4 or 3-[(2-methyl-5H-imidazo [4,5-c] pyridine-5-yl) methyl]-methyl esters (X=CH
2, Y=CH
2, R
1=H, R
2=H, R
3=in contraposition or a position by a R
17The phenyl that replaces, wherein, R
17Be (C=O) R
18, R
18=alkoxyl group) (as US 5,486,525 announcements);
(t) this compound is the 5-[(fluorophenyl) methyl]-2-amino-5-H-imidazo [4,5-c]-pyridine (XR
3=luorobenzyl, Y=NR
11, R
11=methyl, R
1=H, R
2, R
3, R
4=H) (as US 5,137,896 announcements);
(u) this compound is ((5-[4-(fluorophenyl) methyl]-5-H-imidazo [4,5-c]-pyridine-2-yl) methyl)-carbamate, methyl esters (XR
3=luorobenzyl, Y=C (=O) R
12, R
12=methyl, R
1=H, R
2, R
3, R
4=H) (as US 5,137,896 disclose);
(v) this compound is 5-(4-Chlorophenylmethyl)-2-(piperidines-1-ylmethyl)-5H-imidazo [4,5-c] pyridine and dihydrochloride (XR thereof
3=benzyl chloride base, Y=-CH
2-, R
1=piperidyl) (as Justus Liebigs Annalen derChemie (1971), 747,158-171 discloses);
(w) this compound is 5-(4-Chlorophenylmethyl)-2-(4-methyl-piperazine-1-ylmethyl)-5H-imidazo [4,5-c] pyridine (XR
3=benzyl chloride base, Y=-CH
2-, R
1=piperazinyl, R
6=methyl) (as Journal of theChemical Society[section B]: Physical Organic (1966), 4,285-291 discloses);
(x) compound is specially Cleve etc., the compound 9 that " Liebigs Ann.Chem.747:158-171 (1971) " the 160th page;
(y) compound is specially the compound 19 and 20 in " Chem.Pharm.Bull.43 (3): 450-460 (1995) " such as Kiyama; And
(z) compound is specially the compound 14 of " Tet.Lt. " 48 (48): 10549-10558 (1992) such as Medereslci.
Compound of the present invention is randomly got rid of aforesaid those general formulas (A) compound, wherein, and (a) YR
1Phenyl for being replaced by OH in contraposition, or (b) be H, unsubstituted C
3-10Cycloalkyl, or C
1-6Alkyl.
Compound of the present invention is randomly got rid of aforesaid those general formulas (A) compound, wherein, and R
1Be not H, Y is not NR
11, R
11Be C
1-6Alkyl or methyl, and/or YR
1Be not monomethyl amino.
Compound of the present invention is randomly got rid of aforesaid those general formulas (A) compound, wherein, and R
1For by a R
6The phenyl that replaces, R
6Be C (=O) R
18, R
18Be tert.-butoxy.
Compound of the present invention is randomly got rid of aforesaid those general formulas (A) compound, wherein, and R
1Be not piperidyl, and be not by methyl substituted piperazinyl.
Compound of the present invention is got rid of the compound that WO 2004/005286 is disclosed, and is specially compound listed in its table 8.
Compound of the present invention is randomly got rid of following compound: XR
3Definition and United States Patent (USP) 5,302, the substructure (CH in the comparable announcement of 60l l hurdle the 49th row-Di 2 hurdles the 38th row and any patent families thereof
2) n-Y-C (O)-N (R
1) (R
2) identical, the announcement in these patents is included this paper in as a reference.
Compound of the present invention is randomly got rid of R
5Be included in any substituting group that is designated as " Ar " among the WO 00/39127, be specially aryl, aryl phenoxy group or benzyl.
Compound of the present invention does not randomly comprise the compound among the embodiment of following patent: United States Patent (USP) 5,302,601 embodiment 35, United States Patent (USP) 4,990, embodiment 6 in 518, United States Patent (USP) 4,988,707 embodiment 1-5, United States Patent (USP) 5,208,241 embodiment 1-5, United States Patent (USP) 5,137,896 embodiment 39, pyridine benzimidazole compounds among the WO99/27929, United States Patent (USP) 5,227,384 embodiment 1-20 and 45, the embodiment 3 and/or 11 of WO96/12703, and/or the compound 340A of WO 96/11192,347C, 349C, 35lC, 355C and/or 356C.
Compound of the present invention is randomly got rid of XR
3Be equal to United States Patent (USP) 4,990, listed substructure-(CH in the 41st row-Di 2 hurdles, 518 the 1st hurdles the 24th row
2)
n-Het-C (O)-N (R
1) (R
2).
Compound of the present invention do not comprise in the background of invention above in the listed patent the compound that disclosed among the compound, Chemical Abstracts acc no.1987:18435 and the Chemical Abstracts acc no.1983:594812 that clearly disclose.
Compound of the present invention does not comprise Justus Liebigs Annalen der Chemie (1971), 747,158-171 or the Journal of the Chemical Society[section B]: PhysicalOrganic (1966), 4, among the 285-291 the compound that clearly discloses.
Randomly, compound of the present invention is got rid of YR
1Be United States Patent (USP) 5,486, the capable R that is appointed as of 525 the 5th hurdle 22-38
13One of substituting group, and/or R
2And/or R
5Be United States Patent (USP) 5,486, the capable compound of concentrating one of specified substituting group of 525 the 5th hurdle 38-53.
Randomly, compound of the present invention is got rid of the compound in any patent families of any announcement or the patent of mandate (especially in the patent of quoting in this mandate).
At last, compound of the present invention is also randomly got rid of the methylene radical analogue of the aforementioned known compound of getting rid of in the scope of the invention.Should understand the compound of randomly getting rid of and also comprise its esters.
With being coated with
Compound of the present invention or have a large amount of purposes by the metabolite that these compounds produce in vivo.They can be used on fields such as immunology, chromatographic science, diagnostics and treatment.
With formula (A) but compound and immunogenic polypeptide engage with as inducing the generation specificity to combine the reagent of the antibody of this polypeptide, this compound or their meta-bolites (it has kept the epi-position of immune identification, i.e. the site of antibodies).Therefore, these immunogenic compositions can be used as that preparation is used for diagnosing, the antibody of quality control etc. or the intermediate of test formula (A) compound or their new meta-bolites.This compound can be used for producing the antibody of anti-other non-immunogenic polypeptide, this be since this compound as the haptens site stimulate can with the immune response of the conjugated protein generation cross reaction of unmodified.
Formula (A) compound and immunogenic polypeptide (for example albumin or keyhole
Hemocyanin) binding substances is often used as antigen.This polypeptide with supply with amino acid whose same loci on combine.Above-mentioned meta-bolites can keep the immune cross-reactivity with the roughly the same degree of compound of the present invention.Therefore, antibody of the present invention can with without the protection compound of the present invention combine, and not with through the protection compound combine.Perhaps, this meta-bolites can with through the compound of protection and/or combine with this meta-bolites and can not combine with compound of the present invention through protecting, or can be specifically arbitrary or whole in conjunction with among the three.Substantial cross reaction will can not take place with naturally occurring material in ideal antibody.Substantive cross reaction (Substantial cross-reactivity) is the reaction that can make the effective distrubed test result of specific analyte under the fc-specific test FC condition.
Immunogen of the present invention comprises compound of the present invention, and described compound can the required epi-position of submission when combining with immunogenic substance.In full text of the present invention, this combination is meant that covalent attachment is to form immunogenic conjugates (at where applicable) or the mixture of non-covalent bond material or above-mentioned combination.Immunogenic substance comprises: adjuvant, for example freund's adjuvant; Immunogenic protein, for example virus, bacterium, yeast, plant and animal polypeptide, especially keyhole: hemocyanin, serum albumin, bovine thyroglobulin or Trypsin inhibitor SBTI and immunogenicity polysaccharide.Usually, the crosslinking reaction agent of multifunctional by using (being generally two senses) makes the compound with required epi-position structure combine with immunogenic polypeptide or polysaccharide covalent.Being used to prepare the immunogenic method of haptens is conventional in essence, also should use be used for haptens is attached to any method of immunogenic polypeptide etc. up to now, and consider to can be used on precursor or the hydrolysate possibility of the antibody of crosslinked functional group and the generation unknown epitope specificity opposite with immunogenic substance.
Usually polypeptide chain is connected on away from being identified on the site of epi-position on the The compounds of this invention.
Mode with routine prepares this binding substances.For example, linking agent N-hydroxy-succinamide, succinyl oxide or alkyl N=C=N alkyl (alkN=C=Nalk) are used to prepare binding substances of the present invention.This binding substances comprises by key or has 1-100, is generally 1-25, is more typically the linking group of 1-10 carbon atom, the compound of the present invention that is connected with immunogenic substance.By methods such as chromatograms, this connector is separated from parent material and by product, sterile filtration and bottling store then.
Usually animal is carried out the immunity of anti-immunogenic conjugates or derivative, and prepare antiserum(antisera) or monoclonal antibody in a conventional manner.
Compound of the present invention can be used as in the preparation affinity adsorbing base affinity (being generally hydrophobicity) partly, connector or spacer.Randomly with the insoluble matrix covalent attachment and be used for the affinity chromatography partition method, this depends on the character of compound group, for example the compound that has aryl side can be used to prepare hydrophobic affinity post with compound of the present invention.
They also can be in the preparation of immobilized enzyme as the connector and the spacer that are used for process control, or as connector and spacer in the immunoassay agent preparation.The functional group that compound comprised of this paper is suitable for as carrying out crosslinked site with desired substance.For example, conventional is that affinity reagent is combined with insoluble matrix, and described affinity reagent is for example hormone, peptide, antibody, medicine etc.Use these insoluble reagent in a known manner, with from the preparation, test sample and other the impure mixture that make absorption affinity reagent in conjunction with counterpart.Similarly, immobilized enzyme is used to be easy to reclaim the catalyzed conversion of enzyme.When the preparation diagnostic reagent, with two functional compounds analyte is linked to each other with detectable group usually.
For diagnostic purpose, available detectable part (biological example element, radio isotope, enzyme etc.) is carried out mark to compound of the present invention.Known realization is to the Appropriate technology of formula (A) compound mark, and after this specification sheets integral body is considered, these technology will be conspicuous for technicians.For example, a site that is suitable for mark is R
17Or R
18
Yet, having more representational is that compound of the present invention is used for the treatment of or prophylaxis of viral infections, for example yellow fever virus, dengue fever virus, hepatitis B virus, hepatitis G virus, typicalness Pig Fever virus or edge disease virus infect, but more particularly be used for the treatment of or virus infection, especially HCV and the BVDV of prevention of flavivirus section or pico+ribonucleic acid+virus section.
Can give mammalian object (comprising the people) with one or more therapeutic compounds of the present invention by any mode well known in the art, promptly by oral, nose interior, subcutaneous, intramuscular, intracutaneous, intravenously, intra-arterial, gi tract are outer or mode administration such as conduit insertion.The treatment significant quantity of described one or more compounds is growth-inhibiting amounts of flavivirus or pico+ribonucleic acid+virus.More preferably, it duplicates formula (A) compound of amount of suppression or flavivirus or pico+ribonucleic acid+virus enzyme amount of suppression for flavivirus or pico+ribonucleic acid+virus.It is believed that this is equivalent to guarantee that blood plasma level is about 1 μ g/ml-100mg/ml, randomly is the amount of 10mg/ml.This selected value is by administration of human every kg body weight every day 0.001-60mg, preferred 0.01-10mg, more preferably the dosage of 0.1-1mg obtains.These are the starting points that are used for the preferred dose of definite The compounds of this invention.Accurately amount will depend on many factors known to the skilled, and these factors comprise: the bioavailability of compound, whether it comprises, and prodrug is functional, its metabolism and distribution and its effectiveness etc. in object.Usually be necessary in clinical adjustment to determine suitable dosage, and this point is known to those of ordinary skills.The treatment significant quantity of one or more compounds of the present invention randomly can be divided into several subunits every day, or give every day or surpass a world at interval to give, this depends on the state of an illness that will treat, patient's situation and the character of The compounds of this invention.
As the routine in this area, can by analyze between each medicine interactional quantitatively, adopt Chou etc. at the intermediate value principle of effect (median effect principle) described in Adv Enzyme Reg. (1984) 22:27 or with the test that includes but not limited to isobologram (as Elion etc. at J.Biol.Chem. (1954) 208:477-488 and Baba etc. described in Antimicrob.Agents Chemother. (1984) 25:515-517), use EC
50Come calculating section inhibition concentration (fractional inhibitory concentration) to assess the synergy of pharmaceutical composition.
Can be included in the antiviral composition or the suitable antiviral agent that gives jointly in a course of treatment comprises, for example: interferon alpha, virazole, fall within EP1162196, WO 03/010141, compound in the scope that WO 03/007945 and WO 03/010140 are disclosed, fall within the compound in WO 00/204425 and other patent or their scope that patent family application disclosed, dosage is the 1-99.9 weight % that accounts for The compounds of this invention, preferred 1-99 weight %, more preferably 5-95 weight %, this dosage can be determined at an easy rate by those skilled in the art.Need not this type of common administered agents is formulated in the formulation identical with compound of the present invention.The course of treatment that gives object formula (A) compound, can randomly they be given the object in the course of treatment separately.
The present invention also provides veterinary composition, and said composition comprises at least a activeconstituents as defined above and carrier for animals thereof, for example is used for the treatment of BVDV.Carrier for animals is the material that is used to give the purpose of composition, and it is an acceptable vehicle in inertia or the veterinary field, and can be compatible with compound of the present invention.Can be oral, outside gi tract or by other required approach, give these veterinary compositions.
Salt
As used herein, term " pharmacy acceptable salt " refers to the non-toxic salt form by the therapeutic activity of formula (A) compound formation.Such salt can comprise the salt that suitable positively charged ion (as basic metal and alkaline-earth metal ions or ammonium and quaternary ammonium ion) is obtained with acid anion part (normally carboxylic acid) chemical combination.
The compounds of this invention can have a plurality of positive charges or negative charge.The net charge of The compounds of this invention can be for just or for negative.Usually can adopt the synthetic and/or separation method that obtains this compound to introduce any associating counter ion.Typical counter ion include but not limited to: ammonium, sodium, potassium, lithium, halogen, acetate moiety, trifluoroacetic acid root etc. and their mixture.Be understood that any associating counter ion kind is not a key feature of the present invention, the present invention includes and the associating compound of any kind counter ion.In addition, because The compounds of this invention can various multi-form existence, the present invention not only is intended to comprise and the associating compound form of counter ion (for example dried salt), also comprise not with the associating form of counter ion (as, the aqueous solution or organic solution).Usually, can make metal-salt by metal hydroxides and The compounds of this invention are reacted.The example of Zhi Bei metal-salt is by this way: contain Li
+, Na
+, Ca
2+, Mg
2+And K
+Salt.Can make more insoluble salt from the solution of more diffluent salt, separate out by adding suitable metallic compound.In addition, can form salt in the acid groups by some organic acid and mineral acid are joined alkali center (being generally amine) or join.The example of this suitable acid comprises, for example: and mineral acid, as haloid acid (example hydrochloric acid or Hydrogen bromide), sulfuric acid, nitric acid, phosphoric acid etc.; Or organic acid, as acetate, propionic acid, oxyacetic acid, phenylformic acid, 2 hydroxy propanoic acid, 2-oxo propionic acid, lactic acid, fumaric acid, tartrate, pyruvic acid, toxilic acid, propanedioic acid, oxysuccinic acid, Whitfield's ointment (that is 2 hydroxybenzoic acid), para-aminosalicylic acid, ethylenehydrinsulfonic acid, lactobionic acid, succsinic acid, oxalic acid and citric acid; Organic sulfonic acid is as methylsulfonic acid, ethyl sulfonic acid, Phenylsulfonic acid and tosic acid; And mineral acid, for example hydrochloric acid, sulfuric acid, phosphoric acid and thionamic acid; C
1-C
6Alkylsulphonic acid, Phenylsulfonic acid, right-toluenesulphonic acids, cyclohexane sulfamic acid etc.Preferred salt comprises: mesylate and hydrochloride.
Compound of the present invention comprises the solvate by formula (A) compound and salt formation thereof, hydrate for example, alcoholate etc.Composition as herein described comprises the compound of the present invention and the zwitterionic form thereof of unionization form and combines the hydrate forms of formation with the water of stoichiometry.
Also comprise formula (A) compound and one or more aforesaid amino acids formed salt in the scope of the invention.Described amino acid has the side chain with basic group or acidic-group usually, as Methionin, and arginine or L-glutamic acid, or have the side chain of neutral group, and as glycine, Serine, Threonine, L-Ala, Isoleucine or leucine.
Also can use not as the salt of acid of being accepted on the physiology or alkali, for example, be used for preparation or purifying formula (A) compound., derived from physiologically acceptable acid or alkali whether all salt all within the scope of the invention no matter.
Isomers
As used herein, term " isomers " is meant all possible isomeric form of formula (A) compound, comprises change and stereochemical form, but does not comprise positional isomers.Usually, structure shown in this article is only enumerated a kind of change form or the resonance form of compound, but also comprises other corresponding configuration.Except as otherwise noted, the chemical symbol of compound (designation) refers to the mixture of all possible form of three-dimensional chemical isomer, described mixture comprises all diastereomers and enantiomorph (because formula (A) compound can have one or more chiral centres), and stereochemistry isomer pure or enrichment.More specifically, three-dimensional center can have R-or S-configuration, and two key or triple bond can randomly be cis-or transconfiguration.
The isomeric form of the enrichment of The compounds of this invention is meant substantially the not individual isomer of other enantiomeric form of this compound or diastereo-isomerism form.Particularly, term " enrichment on the stereoisomerism " or " the chirality enrichment " are meant that the single stereoisomers ratio is at least about 80% (promptly, a kind of isomer of at least 90% and maximum 10% other possible isomer), preferably at least 90%, more preferably at least 94%, at least 97% compound most preferably.Term " enantiomer-pure " and " diastereisomericallypure pure " contain can not detection level any other isomer.
Can finish separation by standard method known in the art to steric isomer.Can be by method as use optical activity resolution reagent, with a kind of Chiral Separation of The compounds of this invention is not have its opposite enantiomorph (" stereochemistry of carbon compound " basically, " Stereochemistry of Carbon Compounds " (1962), E.L.Eliel, McGraw Hill; Lochmuller, C.H., (1975) J.Chromatogr., 113:(3) 283-302).The separation of isomer can be undertaken by any suitable method in the mixture, described method comprises: (1) and chipal compounds form the diastereo-isomerism salt of ionic, and it is separated by fractional crystallization or other method, (2) form the diastereo-isomerism compound with chiral derivatizing agent, separate this diastereomer, and be translated into pure enantiomorph, or (3) under the chirality condition, directly enantiomer separation.For method (1), can be by chiral base (as vauqueline, quinine, ephedrine, brucine, a-methyl-b-phenyl-ethyl amine (Amphetamine) etc.) and the asymmetric compound reaction formation diastereomeric salt that has acidic functionality (as carboxylic acid and sulfonic acid) with enantiomer-pure.
Can randomly impel diastereomeric salt to separate by fractional crystallization or chromatography of ions.Be the optical isomer of separation of ammonia based compound, add chiral carboxylic acids or sulfonic acid (as camphorsulfonic acid, tartrate, amygdalic acid or lactic acid) and can cause forming diastereomeric salt.Perhaps, by using method (2), the material that needs to split can form diastereomer to (Eliel with a kind of enantiomorph reaction of chipal compounds, E. and Wilen, S. (1994). " stereochemistry of organic compound " (Stereochemistry of Organic Compounds), John Wiley﹠amp; Sons, Inc., 322 pages).The method that forms diastereomeric compound can be: make chiral derivatizing agent (as the menthyl derivatives) reaction of asymmetric compound and enantiomer-pure, separate diastereomer then and with its hydrolysis, obtain the xanthene of free enantiomorph enrichment.The method of measuring optical purity comprises the chiral ester for preparing racemic mixture, as menthyl ester or Mosher ester, a-methoxyl group-a-(trifluoromethyl) phenylacetic acid ester (JacobIII. (1982) J.Org.Chem.47:4165), and NMR spectrum analyzed to confirm existing of two kinds of rotation diastereomers.Can (Hoye, T. WO96/15111), separate with reverse-phase chromatography and the stable diastereomer of emanating by positive according to atropisomerrism body (atropisomeric diastereomer) naphthyl-isoquinoline 99.9 separation method.According to method (3), can adopt chiral stationary phase that the racemic mixture of two kinds of asymmetric enantiomorphs is separated by chromatogram.Suitable chiral stationary phase is for example polyose, particularly Mierocrystalline cellulose or straight chain starch derivative.Commercially available polysaccharide base chiral stationary phase is: ChiralCeI
TMCA, OA, OB5, OC5, OD, OF, OG, OJ and OK, and Chiralpak
TMAD, AS, OP (+) and OT (+).The suitable eluent or the moving phase that are used for being used with described polysaccharide base chiral stationary phase are (as ethanol with alcohols, Virahol etc.) (" the chirality liquid chromatography (LC) " such as hexanes of modification, " Chiral Liquid Chromatography " (1989) W.J.Lough compiles, Chapmanand Hall, New York; Okamoto, (1990)." optical resolution of the dihydropyridine enantiomorph that the phenylcarbamate of polysaccharide is carried out as chiral stationary phase by high performance liquid chromatography ", " Optical resolutionof dihydropyridine enantiomers by High-performance liquid chromatographyusing phenylcarbamates of polysaccharides as a chiral stationary phase ", J.of Chromatogr.513:375-378).
Meta-bolites
The present invention also provides the interior metabolism product of compound as herein described, and the announcement degree is novel and non-obvious for this type of product with respect to prior art.This type of product can be available from compound after the administration for example, and oxidation, reduction, hydrolysis, amidation, esterification etc. mainly are to be produced by enzymic process.Therefore, the present invention includes the novel and non-obvious compound that produces by the method that comprises following steps: compound of the present invention is contacted one period that is enough to obtain the meta-bolites of described compound with Mammals.Usually, can differentiate these products as follows: the The compounds of this invention of preparation radio-labeling (as C14 or H3), with detectable dosage (as greater than about 0.5mg/kg) it is passed through parenteral administration animal (for example rat, mouse, cavy, monkey or people), give the sufficiently long time carrying out metabolism (being generally about 30 seconds-30 hours), and from urine, blood or biological sample, separate its converted product.Because these products are through mark, they are easy to separate (other material is can come isolating in conjunction with the antibody of the epi-position that exists in the metabolite by using).The method of available routine is determined the structure of this meta-bolites, for example analyzes by MS or NMR.Usually, can adopt the method identical to analyze meta-bolites with conventional medicament metabolism research well known to those skilled in the art.As long as do not find these converted products in vivo in addition,, they can be used for the diagnositc analysis of The compounds of this invention therapeutic dose yet even they itself do not have antiviral activity.
Preparation
Can be randomly that compound of the present invention is formulated together with conventional pharmaceutical carriers and vehicle, the selection of described carrier and vehicle will be carried out according to the practice of routine.Tablet can contain vehicle, glidant, weighting agent, tackiness agent etc.Aqueous formulation prepares with sterile form, by other administration except that oral administration the time, generally is isoosmotic.Preparation is optional can to comprise vehicle, those vehicle of in " handbook of pharmaceutical excipients " (" Handbookof Pharmaceutical Excipients ", 1986), enumerating for example, and comprise: xitix and other antioxidant; Sequestrant is as EDTA; Carbohydrate is as dextrin, hydroxy alkyl cellulose, hydroxyalkyl methylcellulose gum, stearic acid etc.
Subsequently, as used herein, term " pharmaceutically acceptable carrier " refers to active ingredient formulated together, so that activeconstituents is easy to use or be distributed to and needs treatment part dissolving, dispersion or the diffusion of described composition (for example by) and/or make it be easy to store, transport or handle and can not damage any material or the material of activeconstituents effect.Pharmaceutically acceptable carrier can be the gas of solid or liquid or compressed formation liquid, and promptly the present composition is suitable for enriched material, emulsion, solution, granule, pulvis, sprays, aerosol, suspensoid, ointment, creme, tablet, pill or powder type use.
The pharmaceutical carrier that is applicable to described pharmaceutical composition and preparation thereof is well known to those skilled in the art, in the present invention its selection is not particularly limited.They also comprise additive, as: wetting agent, dispersion agent, tackiness agent, tackiness agent, emulsifying agent, solvent, Drug coating, antiseptic-germicide and anti-mycotic agent (for example phenol, Sorbic Acid, butylene-chlorohydrin), isotonic agent (as sugar or sodium-chlor) etc., prerequisite is that these additives are consistent with medicinal practice, and promptly carrier and additive can not produce permanent damage to Mammals.Can prepare pharmaceutical composition of the present invention by any known way, for example pass through in a step or a plurality of step with active ingredient and carrier uniform mixing, dressing and/or pulverizing, if be fit to also can add other additive (for example tensio-active agent) through selecting.Also can be prepared, for example, promptly make the microcapsule that are used for controlled release or slowly-releasing active ingredient for obtaining to typically have a diameter from the microspheres form of about 1-10gm by micronization.
Can be used for the suitable tensio-active agent (being also referred to as emulgent or emulsifying agent) of pharmaceutical composition of the present invention, is the non-ionic type with well emulsify, dispersion and/or wettability, cationic and/or anionic material.Suitable aniorfic surfactant had both comprised water miscible soap, comprised water miscible synthetic tensio-active agent again.Suitable soap is higher fatty acid (C
10-C
22) an alkali metal salt or alkaline earth salt, the unsubstituted or ammonium salt that replaces, as oleic acid or stearic sodium salt or sylvite or can be available from the sodium salt or the sylvite of the natural acid mixture of Oleum Cocois or tallow oil.Synthetic surfactant comprises: polyacrylic sodium salt or calcium salt; Fat sulfonate or fat sulphate; Sulphonated benzimidazole derivative and alkylaryl sulphonate.Fat sulfonate or vitriol is basic metal or alkaline-earth metal salt form normally; the alkyl of 8-22 carbon atom or the ammonium salt or the unsubstituted ammonium salt of acyl substituted are arranged; sodium salt or calcium salt as lignosulfonic acid or dodecyl sodium sulfonate; or available from the mixture of the aliphatic alcohol sulfate of natural acid, the affixture of the basic metal of sulfuric acid or sulphonate or alkaline earth salt (as Sodium Lauryl Sulphate BP/USP) and Fatty Alcohol(C12-C14 and C12-C18) sulfonic acid/oxyethane.Suitable sulphonated benzimidazole derivative preferably contains 8-22 carbon atom.The example of alkylaryl sulphonate is sodium salt, calcium salt or the pure amine salt of dodecyl sodium sulfonate or dibutyl-naphthene sulfonic acid or naphthalene-sulfonic acid/formaldehyde condensation products.Corresponding phosphoric acid salt is fit to too, as the salt of phosphoric acid ester, to nonylphenol and the affixture or the phosphatide that contain oxyethane and/or propylene oxide.The suitable phosphatide that is used for this purpose is natural (being derived from the animal or plant cell) or synthetic kephalin or Yelkin TTS type phosphatide, as, phosphatidylethanolamine, phosphatidylserine, phosphatidyl glycerol, lysolecithin, Val, dioctyl phosphatidyl-choline, two palmityl phosphatidyl-choline, and their mixture.
Suitable ionic surfactant pack is drawn together: the polyethoxylated of following material and poly-propoxylated derivative: alkylphenol, Fatty Alcohol(C12-C14 and C12-C18), lipid acid, the aliphatic amine or the acid amides that contain at least 12 carbon atoms in the molecule, alkylated aromatic sulfonic acid salt (alkylarenesulphonate) and dialkyl sulfosuccinates, as aliphatic series and alicyclic alcohol, the polyglycol ether derivative of saturated and unsaturated fatty acids and alkylphenol, described derivative preferably partly contain 3-10 ethylene glycol ether group and 8-20 carbon atom and at moieties 6-18 carbon atom are arranged at (aliphatic series) hydrocarbon of alkylphenol.Other suitable nonionogenic tenside is polyethylene oxide and gathers the water-soluble affixture that contains the second diamino polypropylene glycol of 1-10 carbon atom in interior glycol, the alkyl chain that this affixture contains 20-250 ethylene glycol ether group and/or 10-100 propylene glycol group.Such compound contains 1-5 ethylene glycol unit usually in each propylene glycol unit.The representative example of nonionogenic tenside is nonylphenol-polyethoxyethanols, Viscotrol C polyglycolic acid ether (polyglycolic ether), poly(propylene oxide)/polyethylene oxide affixture, tributyl benzene oxygen polyethoxyethanols, polyoxyethylene glycol and octylphenoxy polyethoxy ethanol.The anhydrate fatty acid ester (as the polyoxyethylene sorbitol olein that anhydrates) of sorbyl alcohol (polyethylene sorbitan), the fatty acid ester of glycerine, the fatty acid ester of the sorbyl alcohol that anhydrates, the fatty acid ester of sucrose and the fatty acid ester of tetramethylolmethane of poly-ethylidene also is suitable nonionogenic tenside.
Suitable cationic surfactants comprises quaternary ammonium salt, particularly halogenated quaternary ammonium salt, and it has 4 and chooses wantonly by the alkyl of the phenyl of halogen, phenyl, replacement or hydroxyl replacement; For example, following quaternary ammonium salt: contain for as substituent at least one C8-C22 alkyl of N-(as hexadecyl, lauryl, palmityl, myristyl, oil base etc.), and as the quaternary ammonium salt of other substituent unsubstituted or halogenated low alkyl group, benzyl and/or hydroxy lower alkyl.
Be fit to this purpose the tensio-active agent more detailed description can referring to for example " McCutcheon ' stain remover and emulsifying agent annual report " (" McCutcheon ' s Detergents and Emulsifiers Annual " (MCPublishing Crop., Ridgewood, New Jersey, 1981), " Tensid-Taschenbucw; second edition (Hanser Verlag; Vienna; 1981) and " tensio-active agent encyclopedia " (" Encyclopaedia of Surfactants "; (Chemical Publishing Co.; New York, 1981).
Can give acceptable salt on compound of the present invention and the physiology thereof (below be referred to as activeconstituents) to need treatments symptom suitable way by any, suitable route of administration comprises: oral, rectum, nasal cavity, local (comprising eye, oral cavity and hypogloeeis), vagina and non-enteron aisle (comprising in subcutaneous, intramuscular, intravenously, intracutaneous, the sheath and epidural administration).Preferred route of administration can change according to the person's that for example is subjected to the medicine situation.
Although can give activeconstituents separately, preferably present with pharmaceutical dosage forms.Preparation of the present invention is no matter veterinary drug and human all comprise at least a aforesaid activeconstituents, with one or more its pharmaceutically acceptable carrier and other optional therapeutic component.Carrier is " acceptable " preferably, and it is compatible and can not be subjected to the medicine to it person is harmful to mean other composition of itself and preparation.Preparation comprises those preparations that are suitable for oral, rectum, nasal cavity, part (comprising oral cavity and hypogloeeis), vagina or non-enteron aisle (comprising in subcutaneous, intramuscular, intravenously, intracutaneous, the sheath and epidural) administration.Said preparation can be presented with unit dosage routinely, and can be by any known method preparation of pharmaceutical field.Such method comprises makes activeconstituents and this step of carrier combinations that constitutes one or more ancillary components.Usually by activeconstituents and liquid or finely divided solid carrier or both are evenly mixed closely, if necessary product shaping is prepared described preparation then.
Be fit to preparation of the present invention (discrete) unit existence individually of oral administration, as capsule, cachet or tablet, they contain the activeconstituents of predetermined amount separately; As powder or particle; As solution in waterborne liquid or the non-aqueous liquid or suspension; Or as O/w emulsion or water-in-oil emulsion.Activeconstituents ball, electuary or paste form greatly exists.
Can suppress or the molded tablet for preparing with one or more ancillary components by optional.Can prepare compressed tablets to optional compacting of the activeconstituents of free-flowing form (as powder or particle) by in suitable equipment with tackiness agent, lubricant, inert diluent, sanitas, tensio-active agent or dispersant.Can carry out the molded molded tablet for preparing to mixture by in suitable equipment with the moistening powdered compound of inert liquid diluent.Can randomly carry out dressing or indentation, and can be mixed with the tablet that activeconstituents is wherein provided slowly-releasing or controlled release tablet.Infection to eyes or other outside organization (as mouth and skin), can randomly 0.075-20%w/w (be included in the activeconstituents of 0.1-20% for example to contain, increment with 0.1%w/w increases, as 0.6%w/w, 0.7%w/w etc.), preferred 0.2-15%w/w, most preferably the local application's cream or the cream of 0.5-10%w/w activeconstituents are used said preparation.When being mixed with ointment, activeconstituents can be used with paraffin or the immiscible ointment matrix of water.Perhaps, activeconstituents and oil-in-water frost matrix can be mixed with creme.If desired, the water of cream base for example can comprise the polyvalent alcohol of 30%w/w at least, the alcohol that promptly has two or more hydroxyls is as propylene glycol, 1,3 butylene glycol, N.F,USP MANNITOL, sorbyl alcohol, glycerine and polyoxyethylene glycol (comprising PEG400) and their mixture.Topical preparation need comprise the compound that energy enhanced activity composition sees through skin or absorption of other involved area or infiltration.The example of such transdermal enhancer comprises dimethyl sulfoxide (DMSO) and related analogs.
The oil phase of emulsion of the present invention is made of by known way known component.Although oil phase only comprises a kind of emulsifying agent (being also referred to as emulgent), need comprise at least a emulsifying agent and oily or fatty and oily both mixture of fat.Also comprise lipophilic emulsifier when randomly, comprising hydrophilic emulsifier as stablizer.Also preferably not only comprise oil but also comprise fat.Constitute so-called emulsifying wax by one or more emulsifying agents jointly when existing or not having one or more stablizers, and described wax constitutes so-called oil in water emulsion cream base matter with oil ﹠ fat, this matrix forms the oily disperse phase of creme.
Because activeconstituents is extremely low in the solubleness of most of oil that may be used for pharmaceutical emulsion, so select to be applicable to the oily or fatty of preparation according to the required makeup performance that will reach.Therefore, creme should be chosen wantonly to (non-staining) of non-oil, non-staining and can wash product, and has suitable consistency to avoid it from pipe or other container leakage.Can use straight or branched, list-or binary alkyl ester, as two-dissident, two acid esters, stearic acid isocetyl ester, propylene glycol coconut fatty acid diester, Isopropyl myristate, decyl oleate, Wickenol 111, butyl stearate, palmitinic acid 2-ethylhexyl or be called the mixture of the branched ester of Crodamol CAP, preferred back three kinds of esters.According to required performance, these esters can be used singly or in combination.Perhaps, can use high-melting-point lipid, as paraffinum molle alba and/or whiteruss or other mineral oil.
The pharmaceutical preparation that is suitable for the topical administration eye also comprises eye drop, and wherein, activeconstituents dissolves or is suspended in the suitable carriers (especially for the aqueous solvent of activeconstituents).Activeconstituents is optional with 0.5-20%, preferred 0.5-10%, and preferably the concentration of about 1.5%w/w is present in the preparation.The preparation that is fit to the topical administration oral area comprises lozenge, and it is included in activeconstituents in the flavoured base, and described seasonings is generally sucrose and gum arabic or tragacanth; Pastille, it is included in activeconstituents in the inert base, and described inert base is for example gelatinum and glycerine or sucrose and gum arabic; And collutory, it is included in activeconstituents in the suitable liquid vehicle.
The preparation that is used for rectal administration can be used as suppository form and exists, described suppository contain suitable for example comprise theobroma oil or salicylate matrix.Be applicable to that the carrier in the preparation of intranasal administration is a solid, it comprises granularity and (comprises the 20-500 micron for for example 20-500 micron, 5 microns of increments, as 30 microns, 35 microns etc.) coarse meal, its mode administration to get with snuffing promptly sucks by nasal cavity fast from the container that powder is housed of being close to nose.The carrier that is used for the appropriate formulation of nasal spray for example or nasal drops administration is a liquid, and this preparation comprises the aqueous solution or the oily solution of activeconstituents.Can be suitable for the preparation of aerosol administration according to the ordinary method manufacturing, and can transmit with other therapeutical agent.
The preparation that is applicable to vagina administration can be vaginal suppository, tampon (tampon), creme, gel, paste, foams or sprays, except that comprising activeconstituents, also comprises suitable carrier known in the art.
The preparation that is applicable to parenterai administration comprises water-based and non-aqueous aseptic injectable solution, and it can comprise antioxidant, buffer reagent, fungistat and make preparation and be subjected to the medicine the isoosmotic solute of person's blood; And water-based and non-aqueous aseptic suspension agent, it can comprise suspension agent and thickening material.This preparation can be present in unitary dose or the multi-dose container, for example Mi Feng ampoule and bottle, and can under freeze-dried (freeze dried) condition, store, only need add at once before use aseptic liquid vehicle, for example water for injection.Interim injection solution of the sterilized powder of available aforementioned type, particle and tablet preparation and suspension.
Preferred unit dose formulations be contain per daily dose or as indicated above unit day time dosage (sub-dose) or those preparations of the activeconstituents of its suitable divided dose.
Should be understood that the composition except above mentioning especially, preparation of the present invention can comprise the conventional reagent in other this area according to the type of the preparation of being discussed, and for example is applicable to those comprised seasoningss of oral administration.
The compounds of this invention can be used for providing the pharmaceutical preparation (" controlled release preparation ") that contains as the controlled release of one or more The compounds of this invention of activeconstituents, wherein, may command and regulate the release of activeconstituents is with the administration frequency that reduces given The compounds of this invention or improve its pharmacokinetics or toxicity profile.Can be applicable to the controlled release preparation of oral administration according to the ordinary method manufacturing, wherein discrete unit comprises one or more The compounds of this invention.
Can comprise the assign to persistence of activeconstituents effect in the control combination thing of other one-tenth.Therefore, by selecting suitable polymer support, for example polyester, polyamino acid, Polyvinylpyrolidone (PVP), vinyl-vinyl acetate copolymer, methylcellulose gum, carboxymethyl cellulose, protamine sulfates etc. can obtain controlled release composition.Can also be by activeconstituents being added control drug release speed and active persistence in the polymer beads (for example minigel), described polymkeric substance is for for example: hydrogel, poly(lactic acid), Walocel MT 20.000PV, polymethylmethacrylate and other above-mentioned polymkeric substance.These class methods comprise the colloid drug delivery system, as liposome, microballoon, micro emulsion, nanoparticle, Nano capsule etc.According to route of administration, pharmaceutical composition may needing protection property dressing.The pharmaceutical dosage form that is applicable to injection comprises its aseptic aqueous solution or dispersion liquid and sterilized powder for interim preparation usefulness.The typical carriers that is used for this purpose comprises biocompatible aqueous buffer, ethanol, glycerine, propylene glycol, polyoxyethylene glycol etc. and their mixture.
In view of this fact, promptly when being used in combination several activeconstituentss, they will their combination therapy effect directly give simultaneously the Mammals that will treat, and correspondent composition can also comprise separately but in adjacent storage column or the medicine box or the packaged form existence of separating two kinds of components in the lattice.In back one situation, each activeconstituents can be mixed with the mode of the route of administration that is suitable for being different from other composition thus, as a kind of composition wherein can be oral or the non-gastrointestinal preparation form, and other composition then is ampoule form or the aerosol form that is used for intravenous injection.
Synthetic method
Use a series of chemical reactions well known to those skilled in the art to come preparation formula (A) compound, and set up the method and the further example of the described compound of preparation simultaneously.The method that further describes only is as an example, and does not mean limiting the scope of the invention.
The invention still further relates to the method for preparing the present composition.Prepare described composition by available technology in any organic synthesis.Many these type of technology are technology well known in the art.Yet many known technology describe in detail in following document to some extent: " methodology of organic synthesis summary " (" Compendium of OrganicSynthetic Methods " (John Wiley﹠amp; Sons, NewYork) volume 1, Ian T.Harrison and ShuyenHarrison, 1971; Volume 2, Ian T.Harrison and Shuyen Harrison, 1974; Volume 3, LouisS.Hegedus and Leroy Wade, 1977; Volume 4, Leroy G.Wade, Jr., 1980; Volume 5, Leroy G.Wade, Jr., 1984; With volume 6, Michael B.Smith; And March, J., " senior organic chemistry " third edition (" Advanced Organic Chemistry, Third Edition ", (John Wiley﹠amp; Sons, New York, 1985)), " comprehensive organic synthesis.Selection in the modern organic chemistry, strategy and effectiveness " (" ComprehensiveOrganic Synthesis.Selectivity,Strategy&Efficiency in Modern OrganicChemistry。Volume 9 ", Barry M.Trost chief editor (Pergamon Press, New York, 1993 printings)).
The illustrative methods of the preparation present composition below is provided.These methods are for the character of these preparations is described, rather than in order to limit the scope of applicable method.
Usually, reaction conditions, for example temperature, reaction times, solvent, last handling process etc. are the common response condition of the concrete reaction that is used in this area carrying out.Reference material of quoting and the material of wherein quoting have comprised the detailed description to these conditions.Typical temperature is-100 to 200 ℃, and solvent is for dredging the solvent of protic or protic, and the reaction times is 10 seconds-10 days.Aftertreatment is made up of following steps usually: unreacted reagent is carried out quencher, distribute (extraction) then in water/organic hierarchical system, and separation contains product layer.
Usually under temperature, carry out oxidation and reduction reaction near room temperature (about 20 ℃), though for the reduction of metal hydride often is to carry out reducing under 0-100 ℃ the temperature, the solvent of reduction reaction is generally thin protic solvent, and the solvent of oxidizing reaction can be protic or thin protic solvent.Can regulate to obtain required conversion product the reaction times.
Usually carrying out condensation reaction under near the temperature of room temperature, also is very common though reduce temperature (0-100 ℃) in the condensation reaction of non-running balance control.Solvent can be protic (being generally in the running balance reaction) or thin protic (being generally in the reaction in kinetic control).
The synthetic technology of standard, for example removing byproduct of reaction and use anhydrous response condition (for example inert gas environment) by azeotropic is very conventional in the art, and can use it at where applicable.
General aspect to these illustrative methods is described hereinafter.For each product in the following method, can be before it be used for subsequent step, to its randomly separate, segregation and/or purifying.
It is abutment, mixing, reaction that term " treated ", " handle (treating) ", " handling (treatment) " are waited, make and react, make and be usually used in showing in its contact and this area so that one or more chemical units are converted into other term that the mode of one or more other chemical units is handled described one or more chemical units.This just mean this " handle compounds 1 " and be synonymous to " make compound 1 and compound 2 reactions ", " compound 1 contact with compound 2 ", " with compound 1 and compound 2 reactions " with compound 2 and be used in the organic synthesis field rationally showing that compound 1 " is handled through compound 2 ", other routine expression of " with compound 2 reactions ", " making compound 1 and compound 2 react " etc.
" processing " is meant the mode reasonable and commonly used that makes the organic chemical reagent reaction.Unless otherwise, concentration (the 0.01M-10M of normal use standard, be generally 0.1M-1M), (100 to 250 ℃ of temperature, be generally-78-150 ℃, be more typically-78-100 ℃, be more typically 0-100 ℃), reaction vessel (being generally glass, plastics, metal), solvent, pressure, atmosphere (usually air being used for oxygen and the insensitive reaction of water) etc. perhaps with the reaction of nitrogen or argon gas to oxygen and water sensitive.The known similar reacting knowledge in organic synthesis field can be used for being chosen in condition and the equipment that given method is used to handle.Particularly, the those of ordinary skill in organic synthesis field can carry out choose reasonable to condition and equipment on the basis of this area knowledge, reach the chemical reaction that carries out described method smoothly with expection.
Exemplary scheme and embodiment are changed the analogue of the concrete exemplary materials that can obtain above-mentioned generation.Can be suitable for carrying out these variations to the suitable methodology of organic synthesis of above quoting.
In exemplary scheme, it is favourable that reaction product is separated from a kind of other and/or parent material.The required product that adopts this area technology commonly used that each step or series of steps are produced separate and/or purifying (hereinafter referred to as separated) to the uniformity of required degree.Usually, this separation comprises heterogeneous extraction, crystallization from solvent or solvent mixture, distillation, distillation or chromatography.Chromatography can comprise any kind of method, for example comprises: size exclusion or ion-exchange chromatography; High, in or low pressure liquid chromatography, small-scale and preparation thin layer or thick layer chromatography, and small-scale thin layer and flash chromatography.
The separation method of other type comprises: with selecting to be used in conjunction with the reagent of required product, unreacted parent material, byproduct of reaction etc. or making isolating agent treated mixtures such as required product, unreacted parent material, byproduct of reaction.These reagent comprise sorbent material or sorbent material, as activated carbon, molecular sieve, Ion Exchange Medium etc.Perhaps, can be acid for this reagent of basic material, then is alkali for this reagent of acid material; Can be wedding agent, for example antibody, conjugated protein; Selectivity chelator, for example crown ether; Liquid/liquid ion extractuin reagent (liqid/liqidion extraction reagent, LIX) etc.
The character that the selection of suitable separation method is depended on related material.For example, the molecular weight in boiling point, distillation and the distillation, in chromatogram, whether have polar functional group, the stability of material in heterogeneous extraction in acidity and alkaline medium etc.Those skilled in the art can use these technology and obtain required separation as much as possible.
Also the proper method that is used to prepare mixture of the present invention can be found in WO 2004/005286, among the scheme 1-13 especially therein.
Scheme 1 is depicted as another synthetic route of 5-benzyl-2-phenyl-5H-imidazo [4,5-c] pyridine and analogue thereof.
Scheme 1:
Comprise the carboxylic acid reaction thing in the condensation ring-closure reaction that can be used for scheme 1 in the following table.The compound that produces will be at its YR
1The position has these sour residues.Randomly, can in the compound of arbitrary embodiment 2-7, find the nubbin of this molecule.
Comprise the alkylating reagent in the pyridyl alkyl reaction that can be used for scheme 1 in the following table.Herein, the residue of described alkylating reagent is positioned at the X R of The compounds of this invention
3The position.Randomly, can in the compound of arbitrary embodiment 2-7, find the nubbin of described compound.
Scheme 2 is depicted as the synthetic route of 5-diaryl methyl-2-phenyl-5H-imidazo [4,5-c] pyridine and 5-benzyl-2-diaryl-5H-imidazo [4,5-c] piperidines.
Scheme 2
Scheme 3 is depicted as the synthetic route of 5-(alkoxybenzyl)-2-phenyl-5H-imidazo [4,5-c] pyridine and 5-benzyl-2-alkoxybenzyl-5H-imidazo [4,5-c] pyridine.R, R ' and R " can be any alkyl, benzylic or assorted benzylic group.
Scheme 3
Known to those skilled in the art, can adopt the mode identical to synthesize similar compound by changing parent material, intermediate, solvent and condition with aforementioned schemes.
Embodiment
The A part
Compound is synthetic
Embodiment 1
2-(2, the 3-difluorophenyl)-3H-imidazo (4,5-c) pyridine
With Vanadium Pentoxide in FLAKES (24.56g) 50 ℃ of following stirring and dissolving in methylsulfonic acid (165.8mL).In above-mentioned solution, add 3, and the 4-diamino-pyridine (12.3g, 0.11mol) with 2, the 3-difluoro-benzoic acid (19.4g, 0.12mol).Reaction mixture was in 190 ℃ of heating 3 hours.Reaction is carried out three times.Reaction mixture is cooled to 50 ℃ and also under agitation pours in the ice.In this stage, all three batch reaction things merge.Reaction mixture neutralizes by under agitation adding NaOH, is 8 until pH.The solid matter that precipitation is separated out solution filters collection and air-dry.End product carries out recrystallization twice with the ethanol/water solvent, obtains 2-(2, the 3-difluorophenyl)-3H-imidazo (4,5-c) pyridine of 36g.1H 300Mhz (CD
3OD) sigma 7.3-7.42 (m, 1p); 7.43-7.58 (m, 1p); 7.70 (d, 1p); 8.0 (m, 1p); 8.34 (d, 1p); With 8.95 (s, 1p) .LC/MS value M/z=232.
According to above-mentioned step of instructing, and replace 2 with the 2-fluorobenzoic acid, the 3-difluoro-benzoic acid can make compound 2-(2-fluorophenyl)-3H-imidazo (4,5-c) pyridine.
Embodiment 2
5-((3-(4-chloro-phenyl-) isoxazole-5-base) methyl)-2-(2-fluorophenyl)-5H-imidazo (4,5-c) pyridine
(11.0g in DMF suspension 50.0mmol), adds the NaOH aqueous solution of 10% (w/v) at 2-(2-fluorophenyl)-3H-imidazo [4,5-c] pyridine.In the gained solution, add 5-(the chloromethyl)-3-be dissolved in DMF (4-chloro-phenyl-) isoxazole (and 13.68g, 60.0mmol).Reaction mixture at room temperature stirs, and adopts the LCMS monitoring per half an hour.LCMS is presented at after reaction gets nowhere between 2 hours control points and the 4 hours control points, termination reaction after 4 hours.Reactant elder generation water uses ethyl acetate (EtoAc) to grind (triturate) (3 *) again.The gained material by with the material heating for dissolving in MeOH, then carry out recrystallization with water precipitation.Carry out this re-crystallization step then repeatedly, ((3-(4-chloro-phenyl-) isoxazole-5-base) methyl)-2-(2-fluorophenyl)-(15.385g 38mmol), is white crystal to 5H-imidazo (4,5-c) pyridine, and productive rate is 74% to obtain 5-.1H300Mhz (d
6-DMSO) sigma 6.02 (s, 2p); 7.13 (s, 1p); 7.26-7.35 (m, 2p); 7.43-7.52 (m, 1p); 7.56 (d, 2p); (7.84 d, 1); 7.89 (d, 2p); (8.24 d, 1); 8.28-8.36 (m, 1p); With 9.19 (s, 1p) .LCMS value M/Z=405.31.
Embodiment 3A
5-(4-(trifluoromethoxy) benzyl)-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine
At first, in the DMF of 430ml, add 2-(2, the 3-difluorophenyl)-3H-imidazo (4,5-c) pyridine (20g, 86.6mmol).The part solid matter is not molten.10%NaOH (w/v) solution that in this solution, adds 43ml.Under high degree of agitation, undissolved material enters solution.Gained solution is divided into the 16.3ml of 30 equal portions, and the 2-of 3mmol (2, the 3-difluorophenyl)-3H-imidazo (4,5-c) pyridine (20g, 86.6mmol), the microwave reaction container of packing into.Add in each reaction vessel 1-(chloromethyl)-4-(trifluoromethoxy) benzene (693mg, 3mmol).Every part of reaction mixture was 110 ℃ of following microwave treatment 1 minute.After all microwave reactions finish, all reaction vessels merging (because the disruptive cause, a container loses) are three batches carry out aftertreatment.All batches vacuum is removed DMF, and the gained material adopts deionized water wash three times.The thick product of gained is dissolved in CH
2Cl
2, and with the SiO of 330g
2Post carries out purifying (Redisep (Isco) 0% to 0%/5 minute to 10%B/30 minute to 20%/5 minute), and the gained material carries out recrystallization with ethanol/water.Three batches obtain 14g, the 5-of 33.5mmol (4-(trifluoromethoxy) benzyl)-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine.1H 300Mhz (CD3OD) sigma5.79 (s, 2p); 7.25-7.35 (m, 1p); 7.37 (d, 2p); 7.38-7.42 (m, 2p); 7.55 (d, 2p); 7.88-7.95 (m, 1p); 8.25 (d, 1p); With 9.05 (s, 1p) .LC/MS M/z=406.23.
Embodiment 3B
According to above-mentioned step of instructing, and, can make compound 5-(4-iodine benzyl)-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine with 1-(chloromethyl)-2,4 difluorobenzene replacement 1-(chloromethyl)-4-(trifluoromethoxy) benzene.
Embodiment 4
5-(2,4-two fluoro-xenyls) methyl-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine
5-(4-iodine benzyl)-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine (460mg, in DMF 1.03mmol) (10ml) solution, add the 2,4 difluorobenzene ylboronic acid (196mg, 1.24mmol).With Na
2CO
3Water-soluble, join in the DMF solution and stir.Then with Pd (PPh
3)
4Join in the DMF reaction mixture.Reaction mixture heated 2 minutes in microwave under 200 ℃.After extracting aftertreatment with ethyl acetate/water, thick product is used Isco 40g SiO in two batches
2Post (0 to 10%B/20 minute, A=CH
2Cl
2, B=MeOH, flow velocity=40ml/ minute) and carry out purifying respectively.The product component of purifying merges and concentrates.Gained solid CH
2The Cl/ hexane carries out recrystallization.The crystal high vacuum dry that collection obtains is spent the night, obtain productive rate and be 5-(2,4-two fluoro-xenyls) methyl-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine of 50% (223mg, 0.515mmol).1H300Mhz (CD30D) sigma 5.8 (s, 2p); 7.0-7.1 (m, 2p); 7.25-7.35 (m, 1p); 7.35-7.45 (m, 1p); 7.45-7.60 (m, 5p); 7.85 (d, 1p); 7.85-8.0 (m, 1p); 8.3 (d, 1p); With 9.10 (s, 1p) .LC/MS value M/z=434.18.
Embodiment 5
5-((3-(4-chloro-phenyl-) isoxazole-5-base) methyl)-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine
(10g in DMF solution 43.3mmol), adds the NaOH aqueous solution of 10% (w/v), then adds 5-(chloromethyl)-3-(4-chloro-phenyl-)-isoxazole (11.8g, 51.9mmol) DMF solution at the azepine benzoglyoxaline.Reaction mixture at room temperature stirred 7 hours, concentrated then.Solid matter is handled with EtOAc/ water, filters and collects.Solid matter water and EtoAc then grinds, and air-dry.Solid is further purified with the MeOH recrystallization, obtain 46.6% productive rate 5-((3-(4-chloro-phenyl-) isoxazole-5-base) methyl)-2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine (and 8.5g, 20.1mmol).1H300Mhz (DMSO-d6) sigma 6.03 (s, 2p); 7.12 (s, 1p); 7.25-7.35 (m, 1p); 7.44-7.53 (m, 1p); 7.55 (d, 2p); 7.88 (d, 3p); 8.11-8.18 (m, 1p); 8.24-8.29 (dd, 1p); With 9.23 (s, 1p) .LC/MS value M/z=423.34,425.22.
Embodiment 6
5-((3-(2,4-trifluoromethyl) isoxazole-5-base) methyl)-2-(2-fluorophenyl)-5H-imidazo [4,5-c] pyridine
2,4-(two-trifluoromethyl) benzaldoxime
To be suspended in EtOH/ water (1: 2,230ml, in aromatic aldehyde 0.09M) (0.021mol), (1.58g 0.023mol), is cooled to 4 ℃ to add hydroxylamine hydrochloride.The NaOH aqueous solution of Dropwise 5 0%w/w in solution (4.13ml, 0.052mol).After the stirring at room 1.5 hours, reaction mixture carries out acidifying and uses CH with the 2N aqueous hydrochloric acid
2Cl
2Extract (3 * 50ml).Gained organic solution is washed dried over sodium sulfate with the saturated NaCl aqueous solution.Remove the thick product (5.3g, quantitative) that solvent obtains oxime, be directly used in subsequent step.
2,4-(two-trifluoromethyl) phenyl-chloride methyl-isoxazole
With 2, (9.75g 0.038mol) is suspended in CH to 4-(two-trifluoromethyl) benzaldoxime
2Cl
2(45ml, 0.85M) in, be cooled to 4 ℃.With propargyl chloride (2.72ml 0.038mol) adds in the reaction soln, then drip NaOCl (the 10-13% free chlorine, 37.6ml, 0.061mol).Reaction mixture stirred 15 minutes down at 4 ℃, reflux 3 hours.After being cooled to room temperature, reaction system is at CH
2Cl
2With distribute in the water.Organic layer separates, and the saturated NaCl aqueous solution washs, and sodium sulfate carries out drying.After removing solvent, the thick product of gained chloromethyl isoxazole is at silicon-dioxide column chromatography (10%CH
2Cl
2/ hexane) (6.5g purifies on 0.020mol).
5-((3-(2,4-trifluoromethyl) isoxazole-5-base) methyl)-2-(2-fluorophenyl)-5H
-imidazo (4,5-c) pyridine
Imidazopyridine (14.28g in being suspended in DMF (40ml), 0.067mol) in, the NaOH aqueous solution of adding 10%w/w (32.2ml, 0.080mol), then add chloromethyl isoxazole (26.3g, DMF 0.020mol) (16ml) solution that abovementioned steps obtains.Stirred 12 hours under the room temperature, obtain brown solid behind the evaporating solvent.Thick product solid water (7 *) grinds, and carries out crystallization (2 *) with MeOH/ water, obtains pure title compound.
NMR;300Mhz D
6MSO
Chemical shift, multiplicity, proton number:
6.1,s,2
7.0,s,1
7.3,t,2
7.4-7.5,m,1
7.8-7.9,d,1
7.9-8.0,d,1
8.2-8.4,m,4
9.2,s,1
Embodiment 7
5-((3-(4-trifluoromethyl-2-fluorophenyl) isoxazole-5-base) methyl)-2-(2-fluorophenyl)-5H-imidazo (4,5-c) pyridine
Isoxazole is synthetic
Compound | MW | Quantity | Mole number | Equivalent |
A | 207.13 | 9.3g | 0.044 | 1 |
NaOCl (10% free chlorine) | 74.44 | 43.0ml | 0.44 | 1.6 |
Propargyl chloride | 74.51 | 3.14ml | 0.044 | 1 |
Methylene dichloride | 48.7ml |
" A " in methylene dichloride, 0 ℃ of fierce down stirring and adding NaOCl, then adds propargyl chloride at 0 ℃ of low suspension.Reactant stirred 5 minutes down at 0 ℃, and then reflux is 2 hours.Cool to room temperature is washed then, dried over sodium sulfate, and vacuum concentration obtains yellow solid.The gained solid carries out purifying on the compound flash chromatography (combiflash) of silicagel column, with 3-50% ethyl acetate-hexane wash-out, obtain the flash of light white solid of 4.5g.
Compound | MW | Quantity | Mole number | Equivalent |
A | 279.62 | 2.0g | 7.6 | 1.2 |
B | 213.21 | 1.373g | 6.4 | 1 |
The 10%w/v NaOH aqueous solution | 2.26ml | |||
DMF | 13.73ml+6.56ml |
" B " is suspended among the 13.73mlDMF, adds the NaOH aqueous solution of 10% (w/v)." A " is dissolved in the DMF of 6.56ml, and gained solution under agitation joins in the above-mentioned system.Reactant was stirring at room 5 hours.The DMF vacuum concentration is removed, and gained solid water grinds twice and grinds with ethyl acetate.The gained solid carries out recrystallization with methanol-water, obtains the required compound of 533mg.
NMR (DMSO) value:
Chemical shift, multiplicity, proton number:
6.14,s,2
7.18,d,1
7.28-7.36,m,2
7.44-7.54,m,1
7.70-7.76,d,1
7.86-7.90,d,1
7.90-7.96,d,1
8.08-8.16,t,1
8.28-8.36,t,2
9.24,s,1
Embodiment 8A
5-((3-(2-trifluoromethyl-4-fluorophenyl)-isoxazole-5-bases) methyl))-2-(2-fluorophenyl)-5H-imidazo (4,5-c) pyridine
At azepine benzoglyoxaline (12.7g, 59.6mmol) DMF (120ml) solution in, NaOH (the 30.5ml that adds 10% (w/v), 76.6mmol) aqueous solution, then add 5-(chloromethyl)-3-(2-trifluoromethyl-4-fluorophenyl)-isoxazoles (21.3g, DMF 76.6mmol) (60ml) solution.Reaction mixture stirring at room 18 hours then concentrates.Adopt MeOH/ water to precipitate, filter and collect.Solid matter carries out recrystallization with the EtoAc/ hexane, obtains 5-((3-(2-trifluoromethyl-4-fluorophenyl) isoxazole-5-base) methyl)-2-(2-fluorophenyl)-5H-imidazo (4, the 5-c) pyridine of 69% productive rate.
The NMR value
300Mhz D
6MSO
Chemical shift, multiplicity, proton number:
6.15,s,2
6.91,s,1
7.3,t,2
7.42-7.52,m,1
7.65-7.9,m,2
7.84-7.9,m,2
8.22-8.45,m,2
9.19,s,1
Embodiment 8B
5-((3-(2-trifluoromethyl-4-fluorophenyl) isoxazole-5-base) methyl))-2-(2-fluorophenyl)-5H-imidazo (4,5-c) pyridinium salt
Mesylate
5-((3-(2-trifluoromethyl-4-fluorophenyl) isoxazole-5-base) methyl))-2-(2-fluorophenyl)-5H-imidazo (4,5-c) pyridine free alkalis (200mg) pulping in 2.0ml acetone.Add methylsulfonic acid (42.6mg), mixture heating up is to~60 ℃.Adding the water yield slightly increases, up to forming solution (needing 110 μ l).The solution cool to room temperature also stirs and spends the night.The gained slurries cool off in ice bath, filter and use washing with acetone then.The gained solid is dry under 40 ℃, obtains the required salt of 149mg.213.1 ℃ of DSC heat absorptions.The NMR value is consistent with desired structure.
HCl salt
5-((3-(2-trifluoromethyl-4-fluorophenyl)-isoxazole-5-bases) methyl)-2-(2-fluorophenyl)-5H-imidazo (4,5-c) pyridine free alkalis (200mg) pulping in 2.0ml acetone.Add concentrated hydrochloric acid (46mg), mixture heating up is to~60 ℃.Add entry in thick slurry, adding the water yield slightly increases, up to forming solution (needing 100 μ l).The solution cool to room temperature also stirs and spends the night.Slurry cools off in ice bath, then filters and washing with acetone.The gained solid carries out drying at 40 ℃, obtains the required salt of 80mg.241.5 ℃ of DSC heat absorptions.The NMR value is consistent with desired structure.
Embodiment 8B
5-(the preparation of (3-(2-trifluoromethyl-4-fluorophenyl) isoxazole-5-base) methyl)-2-(2-fluorophenyl)-5H-imidazo (4,5-c) pyridinium salt
Arbitrary salt of embodiment 7B mixes with 1: 1 weight ratio with the starch of exsiccant pre-gelled.The mixture of 100mg loads in the regid gel capsule.
Other compound of the present invention is prepared by the method for steps A, C, D, E and F step.
Steps A: alkylation
For the compound that array format (array format) makes, the skeleton of 100um (scaffold) (herein being 2-(2,3-two fluoro-phenyl)-3H-imidazo (4,5-c) pyridine) is used for each reaction system.The 2-of all amounts (2,3-two fluoro-phenyl)-3H-imidazo (4,5-c) pyridine is dissolved among the DMF of q.s, obtains 500ul solution/reaction system.10% (w/v) NaOH/H that in every part of solution, adds 60 μ l
2O.Alkylating reagent is dissolved among the DMF with the concentration of 480 μ mol/mL, and 250 μ l gained solution are added each reaction system.Each reaction system was with carry out microwave radiation heating to 110 ℃ a minute.After the cooling, each reaction system is filtered by the 0.45um strainer.Every part of compound adopts 0.1%TFA/ water and 0.1%TFA/ acetonitrile to carry out purification based on quality grading as eluent on the reverse post of C-18.Every part of compound is confirmed with mass spectrum, with 254mn UV absorbance measurement purity.The HPLC fraction concentrates by centrifugal evaporation, and collecting amount is determined in weighing.
Step C:Suzuki boric acid
Aryl boric acid (1.2 equivalent) joins the DMF solution of 5-(4-iodine benzyl)-2-(2, the 3-difluorophenyl)-5H imidazo (4,5-c) pyridine (1 equivalent).With Na
2CO
3(2 equivalent) is dissolved in water, joins in the DMF solution and stirring.Then with Pd (PPh
3)
4(5 moles of %) joins the DMF reaction mixture.Reaction mixture heated two hours in 200 ℃ in microwave.Reaction mixture be applied to 1g solid-phase extraction column cylinder (extraction cartridge) (C-18) on, described post is with the methanol wash of 3 * 2ml.Elutriant filters by the strainer of 0.45um, is concentrated into dried.The gained material is dissolving again in DMF, carries out purifying with reverse hplc/MS.
Step D
The common step of preparation oxime
In the aromatic aldehyde that is suspended in EtOH/ water (1: 2), add hydroxylamine hydrochloride (1.1 equivalent), and be cooled to 4 ℃.The NaOH aqueous solution of Dropwise 5 0%w/w (2.5 equivalent) in this solution.After the stirring at room 1.5 hours, reaction mixture is with the acidifying of 2N aqueous hydrochloric acid and use CH
2Cl
2Extract.Organic solution is washed dried over sodium sulfate with the saturated NaCl aqueous solution.Remove solvent and obtain the thick product of oxime, be directly used in next step.
The common step of cycloaddition
Oxime is suspended in CH
2Cl
2And be cooled to 4 ℃.Propargyl chloride (1 equivalent) joins in the reaction soln, then drips NaOCl (free chlorine of 10-13%, 1 equivalent).Reaction mixture was in 4 ℃ of stirrings 15 minutes, and reflux is 3 hours then.After being cooled to room temperature, reaction system is at CH
2Cl
2And distribute between the water.Separate organic layer, wash with the saturated NaCl aqueous solution, sodium sulfate carries out drying.Except that after desolvating, thick product is by grinding (hexane) or passing through silicon oxide column chromatogram (10%CH
2Cl
2/ hexane) carries out purifying.
Alkylating common step
In being suspended in the imidazopyridine of DMF, drip the NaOH aqueous solution (1.2 equivalent) of 10%w/w, then add the chloromethyl isoxazole (1.2 equivalent) among the DMF.After the stirring at room 12 hours, solvent evaporates, and obtains the thick product of brown solid.Thick product solid water grinds, and methanol (2: 1) is carried out crystallization, obtains pure final product.
Step e: Suzuki bromide
Aromatic bromide (1.2 equivalent) is joined the DMF solution of 4-((2-(2, the 3-difluorophenyl)-5H-imidazo (4,5-c) pyridine-5-yl) methyl) phenyl-boron dihydroxide (1 equivalent).Na
2CO
3(2 equivalent) is dissolved in water, joins in the DMF solution and stirring.Then with Pd (PPh
3)
4(5 moles of %) joins this DMF reaction mixture.Microwave was in 200 ℃ of heating 2 minutes in the reaction mixture.Reaction mixture is applied on the 1g solid-phase extraction column cylinder (C-18), and described post is with the methanol wash of 3 * 2ml.Elutriant filters by the strainer of 0.45um, is concentrated into dried.The gained material is dissolving again in DMF, carries out purifying with reverse hplc/MS.
Step F
The preparation of xenyl array (biphenyl array)
At first in DMF, use aqueous sodium hydroxide solution as alkali reagent, handle 2-(2 with 1-brooethyl-4-iodobenzene (2), 3-two fluoro-phenyl)-3H-imidazo (4,5-c) pyridine (1), suitably replaced 4 '-[2-(2,3-two fluoro-phenyl)-imidazo (4,5-c) pyridine-5-ylmethyl]-xenyl-4-alcohol (5) skeleton.The 2-(2 of gained, 3-two fluoro-phenyl)-5-(4-iodine benzyl)-5H-imidazo (4,5-c) pyridine (3) (1 equivalent) is with three kinds of different 4-hydroxy phenyl boric acid ((4-hydroxy phenyl) boric acid that replace, 4-hydroxyl-2-(trifluoromethyl) phenyl-boron dihydroxide) and (4-hydroxy-2-methyl phenyl) boric acid) and (4-fluoro-2-hydroxyl) phenyl-boron dihydroxide (1.1 equivalent) (yellow soda ash under the Suzuki coupling condition, water, tetrakis triphenylphosphine palladium) handles under, suitably replaced 4 '-(2-(2, the 3-difluorophenyl)-imidazo (4,5-c) pyridine-5-ylmethyl)-biphenyl-4-is pure or (2-(2, the 3-difluorophenyl)-and imidazo (4,5-c) pyridine-5-ylmethyl) biphenyl-2-alcohol.Product precipitates in ethyl acetate, and medium glass filter filters, and washing obtains pure products (5).
The general formula for preparing for array way is the compound of (7), and 50 μ M skeletons (5) among the 250 μ LDMF are used for each reaction system.In each reaction system, add 1.4 normal cesium carbonates.The solution (0.05mmol) that adds the 0.4M of alkylating reagent (6) in DMF.Reaction system is in 60 ℃ of following joltings 4 hours, LC/MS analysis monitoring.Each reaction system is filtered with 0.45 μ M strainer, adopts 0.1%TFA/ water and 0.1%TFA/ acetonitrile to carry out purification based on quality grading as eluent on the reverse post of C-18.Every part of compound is confirmed with mass spectrum, is used in the UV absorbance measurement purity of 254nm.HPLC fraction vacuum concentration and weighing obtain the trifluoroacetate of product (7).
The compound and the part character thereof that prepare according to these steps and embodiment are described in following form.Substituting group with " C " expression is a methyl.
Obs.MW in the following table is meant observed molecular weight.
Embodiment 374
The isoxazole analogue
Ar=(replacement) phenyl, (replacement) heteroaryl (hetaryl)
X=Br,Cl
374a's is synthetic
In the solution of the stirring of 50% ethanol (7ml), add ice (10g) and hydroxylamine hydrochloride (2.1000g) to 4-oxyethyl group-phenyl aldehyde (3.000g), then add 30% aqueous sodium hydroxide solution (3.5ml).After (1 hour) is finished in reaction, add hydrochloric acid and regulate pH to 1, suspension cools off in ice bath and filters.The thick product of oxime can not need purifying promptly to be used for next step.Perhaps, also can carry out recrystallization with diisopropyl ether and ethyl acetate mixture.Productive rate: 71%.
At propargyl chloride (655mg, 1 equivalent) and triethylamine (35mg, 0.1 in methylene dichloride equivalent) (9.5ml) solution, in 15 minutes and under the cooling, add 10% aqueous sodium hypochlorite solution (9.5ml successively, 1.5 equivalent), add oxime solution (1.40g ,~1.3M dichloromethane solution) then, then restir is 1 hour.Reaction is monitored by TLC (silica gel, the dichloromethane solution of eluent: 5%MeOH).Reaction is finished the afterreaction mixture with the dichloromethane extraction of 30ml 3 times.Merge organic phase, anhydrous sodium sulphate is carried out drying, reduction vaporization.Crude product 5-(chloromethyl)-3-(4-ethoxyl phenenyl)-isoxazoles carry out purifying by column chromatography (silica gel, ethyl acetate/petroleum ether=1: 9).Output: 1.1g.
3,4-diamino-pyridine (2.00g), 2, the mixture of 3-difluoro-benzoic acid (1 equivalent) and Tripyrophosphoric acid (50g) was in 180 ℃ of stirring heating 4 hours.Then mixture is cooled to room temperature, pours in ice/water.The gained mixture neutralizes by adding solid NaOH.Thick product 2-(2, the 3-difluorophenyl)-1 (3) H-imidazo (4,5-c) pyridine is collected by filtration, and washing is also dry.Be directly used in next step and do not need purifying.Productive rate: 88%.
2-(2, the 3-difluorophenyl)-1-(3) H-imidazo (4,5-c) pyridines (0.500g) are dissolved among the dry DMF (5ml), and gained solution is cooled to 0 ℃.Add 50% sodium hydroxide (1.5 equivalent), mixture was stirred 15 minutes.Then add 5-(chloromethyl)-3-(4-ethoxyl phenenyl)-isoxazoles (1.2 equivalent), the gained mixture at room temperature stirred 24 hours.At last, add entry (50ml), filter collecting precipitation, drying obtains thick product.
Carry out recrystallization with ethyl acetate; Clear crystal; Productive rate: 35%.
1H NMR (200MHz, DMSO-d
6) δ 9.24 (d, 1H, H4, J=1.2Hz), 8.28 (dd, 1H, H6, J=6.6,1.2Hz), 8.15 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=6.6Hz), 7.77 (AA ' BB ', 2H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.07-7.00 (m, 3H, fragrant H), 6.02 (s, 2H, CH
2), 4.06 (q, 2H, OCH
2, J=6.9Hz), 1.32 (t, 3H, CH
3, J=6.9Hz).
Following examples are by being prepared with the similar method of above-mentioned steps:
374b
From the 4-methoxybenzaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.2Hz), 8.28 (dd, 1H, H6, J=6.6,1.2Hz), 8.15 (m, 1H, phenyl-H), 7.88 (d, 1H, H7, J=6.6Hz), 7.79 (AA ' BB ', 2H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.09-7.00 (m, 3H, fragrant H), 6.01 (s, 2H, CH
2), 3.80 (s, 3H, OCH
3).
374c
From the 4-tolyl aldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.24 (br s, 1H, H4), 8.29 (d, 1H, H6, J=6.7Hz), 8.14 (m, 1H, phenyl-H), 7.88 (d, 1H, H7, J=6.7Hz), 7.58-7.27 (m, 6H, fragrant H), 7.00 (s, 1H , isoxazole-H), 6.04 (s, 2H, CH
2), 2.41 (s, 3H, CH
3).
374d
From the 2-Furan Aldehydes
1H NMR (200MHz, DMSO-d
6) δ 9.24 (br s, 1H, H4), 8.28 (d, 1H, H6, J=6.7Hz), 8.15 (m, 1H, phenyl-H), 7.90-7.87 (m, 2H, fragrance H), 7.51 (m, 1H, phenyl-H), 7.32 (m, 1H, phenyl-H), 7.15 (d, 1H, furans-H, J=3.6Hz), 6.96 (s, 1H , isoxazole-H), 6.68 (m, 1H, furans-H), 6.02 (s, 2H, CH
2).
374e
From thiophene-2-formaldehyde (thiophene-2-carboxal dehyde)
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.6Hz), 8.27 (dd, 1H, H6, J=7.0,1.6Hz), 8.14 (m, 1H, phenyl-H), 7.88 (d, 1H, H7, J=7.0Hz), 7.75-7.70 (m, 2H, fragrance H), 7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.19 (dd, 1H, thiophene-H), 7.06 (s, 1H , isoxazole-H), 6.02 (s, 2H, CH
2).
374f
From the dimethylamino benzaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.6Hz), 8.27 (dd, 1H, H6, J=7.0,1.6Hz Hz), 8.14 (m, 1H, phenyl-H), 7.88 (d, 1H, H7, J=7.0Hz), 7.65 (AA ' BB ', 2H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 6.98 (s, 1H , isoxazole-H), 6.76 (AA ' BB ', 2H, benzyl-H), 5.75 (s, 2H, CH
2), 2.95 (s, 6H, N (CH
3)
2)
374g
From 4-xenyl formaldehyde (4-biphenylcarboxaldehyde)
1H NMR (200MHz, DMSO-d
6) δ 9.25 (d, 1H, H4, J=1.6Hz), 8.30 (dd, 1H, H6, J=7.0,1.6Hz Hz), 8.16 (m, 1H, phenyl-H), and 7.98-7.70 (m, 7H, fragrant H), 7.57-7.26 (m, 5H, fragrant H), 7.18 (s, 1H , isoxazole-H), 6.05 (s, 2H, CH
2).
374h
From the 4-bromobenzaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.6Hz), 8.28 (dd, 1H, H6, J=7.0,1.6Hz), 8.16 (m, 1H, phenyl-H), 7.90-7.68 (m, 4H, fragrant H), 7.51 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.15 (s, 1H , isoxazole-H), 6.05 (s, 2H, CH
2).
374i
From 4-benzyloxy phenyl aldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.6Hz), 8.27 (dd, 1H, H6, J=7.0,1.6Hz Hz), 8.15 (m, 1H, phenyl-H), 7.90-7.76 (m, 3H, fragrant H), 7.57-7.26 (m, 7H, fragrant H), 7.15-7.05 (m, 3H, fragrant H), 6.01 (s, 2H, N-CH
2), 5.16 (s, 2H, O-CH
2).
374j
From 4-(methylthio group) phenyl aldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.2Hz), 8.28 (dd, 1H, H6, J=6.6,1.2Hz), 8.15 (m, 1H, phenyl-H), 7.88 (d, 1H, H7, J=6.6Hz), 7.79 (AA ' BB ', 2H, benzyl-H), 7.50 (m, 1H, phenyl-H), 7.38-7.25 (m, 3H, fragrant H), 7.10 (s, 1H , isoxazole-H), 6.03 (s, 2H, CH
2), 2.51 (s, 3H, SCH
3).
374k
From 2-fluoro-4-methoxybenzaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.26 (d, 1H, H4, J=1.2Hz), 8.30 (dd, 1H, H6, J=6.6,1.2Hz), 8.14 (m, 1H, phenyl-H), 7.88 (d, 1H, H7, J=6.6Hz), 7.80 (m, 1H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.04-6.71 (m, 3H, fragrant H), 6.03 (s, 2H, CH
2), 3.82 (s, 3H, OCH
3).
374w
Preparation according to the method described above is from 4-chloro-2-fluorobenzaldehyde.
1H NMR (200MHz, DMSO-d
6) 9.26 (d, 1H, H4, J=1.4Hz), 8.30 (dd, 1H, H6, J=6.8,1.4Hz), 8.14 (m, 1H, phenyl-H), (7.90-7.87 m, 2H, fragrant H), 7.66 (dd, 1H, fragrant H, J=10.8,1.8Hz), 7.53-7.41 (m, 2H, fragrant H), 7.31 (m, 1H, phenyl-H), 7.10 (d, 1H isoxazole-H, J=2.7Hz), 6.06 (s, 2H, CH
2).
374l
From 4-propoxy-phenyl aldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.2Hz), 8.29 (dd, 1H, H6, J=6.6,1.2Hz), 8.14 (m, 1H, phenyl-H), 7.88 (d, 1H, H7, J=6.6Hz), 7.78 (AA ' BB ', 2H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.06-7.00 (m, 3H, fragrant H), 6.01 (s, 2H, CH
2), 3.97 (t, 2H, OCH2, J=6.5Hz), 1.73 (hex, 2H, CH
2), 0.97 (t, 3H, CH3, J=7.3Hz).
374m
From the 4-phenoxy benzaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.25 (d, 1H, H4, J=1.2Hz), 8.29 (dd, 1H, H6, J=6.6,1.2Hz), 8.16 (m, 1H, phenyl-H), 7.92-7.83 (m, 3H, fragrant H), 7.58-7.05 (m, 10H, fragrant H), 6.04 (s, 2H, CH
2).
374n
From 1-methylpyrrole-2 formaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.24 (d, 1H, H4, J=1.2Hz), 8.28 (dd, 1H, H6, J=6.8,1.2Hz), 8.16 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=6.8Hz), 7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 6.98 (dd, 1H, the pyrroles-H), (6.92 s, 1H , isoxazole H), 6.68 (dd, 1H, the pyrroles-H), 6.12 (dd, 1H, the pyrroles-H), 6.00 (s, 2H, CH
2).
374o
From 4-isopropyl benzene formaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.24 (d, 1H, H4, J=1.4Hz), 8.28 (dd, 1H, H6, J=7.0,1.4Hz), 8.15 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=7.0Hz), 7.76 (AA ' BB ', 2H, benzyl-H), 7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.05-6.98 (m, 3H, fragrant H), 6.01 (s, 2H, CH
2), 4.67 (hept, 1H, OCH, J=6.2Hz), 1.26 (d, 6H, (CH
3)
2, J=6.2Hz).
374p
Be prepared as above-mentioned method, from 5-chlorothiophene-2-formaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.4Hz), 8.27 (dd, 1H, H6, J=7.0,1.4Hz), 8.14 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=7.0Hz), 7.63 (d, 1H, thiophene-H, J=4.0Hz), 7.51 (m, 1H, phenyl-H), 7.37-7.24 (m, 2H, fragrant H), 7.07 (s, 1H , isoxazole-H), 6.03 (s, 2H, CH
2).
374q
Be prepared as above-mentioned method, from 5-bromothiophene-2-formaldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.4Hz), 8.27 (dd, 1H, H6, J=6.6,1.4Hz), 8.14 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=6.6Hz), 7.59 (d, 1H, thiophene-H, J=3.6Hz), 7.50 (m, 1H, phenyl-H), 7.36-7.27 (m, 2H, fragrant H), 7.06 (s, 1H , isoxazole-H), 6.02 (s, 2H, CH
2).
374r
Be prepared as above-mentioned method, from 4-butyl phenyl ether formaldehyde (getting) by the alkylation preparation of 4-hydroxy benzaldehyde.
1H NMR (200MHz, DMSO-d
6) δ 9.24 (d, 1H, H4, J=1.2Hz), 8.28 (dd, 1H, H6, J=6.6,1.2Hz), 8.15 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=6.6Hz), 7.78 (AA ' BB ', 2H, benzyl-H), 7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.07-7.01 (m, 3H, fragrant H), 6.01 (s, 2H, CH
2), 4.01 (t, 2H, OCH
2, J=6.5Hz), 1.72 (m, 2H, CH
2), 1.42 (m, 2H, CH
2), 0.93 (t, 3H, CH
3, J=7.2Hz).
374s
Be prepared as above-mentioned method,, and use 2-(2-fluorophenyl)-1 (3) H-imidazo (4,5-c) pyridine to replace 2-(2, the 3-difluorophenyl)-1 (3) H-imidazo (4,5-c) pyridine from 4-propoxy-phenyl aldehyde.
1H NMR (200MHz, DMSO-d
6) 9.18 (d, 1H, H4, J=1.2Hz), 8.38-8.23 (m, 2H, fragrant H), 7.85 (d, 1H, H7, J=6.6Hz), 7.78 (AA ' BB ', 2H, benzyl-H), 7.54-7.25 (m, 3H, phenyl-H), 7.06-7.00 (m, 3H, fragrant H), 6.00 (s, 2H, CH
2), 3.98 (t, 2H, OCH
2, J=6.6Hz), 1.73 (hex, 2H, CH
2), 0.97 (t, 3H, CH
3, J=7.3Hz).
374t
From 4-allyloxy phenyl aldehyde
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.2Hz), 8.27 (dd, 1H, H6, J=6.7,1.2Hz), 8.14 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=6.7Hz), 7.79 (AA ' BB ', 2H, benzyl-H), 7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.09-7.00 (m, 3H, fragrant H), 6.15-5.98 (m, 3H), 5.45-5.24 (m, 2H), 4.62 (d, 2H, J=4.8Hz).
374u
5-(chloromethyl)-3-(4-chloro-phenyl-)-isoxazoles (2.00g), NCS (11.75g, 10 equivalents), the mixture heating up of Glacial acetic acid (35ml) and 20 vitriol oils refluxed 3 days.After being cooled to room temperature, add methylene dichloride (100ml), gained mixture water (2 * 100ml) and saturated sodium bicarbonate aqueous solution (2 * 100ml) extract.Organic phase is carried out drying and evaporation with anhydrous sodium sulphate.The thick product of gained carries out purifying (silica gel, eluent: petrol ether/ethyl acetate=19: 1) obtain the product of 1.14g by column chromatography.
Last step step is as mentioned previously carried out.Carry out recrystallization with ethyl acetate and alcohol mixture.Productive rate: 60%.
1H NMR (200MHz, DMSO-d
6) 9.20 (d, 1H, H4, J=1.4Hz), 8.25 (dd, 1H, H6, J=6.8,1.4Hz), 8.15 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=6.8Hz), 7.83 (AA ' BB ', 2H, benzyl-H), 7.66 (AA ' BB ', 2H, benzyl-H), 7.51 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 6.14 (s, 2H, CH
2).
374v
1H NMR (200MHz, DMSO-d
6) δ 9.18 (d, 1H, H4, J=1.4Hz), 8.22 (dd, 1H, H6, J=6.8,1.4Hz), 8.14 (m, 1H, phenyl-H), 7.89 (d, 1H, H7, J=6.8Hz), 7.80 (AA ' BB ', 2H, benzyl-H), 7.65 (AA ' BB ', 2H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.30 (m, 1H, phenyl-H), 6.11 (s, 2H, CH
2).
To synthesize with the similar method of Lv Isoxazole derivative 374u, 4 normal NBS refluxed productive rate: 91% in 2.5 hours.
Embodiment 375
In the 4ml carbon tetrachloride solution of the 3-of 500mg methyl isophthalic acid-phenylpyrrole, in 70 ℃ of mixtures that add 678mg (1.2 equivalent) NBS and AIBN (62.3mg, 0.12 equivalent) in batches.The gained mixture continued reflux 15 minutes, was cooled to room temperature.Filter out precipitation, filtrate concentrates postprecipitation and obtains thick product (380mg), after filtration collection and the drying, need not purifying and is directly used in subsequent step.
Final step method is as described above carried out.Use re-crystallizing in ethyl acetate.Productive rate: 35%.
Embodiment 376
Imidazo (4,5-c) pyridine-4-keto analog
The mixture of 4-chloro-3-nitro-pyridin-2-ones (1.00g), 4-(trifluoromethyl) benzyl chloride (1.226g), Anhydrous potassium carbonate (0.871g) and dry DMF (10ml) stirred under room temperature 24 hours.Then add entry (100ml), the gained sedimentation and filtration is collected, and washing is also dry.Productive rate: 4-chloro-3-nitro-1-(4-trifluoromethyl) benzyl-pyridin-2-ones of 58.2%.
4-chloro-3-nitro-1-(4-trifluoromethyl) benzyl-pyridin-2-ones (500mg) is dissolved in anhydrous THF (10ml).Add strong aqua (7.5ml), the gained mixture was in stirring at room 24 hours.Add entry (50ml), the gained sedimentation and filtration is collected, and washing is also dry.Productive rate: 4-amino-3-nitro-1-(4-trifluoromethyl) benzyl-pyridin-2-ones of 45.8%.
The mixture of 4-amino-3-nitro-1-(4-trifluoromethyl) benzyl-pyridin-2-ones (1.400g), saturated aqueous ammonium chloride (9.4ml), zinc powder (1.400g) and methyl alcohol (235ml) was in stirring at room 1 hour.Add zinc powder (1.400g) in addition again, gained mixture restir 23 hours.After the solvent evaporation, add entry (30ml), regulate pH to 8-9 by the NaOH that adds 2N.(3 * 30ml) extract the gained mixture, merge organic phase and wash (30ml), anhydrous sodium sulfate drying and evaporation with ethyl acetate.Productive rate: 53.4% 3,4-diaminostilbene-(4-trifluoromethyl) benzyl-pyridin-2-ones.
3,4-diaminostilbene-(4-trifluoromethyl) benzyl-pyridin-2-ones (0.200mg), 2, the mixture of 3-difluorobenzaldehyde (100mg), Sodium Pyrosulfite (0.134g) and N,N-dimethylacetamide (4.6ml) heated 24 hours down in 130 ℃.Then add entry (30ml), the gained sedimentation and filtration is collected, and washing is also dry.Thick product is through column chromatography (silica gel, eluent: methylene chloride=12/1) carry out purifying, then carry out recrystallization with diisopropyl ether and ethyl acetate.Productive rate: 16.8%.Fusing point: 279-283 ℃.
1H NMR (200MHz, DMSO-d
6) δ 13.05 (br s, 1H, NH), 7.88 (m, 1H, phenyl-H), 7.74-7.32 (m, 7H, fragrant H), 6.69 (br d, 1H, H7, J=6.0Hz), 5.34 (s, 2H, CH
2).
Embodiment 377
Synthesizing of 4-methyl analogue 377
The mixture of the methyl trioxy-rhenium (methyltrioxorhenium) of 2-(2, the 3-difluorophenyl)-1 (3) H-imidazo (4,5-c) pyridines (2.00g), 50mg, the methyl alcohol of 100ml and 30% aqueous hydrogen peroxide solution (4ml) was in stirring at room 4 days.Then, add methyl trioxy-rhenium and 30% aqueous hydrogen peroxide solution (4ml) of 50mg in addition, the gained mixture then stirred 2 days.After boiling off methyl alcohol, add entry (200ml), regulate pH to 9 by the NaOH that adds 2N.Gained precipitation filters, dry, carry out recrystallization with ethyl acetate (20ml) and ethanol (53ml) mixture, obtain 2-(2, the 3-difluorophenyl)-1-(3) H-imidazo (4, the 5-c) pyridine-5-oxide compound of 1.208g (56.5%).
2-(2, the 3-difluorophenyl)-1 (3) H-imidazo (4,5-c) pyridine-5-oxide compound (1.00g) is dissolved in exsiccant tetrahydrofuran (THF) (100ml), and argon shield drips MeMgBr solution (14ml, the diethyl ether solution of 3M) down.The gained mixture stirred under room temperature 1.5 hours.Slowly add water (100ml), pH regulator to 8.5.(3 * 70ml) extract ethyl acetate, and the organic phase of merging is carried out drying with anhydrous sodium sulphate, boil off 2-(2, the 3-difluorophenyl)-thick product of 4-methyl isophthalic acid (3) H-imidazo (4,5-c) pyridine that solvent obtains 0.630g (60%).Mixture with diisopropyl ether (20ml) and ethyl acetate (34ml) carries out recrystallization, obtains the pure 2-of 240mg (24.2%) (2, the 3-difluorophenyl)-4-methyl isophthalic acid (3) H-imidazo (4,5-c) pyridine.
Final step such as above-mentioned method are carried out.By column chromatography (silica gel, eluent: methylene chloride=20/1) carry out purifying.Productive rate: 22.4%.
1H NMR (200MHz, DMSO-d
6) δ 8.25 (d, 1H, H6, J=6.8Hz), 8.11 (m, 1H, phenyl-H), 7.89 (AA ' BB ', 2H, benzyl-H), 7.77 (d, 1H, H7, J=6.8Hz), 7.60-7.41 (m, 3H, fragrant H), 7.30 (m, 1H, phenyl-H), 7.12 (s, 1H , isoxazole-H), 6.05 (s, 2H, CH
2), 3.05 (s, 3H, CH
3).
Embodiment 378
7 replace the synthetic of analogue
378a
3-methyl-4-nitropyridine 1-oxide compound (5.85g) is dissolved in Glacial acetic acid (115ml), in room temperature at Pa Er (Parr) hydrogenation apparatus (catalyzer: 220mg PtO
2* 2H
2O carried out hydrogenation 2.5 hours in 50psi).Then the elimination catalyzer boils off solvent.After adding the water of 150ml, the NaOH by adding 2N is with pH regulator to 12.Gained solution extracts 10 times with the methylene dichloride (containing 5% methyl alcohol) of 100ml.Merge organic phase, anhydrous sodium sulfate drying and evaporation obtain the 4-amino-3-picoline of 3.81g (83.6%).
Under ice-cooled, 4-amino-3-picoline (3.00g) is dissolved in the vitriol oil (36ml).Then drip nitrosonitric acid (4,72g).After the stirring at room 1 hour, solution was in 60 ℃ of heating 14 hours.After being cooled to room temperature, reaction mixture is poured in the ice, and gained solution is regulated pH to 13 by adding solid KOH.Precipitation is filtered, washing and dry.The 4-amino of productive rate: 1.198g (31.3%)-3-methyl-5-nitro pyridine.
The mixture heating up of 4-amino-3-methyl-5-nitro pyridine (1.198g), iron powder (1.748g), ethanol (52ml) and hydrochloric acid (13ml) refluxed 3 hours.After being cooled to room temperature, ethanol distillation is removed, and gained suspension is diluted with water to 50ml, regulates pH to 13 by the NaOH that adds 2N.(3 * 70ml) extract, and the organic phase of merging is carried out drying with anhydrous sodium sulphate, boil off solvent and obtain 3 of 0.579g (60%), 4-diamino-5-picoline with ethyl acetate.
With as above-mentioned method in PPA with 2, the 3-difluoro-benzoic acid carries out cyclization.Column chromatography is carried out purifying (silica gel, eluent: methylene chloride=12/1).Productive rate: 22.2%.
Last step is carried out with foregoing method.With ethyl acetate and alcohol mixture recrystallization.Productive rate: 42.9%378a.
1H NMR (200MHz, DMSO-d
6) δ 9.14 (d, 1H, H4, J=1.2Hz), 8.17-8.10 (m, 2H, fragrant H), 7.90 (AA ' BB ', 2H, benzyl-H), 7.60-7.42 (m, 3H, fragrant H), 7.32 (m, 1H, phenyl-H), 7.15 (s, 1H , isoxazole-H), 5.99 (s, 2H, CH
2), 2.58 (s, 3H, CH
3).
Following compound is used with the similar method of above-mentioned steps and is prepared:
378b
1H NMR (200MHz, DMSO-d
6) δ 9.32 (d, 1H, H4, J=1.4Hz), 8.67 (d, 1H, H6, J=1.4Hz), 8.16 (m, 1H, phenyl-H), 7.78 (AA ' BB ', 2H, benzyl-H), 7.54 (m, 1H, phenyl-H), 7.34 (m, 1H, phenyl-H), 7.07-7.00 (m, 3H, fragrant H), 6.00 (s, 2H, CH
2), 4.07 (q, 2H, OCH
2, J=7.0Hz), 1.33 (t, 3H, CH
3, J=7.0Hz).
378c
1H NMR (200MHz, DMSO-d
6) δ 9.47 (d, 1H, H4, J=1.4Hz), 8.94 (d, 1H, H6, J=1.4Hz), 8.16 (m, 1H, phenyl-H), 7.89 (AA ' BB ', 2H, benzyl-H), 7.63-7.50 (m, 3H, fragrant H), 7.35 (m, 1H, phenyl-H), 7.16 (s, 1H , isoxazole-H), 6.10 (s, 2H, CH
2).
378d
1H NMR (200MHz, DMSO-d
6) δ 9.30 (br s, 1H, H4), 8.66 (dd, 1H, H6, J=7.4,1.4Hz), 8.15 (m, 1H, phenyl-H), 7.89 (AA ' BB ', 2H, benzyl-H), 7.61-7.47 (m, 3H, fragrant H), 7.33 (m, 1H, phenyl-H), 7.16 (s, 1H , isoxazole-H), 6.04 (s, 2H, CH
2).
Embodiment 379
1,2, the 4-oxadiazole
379a
The mixture heating up of 4-HOMOVERATRONITRILE (1.00g), hydroxylamine hydrochloride (0.785g), KOH (0.640g) and methyl alcohol (20ml) refluxed 3 hours.After being cooled to room temperature, the elimination precipitation, filtrate is evaporated.The gained residue is dissolved in the HCl (100ml) of 1N, and the solution that obtains extracts with diethyl ether (100ml).Water is by adding solid NaHCO
3Neutralize, diethyl ether extracts (2 * 100ml).Merge organic phase, anhydrous sodium sulphate is carried out drying, obtains the required amidoxime (amidoxime) of 450mg after the evaporation, and not needing further purifies directly uses.
Toluene (30ml) vlil of the anhydrous chloroacetic acid acid anhydride of (4-p-methoxy-phenyl) amidoxime of 700mg and 1.08g (1.5 equivalent) 3 hours.After being cooled to room temperature, reaction mixture water (twice of 50ml), saturated sodium bicarbonate solution (twice of 50ml) and water (50ml) successively extracts.At last, toluene is used anhydrous sodium sulfate drying mutually, obtains the Suo Xu oxadiazole of 660mg after the evaporation, and not needing further purifies directly uses.
Final step carries out (for example, with reference to the isoxazole analogue) with aforesaid method.Carry out recrystallization with ethyl acetate and alcohol mixture.Productive rate: 35%.
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.4Hz), 8.28 (dd, 1H, H6, J=6.8,1.4Hz), 8.15 (m, 1H, phenyl-H), 7.92-7.77 (m, 3H, fragrant H), 7.49 (m, 1H, phenyl-H), 7.33 (m, 1H, phenyl-H), 7.08-7.00 (m, 3H, fragrant H), 6.01 (s, 2H, CH
2), 3.80 (s, 3H, OCH
3).
379b
Be prepared with aforesaid method, from 4-methyl benzonitrile.
1H NMR (200MHz, DMSO-d
6) δ 9.23 (d, 1H, H4, J=1.4Hz), 8.31 (dd, 1H, H6, J=6.8,1.4Hz), 8.14 (m, 1H, phenyl-H), 7.93-7.78 (m, 3H, fragrant H), 7.50 (m, 1H, phenyl-H), 7.35-7.27 (m, 3H, fragrant H), 6.25 (s, 2H, CH
2), 2.35 (s, 3H, CH
3).
379c
With aforesaid method preparation, from pyridine-2-nitrile.
1H NMR (200MHz, DMSO-d
6) δ 9.24 (d, 1H, H4, J=1.4Hz), 8.72 (ddd, 1H, pyridine-H), 8.32 (dd, 1H, H6, J=6.8,1.4Hz), 8.15 (m, 1H, phenyl-H), 8.00-7.90 (m, 3H, fragrant H), 7.64-7.27 (m, 3H, fragrant H), 6.30 (s, 2H, CH
2).
379d
With aforesaid method preparation, from 4-benzyl chloride nitrile.
1H NMR (200MHz, DMSO-d
6) δ 9.24 (d, 1H, H4, J=1.4Hz), 8.31 (dd, 1H, H6, J=6.8,1.4Hz), 8.16 (m, 1H, phenyl-H), 7.96-7.90 (m, 3H, fragrant H), 7.60 (AA ' BB ', 2H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.34 (m, 1H, phenyl-H), 6.28 (s, 2H, CH
2).
379e
With aforesaid method preparation, from pyridine-4-nitrile.
1H NMR (200MHz, DMSO-d
6) δ 9.24 (d, 1H, H4, J=1.4Hz), 8.77 (AA ' BB ', 2H, pyridine-H2/6), 8.32 (dd, 1H, H6, J=7.0,1.4Hz), 8.15 (m, 1H, phenyl-H), 7.93 (d, 1H, H7, J=7.0Hz), 7.86 (AA ' BB ', 2H, pyridine-H3/5), 7.51 (m, 1H, phenyl-H), 7.32 (m, 1H, phenyl-H), 6.32 (s, 2H, CH
2).
The B part
Measure antiviral and method cell inhibitory activity
Cell and virus
Madin-Darbey Bovine Kidney (MDBK) cell remains on 37 ℃, the 5%CO of humidification
2Under the atmosphere, in the Eagle substratum (DMEM) of Dulbecco improvement, replenish described substratum with 5% foetal calf serum (DMEME-FCS) that does not contain BVDV-.Adopt the antiviral activity of BVDV-1 (bacterial strain PE515) evaluation in the MDBK cell.
Anti--BVDV measures
In DMEM-FCS, inoculate the MDBK cell in the 96 porocyte culture plates, cell was reached after 24 hours converge (confluency).Then, remove substratum, add 5 times of diluents of a series of test compounds, cumulative volume is 100ul, afterwards, adds virus inoculation thing (100ul) in each hole.Used virus inoculation thing after 5 days, causes destroying more than 90% of cell monolayer 37 ℃ of hatchings.In each assay plate, comprise non-infected cells and receive virus but do not receive the cell of compound.After 5 days, remove substratum, in each hole, add the DMEM-FCS of 90 μ l and the MTS/PMS solution (Promega) of 10ul.After 2 hours, on microplate, read the optical density(OD) of each hole under 498nm 37 ℃ of hatchings.50% effective concentration (EC
50) value defined avoids taking place the compound concentration of virus-inductive cytopathic effect for protecting 50% cell monolayer.
Whose anti-HCV mensuration/replicon measures-1
The Huh-5-2 cell [has the cell strain that continues HCV replicon I389luc-ubi-neo/NS3-3 '/5.1; This replicon is the replicon that has the NS3-5B HCV polyprotein of Lampyridea luciferase-ubiquitin-neomycin phosphotransferase fusion rotein and EMCV-IRES driving] in RPMI substratum (Gibco), cultivate, be supplemented with 10% foetal calf serum in the described substratum, 2mM L-glutaminate (Life Technologies), the non-primary amino acid of 1x (Life Technologies); 100IU/ml penicillin and 100ug/ml Streptomycin sulphate and 250ug/ml G418 (Geneticin, Life Technologies).Cell is seeded in 96 hole View Plate with the density of 7000 cells/well
TM(Packard) in the substratum, except G418, described substratum contains the component identical with the above.Make cell attachment and hyperplasia 24 hours.At this moment, remove substratum, in lacking the substratum of G418, add a series of diluents of test compounds.Comprise interferon alpha 2a (500IU) conduct over against photograph.Plate is again in 37 ℃ and 5%CO
2Middle hatching 72 hours.HCV replicon being replicated in the Huh-5 cell produces luciferase activity in the cell.Luciferase activity can add the Steady-Glo luciferase assay reagent (Promega) of 50ul by the 1x Glo-lysis buffer reagent (Promega) that added 50 μ l in 15 minutes subsequently and measure.The activity of luciferase is with photometric determination, and the signal indication in each hole is the percentage ratio of culture of being untreated.The parallel culture of Huh-5-2 cell, be seeded in traditional 96-porocyte culture plate (Becton-Dickinson) with 7000 cells/well density, this culture is handled in a similar manner, and difference is not add Glo-lysis buffer reagent or Steady-Glo luciferase reagent.Adopt MTS method (Promega) to measure culture density in addition.
Come quantitative analysis HCV RNA by the Taqman real-time RT-PCR
The replicon cell is with 7.5 * 10
3Cells/well is in 37 ℃ and 5%CO
2In the 96-orifice plate, containing 10% foetal calf serum, in the minimum medium of Dulbecco ' the s improvement of 1% non-primary amino acid and 1mg/ml Geneticin.Behind the cell attachment 24 hours, in culture, add different dilution compounds.Plate hatching 5 days, at this moment, (Qiagen, Hilden Germany) extract RNA with Qiamp Rneazyi Kit.A 50 μ LPCR reactants comprise TaqMan EZ buffer reagent (50mmol/L N, N-two (hydroxyethyl) glycine, the 115mmol/L potassium acetate, 0.01mmol/L EDTA, 60nmol/L 6-carboxyl-X-rhodamine and 8% glycerine, pH 8.2; Perkin Elmer Corp./Applied Biosystems), 300 μ mol/L deoxyadenosine triphosphates, 300 μ mol/L deoxyguanosine triphosphates, 300 μ mol/L dCTPs, 600 μ mol/L Deoxycytidine triphosphates, 200 μ mol/L forward primers (forward primer) [5 '-ccg gcT Acc TgcccA TTc], 200 μ mol/L reverse primers (reverse primer) [ccA GaT cAT ccT gAT cgAcAA G], 100 μ mol/L TaqMan probe[6-FAM-AcA Tcg cAT cgA gcg Agc AcgTAc-TAMRA], the 3mmol/L manganous acetate, 0.5U AmpErase uridylic-N-transglycosylase, 7.5U rTthDNA polysaccharase and 10 μ lRNA elutriants.Uridylic-N-transglycosylase is in 50 ℃ of initiate activations after 2 minutes, carries out RT 30 minutes in 60 ℃, and uridylic-N-transglycosylase carried out deactivation 5 minutes in 95 ℃ subsequently.PCR amplification subsequently comprises 40 circulations, and each circulation was annealed and spread 1 minute in 62 ℃ in ABI 7700 program detectors for 94 ℃ of sex change 20 seconds.To each PCR operation, use negative norm plate and positive template sample.This round-robin threshold value (Ct-value) is defined as the PCR cycle number that signal surpasses baseline, it define on the occasion of.If the Ct-value is<50, think that this sample is for just.The result is expressed as genome equivalent (GE).
Anti-HCV mensuration/replicon measures-2
HCV replicon nutrient solution
The high sugar of DMEM w/ (or MEM)
1 * glutamine
1 * Sodium.alpha.-ketopropionate
10% heat-inactivated FBS
1 * microbiotic
Cell cultures is prepared
1, the freezing stock solution that in the substratum of 10-12ml, thaws.
2, add G418 (4-6 hour) and make cell attachment before.
3, add G418, to the last concentration is 200ug/ml (also can adopt higher concentration, but cell poor growth)
4, cell fission is that feasible growth in 1: 4 to 1: 6 is optimized
5, Nei Bu (In-house) replicon demonstrates and keeps luciferase signal~20 passages
The HCV replicon is measured
1, diluted chemical compound is in the HCV of 100ul replicon substratum (not containing G418).If compound dilutes, in medium, add DMSO (final DMSO concentration answers<1%) in DMSO
If 2 cells reach converging of 80-90%, carry out trysinization with 1 * trypsinase
3, excessively trysinization.If trysinization is excessive, the easy grumeleuse of cell.
4, every hole adds 6 in 96 pore structures (format), 000-8,000 cell (G418 keeps (withheld) during the compound test).
5, in 37 ℃ of hatchings 3 days.Cell must be very near converging.
6, remove medium, with 1 * PBS washed cell.
7, remove PBS, add the cracking buffer reagent of 100 μ l Promega
8, hatched cell 5-20 minute in room temperature
9, in Microfluor Black Plate (VWR), add under the room temperature of 100 μ l luciferase substrate solution (Promega) extremely.
10, before being added to the luciferase substrate, lysate (lysate) is mixed (up-down vibration transfer pipet) fully.
11, the lysate that in the luciferase substrate solution, adds 75 μ l
12, on Top Count, read plate (Fusion LucB program~5 seconds readings)
13, the lysate of leaving over can freezingly be used for follow-up analysis.
Mensuration is to the cyto-inhibition of MDBK cell
Following mensuration medicine is to the effect with the MDBK cell of exponential growth.Cell is seeded in the density of 5000 cells/well in the plate in 96 holes of MEM substratum (Gibco), is supplemented with 10% foetal calf serum in the substratum, 2mM L-glutaminate (Life Technologies) and supercarbonate (Life Technologies).Cell cultures 24 hours adds a series of diluents of test compounds then.Culture was hatched 3 days again, adopted the effect of MTS method (Promega) quantitative evaluation cell growth then.The concentration that produces cell growth 50% inhibition is defined as 50% cell inhibition concentration (CC
50).
HCV CC50 measuring method
HCV replicon substratum
The high sugar of DMEM w/ (or MEM)
1 * glutamine
1 * Sodium.alpha.-ketopropionate
10% heat-inactivated FBS
1 * microbiotic
Cell cultures is prepared
1, the freezing stock solution that in the substratum of 10-12ml, thaws.
2, add G418 (4-6 hour) and make cell attachment before.
3, add G418, to the last concentration is 200ug/ml (also can adopt higher concentration, but cell poor growth)
4, cell fission is that feasible growth in 1: 4 to 1: 6 is optimized
5, Nei Bu replicon demonstrates and keeps luciferase signal~20 passages
The HCV replicon is measured
1, diluted chemical compound is in the HCV of 100ul replicon substratum (not containing G418).If compound dilutes, in substratum, add DMSO (ultimate density answers<1%) in DMSO
If 2 cells reach converging of 80-90%, carry out trysinization with 1 * trypsinase
3, excessively trysinization.If trysinization is excessive, the easy grumeleuse of cell.
4, every hole adds 6 in 96 pore structures (format), 000-8,000 cell (G418 keeps (withheld) during the compound test).
5, in 37 ℃ of hatchings 3 days.Cell must be very near converging.
6, remove substratum, add the 0.2mg/mLMTT solution that in substratum, makes of 200 μ l.
7, hatching is 1.5-2 hour
8, remove substratum, add the DMSO of 150 μ l
9, in mixed at room temperature and hatched 5 minutes
10, read plate in 530nm reading the plate device.
The result
Find embodiment 2,3A, the EC50 of 4 and 5 compound in replicon mensuration 2 is respectively 0.01,0.02,0.01 and 0.0039 micromole, and the CC50 in the CC50 measuring method is respectively 26,34,19 and 10.8 (repeating (replicate) 13.4) micromole.
Basically all compounds demonstrate at least 1 micromolar activity in the table 1 in whose anti-HCV/replicon mensuration system.In addition, a lot of compounds have also shown anti--BVDV activity.
Claims (40)
1. compound with general formula (A), and salt, tautomer, steric isomer, hydrate and alcoholate,
In the formula:
It is to be adjacent to each other that the optional two keys of dotted line representative, prerequisite do not have two two keys, and at least 3 two keys of this dotted line representative;
R
1Be selected from: hydrogen, aryl, heterocyclic radical, C
1-C
10Alkoxyl group, C
1-C
10Alkylthio, C
1-C
10Alkyl-amino, C
1-C
10Dialkyl-7-amino, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group and C
4-10Cycloalkynyl radical, wherein, each group is randomly by one or more R
6Replace;
Y is selected from: singly-bound, O, S (O) m, NR
11, or C
1-10Alkylidene group, C
2-10Alkenylene, C
2-10Alkynylene, wherein, each group can randomly comprise 1-3 heteroatoms that is selected from O, S or N;
R
2And R
4Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical, prerequisite is for working as R
25Or R
26One of when existing, R then
2Or R
4Be selected from: (=O), (=S) and=NR
27
X is selected from: C
1-C
10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene, wherein, each group can comprise the heteroatoms of one or more O of being selected from, S or N, prerequisite be any this kind heteroatoms not with the ring in the N adjacency;
M is any integer of 0-2;
R
3Be randomly by at least one R
17The heterocyclic radical that replaces, however prerequisite is randomly by at least one R
17The R that replaces
3Not pyridyl or 5-chlorothiophene base;
R
5Be selected from: hydrogen; C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=O) OR
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical;
R
6Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, heterocyclic radical, C
1-18Alkoxyl group, C
1-18Alkylthio, C
1-18Alkyl sulfoxide, C
1-18Alkyl sulfone, C
1-18Halo-alkyl, C
2-18Halo-thiazolinyl, C
2-18Halo-alkynyl, C
1-18Halo-alkoxyl group, C
1-18Halo-alkylthio, C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, OH, CN, cyano group alkyl ,-CO
2R
18, NO
2,-NR
7R
8, C
1-18Haloalkyl, C (=O) R
18, C (=S) R
18, SH, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, aryl (C
1-18) alkyl, aryl (C
1-18) alkoxyl group, aryl (C
1-18) alkylthio, C
1-18Hydroxyalkyl, wherein, each group can be randomly by at least one R
19Replace;
R
7And R
8Be independently selected from: hydrogen, C
1-18Alkyl, C
1-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, heterocyclic radical ,-C (=O) R
12-C (=S) R
12, the amino-acid residue that connects by amino acid whose carboxyl, or R wherein
7And R
8Form heterocyclic radical with nitrogen;
R
9And R
18Be independently selected from: hydrogen, OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
1-18Alkoxyl group ,-NR
15R
16, aryl, by amino acid whose amino amino-acid residue, the CH that connects
2OCH (=O) R
9aOr CH
2OC (=O) OR
9a, wherein, R
9aBe C
1-C
12Alkyl, C
6-C
20Aryl, C
6-C
20Alkylaryl or C
6-C
20Aralkyl;
R
11Be selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, aryl ,-C (=O) R
12, heterocyclic radical or amino-acid residue;
R
12Be selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
15And R
16Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
17Be independently selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, C
1-18Alkyl sulfoxide, C
1-18Alkyl sulfone, C
1-18Haloalkyl, C
2-18Haloalkenyl group, C
2-18Halo alkynyl, C
1-18Halogenated alkoxy, C
1-18Halogenated alkylthio, C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, OH, CN, CO
2H, CO
2R
18, NO
2, NR
7R
8, haloalkyl, C (=O) R
18, C (=S) R
18, SH, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, arylalkyl, alkoxy aryl, alkylthio-aryl, heterocyclic radical, C
1-18Hydroxyalkyl, wherein, described each aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, arylalkyl, alkoxy aryl, alkylthio-aryl, heterocyclic radical or C
1-18Hydroxyalkyl is randomly by one or more R
19Replace;
R
19Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
2-18Alkene oxygen base, C
2-18Alkynyloxy group, C
1-18Alkylthio, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
4-10Cycloalkynyl radical, halogen ,-OH ,-CN, cyano group alkyl ,-NO
2,-NR
20R
21, C
1-18Haloalkyl, C
1-18Halogenated alkoxy ,-C (=O) R
18,-C (=O) OR
18,-O-thiazolinyl-C (=O) OR
18,-O-alkyl-C (=O) NR
20R
21,-O-alkyl-OC (=O) R
18,-C (=S) R
18, SH ,-C (=O) N (C
1-6Alkyl) ,-(O) (C of N (H) S (O)
1-6Alkyl), aryl, heterocyclic radical, C
1-18Alkyl sulfone, aryl sulfoxide, aryl sulfonamide, aryl (C
1-18) alkoxyl group, aryloxy, aryl (C
1-18Alkyl) oxygen base, arylthio, aryl (C
1-18) alkylthio or aryl (C
1-18) alkyl, wherein, each group can randomly be replaced by one or more groups that are selected from down group :=O ,-NR
20R
21, CN, C
1-18Alkoxyl group, heterocyclic radical, C
1-18Haloalkyl, heterocyclic radical alkyl, by alkyl, alkoxyl group alkoxy or halogen and R
17The heterocyclic radical that connects;
R
20And R
21Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12, the heterocyclic radical that replaces of carboxyl ester or-C (=S) R
12
R
25And R
26Do not exist or be independently selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, aryl, heterocyclic radical, wherein, each group can be chosen wantonly independently and be replaced by 1-4 group that is selected from down group: C
1-8Alkyl, C
1-6Alkoxyl group, halogen, CH
2OH, benzyloxy and OH; And
R
27Be selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl-C
1-6Alkyl, aryl and aryl C
1-18Alkyl.
2. compound as claimed in claim 1 is characterized in that YR
1Phenyl for halogenophenyl or monochloromethyl replacement.
3. compound as claimed in claim 2 is characterized in that, halogenophenyl is the ortho-fluorophenyl base.
4. compound as claimed in claim 1 is characterized in that R
3For by 1-3 R
17Replace the De isoxazolyl.
5. compound as claimed in claim 1 is characterized in that R
17For further by 1,2 or 3 R
19The aryl or the heterocycle that replace.
6. compound as claimed in claim 1 is characterized in that YR
1Be not hydrogen, unsubstituted C
3-10Cycloalkyl or C
1-6One of alkyl.
7. compound as claimed in claim 1 is characterized in that R
19Be trihalomethyl group, three halogenated methoxies, alkoxy or halogen.
8. compound as claimed in claim 1 is characterized in that R
1For by 1,2 or 3 R
6The aromatic heterocycle or the aryl that replace, wherein, R
6Be halogen, C
1-18Alkoxyl group or C
1-18Haloalkyl.
9. compound as claimed in claim 1 is characterized in that, Y is a key.
10. compound as claimed in claim 2 is characterized in that, halogen or halogenated methyl are an ortho position or a position.
11. compound as claimed in claim 1 is characterized in that, X is selected from down group :-CH
2-,-CH (CH
3)-,-CH
2-CH
2-,-CH
2-CH
2-CH
2-,-CH
2-CH
2-CH
2-CH
2,-(CH
2)
2-4-O-(CH
2)
2-4-,-(CH
2)
2-4-S-(CH
2)
2-4-,-(CH
2)
2-4-NR
10-(CH
2)
2-4-, C
3-10Cycloalkylidene, C
2-6Alkenylene and C
2-6Alkynylene;
R wherein
10Be selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, aryl ,-C (=O) R
12, heterocyclic radical or amino-acid residue.
12. compound as claimed in claim 1 is characterized in that, X is a methylene radical.
13. compound as claimed in claim 1 is characterized in that, R
3For by 0-3 R
17The heterocycle that replaces.
14. compound as claimed in claim 13 is characterized in that, described heterocycle is an aromatic heterocycle.
15. compound as claimed in claim 14 is characterized in that, comprises 1,2 or 3 N, S or O atom in the described heterocyclic ring, described heterocycle is connected with X by ring carbon atom, and comprises 4-6 annular atoms.
16. compound as claimed in claim 1 is characterized in that, R
17Be selected from down group: C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, arylalkyl; Alkoxy aryl; Alkylthio-aryl or heterocyclic radical; Wherein, each described group is not for replacing or by one or more R
19Replace.
17. compound as claimed in claim 1 is characterized in that, R
9And R
18Be H, OH or alkyl.
18. compound as claimed in claim 1 is characterized in that, R
5Be H.
19. compound as claimed in claim 1 is characterized in that, R
6Be halogen.
20. compound as claimed in claim 1 is characterized in that, R
7, R
8, R
11, R
15, R
16, R
20And R
21Be H or C independently
1-18Alkyl.
21. compound as claimed in claim 1 is characterized in that, R
12Be OH or alkyl.
22. compound as claimed in claim 1 is characterized in that, R
19Be selected from down group: H; C
1-18Alkyl; C
2-18Thiazolinyl; C
2-18Alkynyl; C
1-18Alkoxyl group; Alkene oxygen base; Alkynyloxy group; C
1-18Alkylthio; C
3-10Cycloalkyl; C
4-10Cycloalkenyl group; C
4-10Cycloalkynyl radical; Halogen; OH; CN; The cyano group alkyl; NO
2NR
20R
21Haloalkyl; Halogenated alkoxy; C (=O) R
18C (=O) OR
18O-thiazolinyl-C (=O) OR
18-O-alkyl-C (=O) NR
20R
21Aryl; Heterocycle;-O-alkyl-OC (=O) R
18C (=O) N (C
1-6Alkyl), (O) (C of N (H) S (O)
1-6Alkyl); Alkoxy aryl; Aryloxy; Alkoxy aryl; And aralkyl; Wherein, each group is not for replacing or being replaced by one or more groups that are selected from down group :=O;-NR
20R
21CN; Alkoxyl group; Heterocyclic radical; Haloalkyl-or the heterocycle that replaces of alkyl; And by alkyl, alkoxyl group alkoxy or halogen and R
17The heterocyclic radical that connects.
23. compound as claimed in claim 22 is characterized in that, R
19Be independently selected from down group: halogen, N (R
20R
21), alkoxyl group, haloalkyl and halogenated alkoxy.
24. compound as claimed in claim 1 is characterized in that, R
25And R
26Do not exist.
25. compound as claimed in claim 1 is characterized in that, haloalkyl or halogenated alkoxy are-CF
3Or-OCF
3
26. compound as claimed in claim 1 is characterized in that, Y is a singly-bound, and R
1Be phenyl.
27. the compound with general formula (C), and salt, tautomer, steric isomer, hydrate and alcoholate,
In the formula:
R
1Be selected from: hydrogen, aryl, heterocyclic radical, C
1-C
10Alkoxyl group, C
1-C
10Alkylthio, C
1-C
10Alkyl-amino, C
1-C
10Dialkyl-7-amino, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group and C
4-10Cycloalkynyl radical, wherein, each group is randomly by one or more R
6Replace;
Y is selected from: singly-bound, O, S (O) m, NR
11Or C
1-10Alkylidene group, C
2-10Alkenylene, C
2-10Alkynylene, wherein, each group can randomly comprise 1-3 heteroatoms that is selected from O, S or N;
R
2And R
4Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical, prerequisite is for working as R
25Or R
26One of when existing, R
2Or R
4Be selected from: (=O), (=S) and=NR
27
X is selected from: C
1-C
10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene, wherein, each group can comprise the heteroatoms of one or more O of being selected from, S or N, prerequisite be any this kind heteroatoms not with the ring in the N adjacency;
M is any integer of 0-2;
R
3Be selected from: aryl, aryloxy, arylthio, cycloalkyl, cycloalkenyl group, cycloalkynyl radical, aryl-N (R
10)-or heterocyclic radical, wherein, each described substituting group can be randomly by at least one R
17Replace, prerequisite is for cycloalkenyl group, its pair key not with nitrogen adjacency, and R
3M-Q-is not an xenyl;
R
5Be selected from: hydrogen; C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, halogen ,-OH ,-CN ,-NO
2,-NR
7R
8, halogenated alkoxy, haloalkyl ,-C (=O) R
9,-C (=O) OR
9,-C (=S) R
9, SH, aryl, aryloxy, arylthio, arylalkyl, C
1-18Hydroxyalkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl oxy, C
3-10Cycloalkyl sulfenyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical or heterocyclic radical;
R
6Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
1-18Alkylthio, C
1-18Alkyl sulfoxide, C
1-18Alkyl sulfone, C
1-18Halo-alkyl, C
2-18Halo-thiazolinyl, C
2-18Halo-alkynyl, C
1-18Halo-alkoxyl group, C
1-18Halo-alkylthio, C
3-10Cycloalkyl, C
3-10Cycloalkenyl group, C
7-10Cycloalkynyl radical, halogen, OH, CN, cyano group alkyl ,-CO
2R
18, NO
2,-NR
7R
8, C
1-18Haloalkyl, C (=O) R
18, C (=S) R
18, SH, aryl, aryloxy, arylthio, aryl sulfoxide, aryl sulfone, aryl sulfonamide, aryl (C
1-18) alkyl, aryl (C
1-18) alkoxyl group, aryl C
1-18Alkylthio, heterocyclic radical, C
1-18Hydroxyalkyl, wherein, each group can be randomly by at least one R
19Replace;
R
7And R
8Be independently selected from: hydrogen, C
1-18Alkyl, C
1-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, heterocyclic radical ,-C (=O) R
12-C (=S) R
12, the amino-acid residue that connects by amino acid whose carboxyl, or R wherein
7And R
8Form heterocyclic radical with nitrogen;
R
9And R
18Be independently selected from: hydrogen, OH, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
1-18Alkoxyl group ,-NR
15R
16, aryl, by amino acid whose amino amino-acid residue, the CH that connects
2OCH (=O) R
9aOr CH
2OC (=O) OR
9a, wherein, R
9aBe C
1-C
12Alkyl, C
6-C
20Aryl, C
6-C
20Alkylaryl or C
6-C
20Aralkyl;
R
10And R
11Be independently selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, aryl ,-C (=O) R
12, heterocyclic radical or amino-acid residue;
R
12Be selected from down group: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
15And R
16Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group or amino-acid residue;
R
17Be M-Q-independently, wherein, M is for randomly by one or more R
19The ring that replaces, and Q is key or M is connected to R
3Linking group, described linking group comprises 1-10 atom and randomly by one or more R
19Replace;
R
19Be selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, C
1-18Alkoxyl group, C
2-18Alkene oxygen base, C
2-18Alkynyloxy group, C
1-18Alkylthio, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group, C
4-10Cycloalkynyl radical, halogen ,-OH ,-CN, cyano group alkyl ,-NO
2,-NR
20R
21, C
1-18Haloalkyl, C
1-18Halogenated alkoxy ,-C (=O) R
18,-C (=O) OR
18,-O-thiazolinyl-C (=O) OR
18,-O-alkyl-C (=O) NR
20R
21,-O-alkyl-OC (=O) R
18,-C (=S) R
18, SH ,-C (=O) N (C
1-6Alkyl) ,-(O) (C of N (H) S (O)
1-6Alkyl), aryl, heterocyclic radical, C
1-18Alkyl sulfone, aryl sulfoxide, aryl sulfonamide, aryl-C
1-18Alkoxyl group, aryloxy, arylthio, aryl-C
1-18Alkylthio or aryl-C
1-18Alkyl, wherein, each group can randomly be replaced by one or more groups that are selected from down group :=O ,-NR
20R
21, CN, C
1-18Alkoxyl group, heterocyclic radical, C
1-18Haloalkyl, heterocyclic radical-alkyl, by alkyl, alkoxyl group alkoxy or halogen and R
17The heterocyclic radical that connects;
R
20And R
21Be independently selected from: hydrogen, C
1-18Alkyl, C
2-18Thiazolinyl, C
2-18Alkynyl, aryl, C
3-10Cycloalkyl, C
4-10Cycloalkenyl group ,-C (=O) R
12Or-C (=S) R
12
R
27Be selected from: hydrogen, C
1-18Alkyl, C
3-10Cycloalkyl, C
3-10Cycloalkyl-C
1-6Alkyl, aryl and aryl C
1-18Alkyl.
28. compound as claimed in claim 27 is characterized in that, Y is a singly-bound, and R
1Be aryl.
29. compound as claimed in claim 27 is characterized in that, X is C
1-10Alkylidene group, C
2-10Alkenylene or C
2-10Alkynylene.
30. compound as claimed in claim 27 is characterized in that, R
3Be heterocyclic radical.
31. compound as claimed in claim 27 is characterized in that, R
3For by R
17The heterocyclic radical that replaces, wherein Q is that key and M are aryl.
32. compound as claimed in claim 27 is characterized in that, R
3For by R
17Replace the De isoxazole, wherein Q is that key and M are aryl.
33. a pharmaceutical composition, described composition comprise each described compound among pharmaceutically acceptable vehicle and the claim 1-32.
34. the purposes of each described compound among the claim 1-32, it is used to prepare the medicine of treatment or prophylaxis of viral infections.
35. purposes as claimed in claim 34 is characterized in that, described virus infection is an infection with hepatitis C virus.
36. purposes as claimed in claim 35, described medicine also comprise at least a other antiviral therapy agent.
37. purposes as claimed in claim 36 is characterized in that, described other therapeutical agent is interferon alpha or virazole.
38. purposes as claimed in claim 34 is characterized in that, described virus infection is the infection that is caused by the virus that belongs to flaviviridae and pico+ribonucleic acid+virus section.
39. purposes as claimed in claim 34 is characterized in that, described virus infection is the infection that is caused by Coxsackie virus.
40. purposes as claimed in claim 34 is characterized in that, described virus infection is the infection that is caused by bovine viral diarrhea virus.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53229203P | 2003-12-22 | 2003-12-22 | |
US60/532,292 | 2003-12-22 | ||
US53396304P | 2004-01-02 | 2004-01-02 | |
US60/533,963 | 2004-01-02 | ||
US59098904P | 2004-07-26 | 2004-07-26 | |
US59099004P | 2004-07-26 | 2004-07-26 | |
US59106904P | 2004-07-26 | 2004-07-26 | |
US59102404P | 2004-07-26 | 2004-07-26 | |
US60/591,024 | 2004-07-26 | ||
US60/590,989 | 2004-07-26 | ||
US60/590,990 | 2004-07-26 | ||
US60/591,069 | 2004-07-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200480038144 Division CN1902198A (en) | 2003-12-22 | 2004-12-21 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101538267A true CN101538267A (en) | 2009-09-23 |
CN101538267B CN101538267B (en) | 2015-04-29 |
Family
ID=37657541
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200480038144 Pending CN1902198A (en) | 2003-12-22 | 2004-12-21 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
CN200910132469.XA Expired - Fee Related CN101538267B (en) | 2003-12-22 | 2004-12-21 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200480038144 Pending CN1902198A (en) | 2003-12-22 | 2004-12-21 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN1902198A (en) |
SI (1) | SI1706403T1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI438200B (en) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Hepatitis c virus inhibitors |
CN110229150B (en) * | 2018-03-06 | 2022-03-01 | 沈阳药科大学 | Imidazo [4,5-c ] pyridine derivatives and application thereof |
EP4110777A1 (en) * | 2020-02-24 | 2023-01-04 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Pyrrolopyridine and imidazopyridine antiviral compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215293D0 (en) * | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
-
2004
- 2004-12-21 SI SI200431858T patent/SI1706403T1/en unknown
- 2004-12-21 CN CN 200480038144 patent/CN1902198A/en active Pending
- 2004-12-21 CN CN200910132469.XA patent/CN101538267B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101538267B (en) | 2015-04-29 |
CN1902198A (en) | 2007-01-24 |
SI1706403T1 (en) | 2012-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5395844B2 (en) | Imidazo [4,5-c] pyridine compounds and methods of antiviral therapy | |
KR101184032B1 (en) | Viral Inhibitors | |
CN101027303A (en) | Imidazo 4,5-dpyrimidines, their uses and methods of preparation | |
DK2094702T3 (en) | viral inhibitors | |
TW201010977A (en) | Amide compound | |
JP2019503389A (en) | PDE1 inhibitor | |
CN101360748A (en) | Inhibitors of c-met and uses thereof | |
JP6633246B2 (en) | Triazolopyrazinone derivatives useful as human PDE1 inhibitors | |
WO2003106446A1 (en) | Non-peptide gnrh agents, pharmaceutical compositions and methods for their use | |
CN101538267B (en) | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | |
UA82482C2 (en) | Virus inhibitors, pharmaceutical composition on basis of those and use of those |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150429 Termination date: 20151221 |
|
EXPY | Termination of patent right or utility model |